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F-FDG PET can predict response using both qualitative and quantitative measures. PET 
Therapy Response Assessor (PETTRA) software was developed to allow users to view and 
analyse pre- and post- therapy images and compute quantitative measures for predicting 
response to therapy. Additionally, registration methodology was developed to register pre- and 
post- therapy PET/CT images. The methodology registers pre- and post- therapy PET/CT scans 
by registering CT scans using customised rigid and non-rigid registration performed by the 
Image Registration Toolkit (IRTK). Registration success was assessed using qualitative visual 
analysis and quantitative landmark analysis on a cohort of 20 lymphoma patients. Landmark 
analysis results found average misalignment on IRTK of ~10mm for rigid registration and 
~6.5mm for non-rigid registration, in comparison with ~40mm with no registration applied. The 
effect of both rigid and non-rigid registration on transformed images was assessed. While rigid 
registration transformation caused minimal changes on intensity and tumour volume (<2%), 
non-rigid transformations caused changes of 11% and 21% respectively. PETTRA software was 
used to analyse quantitative parameters in 14 patients with mesothelioma and 85 patients with 
diffuse large B-cell lymphoma (DLBCL). For the 14 patients with mesothelioma, a range of 
parameters were used to assess response including SUVmax, SUVpeak, tumour volume (TV), total 
lesion glycolysis (TLG) and intensity volume histogram (IVH) parameters. TV and TLG were 
obtained using 13 fixed and 9 adapative threshold segmentation methods. Pre-and post- therapy 
SUVmax, SUVpeak, TV and TLG all showed promise in predicting survival. The comparison 
between TV and TLG obtained using different segmentation methods was negligible. For the 85 
patients with DLBCL, SUVmax, TV and TLG struggled to predict response in patients according 
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APD    Avalanche Photodiode 
AIF   Arterial Input Function 
AUC   Area Under the Curve 
ASCT   Autologous Stem Cell Transplantation 
BG   Background 
BGO   Bismuth Germanate 
BMI   Body Mass Index 
BSA   Body Surface Area 
11







CAD   Coronary Artery Disease 
CC   Cross Correlation 
CHOP   Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone 
CMR   Complete Metabolic Response 
COM   Centre of Mass 
CR   Complete Response 
CRu   Complete Response (Unconfirmed) 
CT   Computed Tomography 
CTAC   Computed Tomography Attenuation Correction 
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CTV   Clinical Target Volume  
DAR   Dose Absorption Rate  
DEXA   Dual-Energy X-ray Absorptiometry 
DICOM  Digital Imaging and Communications in Medicine 
DLBCL  Diffuse Large B-Cell Lymphoma 
DUR   Differential Uptake Ratio 
EANM   European Association of Nuclear Medicine 
ECOG   European Cooperative Oncology Group 
EFS   Event-Free Survival 











   18
F-fluoromethylcholine 
18
F-FDG  Flourine-18-labelled fluoro-2-deoxy-D-glucose 
18
F-FES   16-α-[18F]-fluoroestradiol 
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FBP   Filtered Back Projection 
FDG   fluoro-2-deoxy-D-glucose 
FLAB   Fuzzy Locally Adaptive Bayesian 
FLE   Fiducial Localisation Error 







GE General Electric 
GIPL Guy’s Image Processing Lab 
GLCM Grey Level Co-occurrence Matrix 
GLUT Glucose Transporters 
GSO   Germanium Oxyorthosilicate 
GTM   Geometric Transform Matrix 
GTV   Gross Tumour Volume 
GUI   Graphical User Interface 
GUIDE   Graphical User Interface Design Component 
HL   Hodgkin’s Lymphoma 
IDIF   Image Derived Input Function 
IMRT    Intensity Modulated Radiotherapy 
IPI   International Prognostic Index 
IRTK   Image Registration Toolkit 
IVH   Intensity Volume Histogram 
IWC   International Working Group Criteria 
LaBr3   Lanthanum Bromide 
LBM   Lean Body Mass 
LGI   Larson-Ginsberg Index 
LOR    Line of Response 
LSO   Lutetium Oxyorthosilicate 
LYSO   Lutetium-yttrium Oxyorthosilicate 
MB   Metabolic Burden 
MCT   Multi-Centre Trials 
MLEM   Maximum Likelihood Expectation Maximisation  
MNL   Maximum Normal Level 
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MPM   Malignant Pleural Mesothelioma 
MR   Magnetic Resonance 
MRglu   Glucose Metabolic Rate 
MRI   Magnetic Resonance Imaging 
MTB   Metabolic Tumour Burden 
MTV   Metabolic Tumour Volume 
MWPC   Multiwire Proportional Chambers 
NaI (Tl)  Sodium Iodide doped in Thallium 
NCI   National Cancer Institute 
NE   Non-Evaluable 
NECR   Noise Equivalent Count Rate  
NEMA   National Electrical Manufacturers Association 
NHL   Non-Hodgkin’s Lymphoma 
NLR   Nonlinear Regression 
NMI   Normalised Mutual Information 
NSCLC  Non-Small Cell Lung Cancer 
OS   Overall Survival 
OSEM   Ordered Subsets Expectation Maximisation 
pcc   Pearson Correlation Coefficient 
PD   Progressive Disease 
PERCIST  PET Response Criteria for Solid Tumours 
PET   Positron Emission Tomography 
PETTRA  Positron Emission Tomography Therapy Response Assessor 
PFS   Progression Free Survival 
PMD   Progressive Metabolic Disease 
PMR   Partial Metabolic Response 
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PMT   Photomultiplier Tube 
PR   Partial Response 
PSF   Point Spread Function 
PV   Partial Volume 
QC   Quality Control 
R-CHOP  Rituximab with CHOP 
R-CEOP  Rituximab with Cyclophosphamide, Etoposide, Prednisolone, 
Vincristine 
RC   Recovery Coefficient 
REAL   Revised European-American Classification of Lymphoid Neoplasms 
RECIST  Response Evaluation Criteria in Solid Tumours 
R-IPI   R-CHOP version of International Prognostic Index 
ROC   Receiver Operator Characteristics 
ROI   Region of Interest 
RTL   Relative Threshold Level 
S/B   Source to Background 
S.D.   Standard Deviation 
SD   Stable Disease 
SKM   Simplified Kinetic Method 
SMD   Stable Metabolic Disease 
SNR   Signal to Noise Ratio 
SPECT   Single Photon Emission Computed Tomography 
SSD   Sum of Squared Differences 
SUL   Standardised Uptake Value normalised by Lean Body Mass 
SUV   Standardised Uptake Value 
SUVBSA  Standardised Uptake Value normalised by Body Surface Area 
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SUVLBM/lean  Standardised Uptake Value normalised by Lean Body Mass 
SUVm   Standardised Uptake Value normalised by a weight index 
SUVmax   Maximum Standardised Uptake Value 
SUVmean  Mean Standardised Uptake Value 
SUVpeak  Peak Standardised Uptake Values 
SV40   Simian Virus 
SWOG   South West Oncology Group 
t½   Half Life 
T   Tumour 
T/B   Tumour to Background 
TGA   Total Glycolytic Activity 
TGV   Total Glycolytic Volume 
TLG   Total Lesion Glycolysis 
ToF   Time of Flight 
TRE   Target Registration Error 
TTP   Time to Progression 
TV   Tumour Volume 
VEGF   Vascular Endothelial Growth Factor 
VOI   Volume of Interest 
WHO   World Health Organisation 
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1) Introduction and Background 
1.1) Positron Emission Tomography 
1.1.1) Overview of PET 
Positron emitters were first used in medical research as early as the 1950s to try and localise 
brain tumours (Brownell and Sweet, 1953), with the first Positron Emission Tomography (PET) 
scanners developed in the 1970s (Ter-Pogossian et al., 1975; Phelps et al., 1975). Advances in 
technology and development of other tracers, most notably fluoro-2-deoxy-D-glucose (FDG) 
(Reivich et al., 1979), have gradually increased research in PET and its use clinically. In the last 
ten years, the introduction of scanners combining PET with computed tomography (CT) have 
resulted in a surge of interest in the modality (Beyer et al., 2000), primarily for cancer imaging, 
due to the ability of PET to show functional in vivo processes compared with anatomical 
information (Juweid and Cheson, 2006). PET has low spatial resolution (~5mm) in comparison 
to other imaging modalities so the complementary combination of metabolic PET images and 
higher resolution anatomical CT images, which typically have a spatial resolution of <1mm, 
make it a very powerful and useful imaging tool. 
 
PET works by injecting a radionuclide tracer into a patient emitting positrons within the body. 
These positrons travel a short distance known as the positron range, dependent upon the isotope 
but usually <1mm for 
18
Flourine, before undergoing annihilation with an electron producing two 
511keV gamma ( γ )  rays which can be absorbed by detectors (Figure 1.1). If two γ rays are 
detected at 180° within a certain time they are deemed to represent a ‘coincidence’ or ‘true’ 
event. These can be tracked to a position somewhere along the line of response (LOR) joining 
them. Detectors absorb emitted γ rays from these events and produce a signal containing enough 
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information to determine when the event occurred and how much energy it deposited. Using the 
information from many events, an image of tracer uptake can be reconstructed. 
 
 
Figure 1.1: Positron Annihilation 
A positron is emitted from the nucleus of a radionuclide and annihilates with an electron producing two 
511 keV γ rays 180° apart (Taken from Cherry, 2001). 
 
1.1.2) PET Noise and Spatial Resolution 
Not all detected coincidence events are from the same ‘true’ annihilation as scatter and random 
coincidences can be detected causing noise in an image. Scatter coincidences occur when γ rays 
undergo Compton scattering and end up in different positions to what would be expected, 
resulting in a false LOR. Random coincidences occur when two coincidences are detected within 
the same time frame and are therefore deemed to represent a true event, when in fact they are not 
from the same annihilation (Figure 1.2). 
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Figure 1.2: Scattered, Random and True Coincidence Events 
Scattered and random coincidences cause noise in an image as true coincidences are ideally the only event 
that PET should detect (Adapted from Rohren et al., 2008). 
 
To gauge the effect of random and scattered coincidences, Strother et al. (1990) introduced the 
Noise Equivalent Count Rate (NECR), designed to measure performance of an imaging system 
in terms of a signal-to-noise ratio (SNR), i.e. the amount of desired signal compared to unwanted 
noise (Strother et al., 1990). NECR is mathematically defined as: 
                                  [1.1] 
Physical factors can affect spatial resolution by up to 2mm, but clinical scanners have a 
resolution of ~6-8mm (Townsend, 2004; Papathanassiou et al., 2009). Spatial resolution is 
affected by positron range, acollinearity of photons and decoding of the PET signal. The positron 
range results in the LOR being recorded at the point where the positron was annihilated, not 
from where it was emitted. The assumption that annihilation photons are ejected at exactly 180° 
is only approximate as they are slightly acollinear, at an average angle of 0.25°, causing a 
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difference in the annihilation point to the LOR. Photon non-collinearity occurs because a 
positron’s centre of mass is not always at rest at the point of annihilation and in order to 
conserve energy and momentum, the annihilation photons are not directly 180° apart. 
Additionally, in decoding the PET signal, there are sampling errors and penetration of γ rays on 
more than one detector element. While these issues adversely affect the spatial resolution, the 
most dominant factor is the size of detector elements (Moses, 2011). 
1.1.3) PET Detectors 
There are two main types of PET detectors. The first uses separate elements, consisting of a 
scintillation crystal and a photomultiplier tube (PMT), to deduce the position of the photon from 
where it hits the detector. The second comes in the form of a gamma camera-like system so the 
position of the photon can be obtained from signals processed by PMTs (Rohren et al., 2004). 
Most installed systems are block detectors (Casey and Nutt, 1986), a mixture of the two designs, 
which are arranged around the patient in a ring configuration and contain blocks of scintillator 
segmented into an array read out by PMTs (Figure 1.3).  
 
 
Figure 1.3: Diagram of a Standard PET Detector 
Photons are absorbed by scintillators, which are attached to PMTs converting scintillation photons into 
electrical currents (Taken from Lecomte, 2009).  
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Other detector designs have been developed in an attempt to improve PET, including PETRRA 
positron cameras which use large area multiwire proportional chambers (MWPC) coupled with 





) and faster timing (1ns) (Herbert et al., 2007), and silicon detectors using 
metallic strips and amplifiers (Park et al., 2007). Five key attributes an ideal detector should 
have are: (i) high stopping power i.e. ability to absorb γ rays, (ii) high spatial resolution to 
determine the exact location of the γ ray in the spatial volume, (iii) good energy resolution to 
stop scattered events, (iv) high temporal resolution and (v) low cost (Lewellen, 2008). Early PET 
detectors used thallium doped sodium iodide (NaI(Tl)) as scintillation crystals, however, 
bismuth germanate (BGO) has been most commonly used in the last two decades due to its high 
density and stopping power (Lecomte, 2009). However, lutetium oxyorthosilicate (LSO) and 
germanium oxyorthosilicate (GSO) are now being used in PET systems and are beginning to 
replace BGO (Patel et al., 2010).  
 
To achieve a spatial resolution of ~2mm, detector elements need to be <4mm in thickness so 
development of smaller elements would result in a higher spatial resolution (Cherry, 2006). 
Detectors with extremely good temporal resolutions, in the range of 500-900 picoseconds 
(Spanoudaki and Levin, 2010), can allow time of flight (ToF) PET imaging, which calculates the 
time difference between detected annihilation photons to approximate where annihilation occurs 
along the LOR. ToF PET’s approximate improvement in SNR is: 
                  [1.2] 
where D is the diameter of the imaged object, c is the speed of light and ∆t is the timing 
resolution of the system (Cherry, 2006). ToF imaging has shown to significantly improve 
tumour detection (Kadrmas et al., 2009; Surti et al., 2011; El Fakhri et al., 2011). The main 
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reason for increased availability and effectiveness of ToF imaging is the development of 
scintillators with high timing resolutions such as LSO, lutetium-yttrium oxyorthosilicate (LYSO) 
and lanthanum bromide (LaBr3) crystals (Peng and Levin, 2010). 
1.1.4) PET Reconstruction 
PET reconstruction takes raw imaging data and produces a 3-D image. Raw data can be 
formatted into a sinogram, formed by projections of LORs from different angles, and an image 
can be created using a reconstruction algorithm. The first reconstruction method to gain 
popularity was filtered back projection (FBP), which filters sinogram data before using 
backprojection to create an image. Iterative methods of reconstruction have now replaced 
analytical methods, such as FBP, demonstrating improved image quality and better tumour 
detectability (Meikle et al., 1994; Hutton, 2011). Iterative algorithms start with an initial guess 
of distribution which is then projected according to scanner geometry and compared to measured 
projections. The difference between the initial guess and measured projections is used to 
continue the iterative process until they agree within their statistics (Ziegler, 2005). One 
advantage of using iterative algorithms is that a priori information, such as noise, attenuation 
and detector nonuniformity, can be incorporated for more accurate reconstruction (Tarantola et 
al., 2003). The most popular method of reconstruction is the maximum likelihood expectation 
maximisation algorithm (MLEM) (Shepp and Vardi, 1982), and its accelerated form, the ordered 
subsets expectation maximisation (OSEM) method which breaks down projection data into 
subsets to reduce computational burden (Hudson and Larkin, 1994).  
1.1.5) PET Attenuation Correction 
Attenuation occurs when photons are absorbed by tissue before reaching a detector causing 
structures deep in the body to have falsely low tracer uptake. To eradicate this problem, 
attenuation correction (AC) can be performed by applying a correction factor to the number of 
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events recorded within each LOR. For example, if five events are counted between two detectors 
and it is deduced that only 10% of photon pairs survive, then it can be corrected so 50 counts are 
recorded rather than five (Rohren et al., 2004). This can be achieved by taking a ‘transmission’ 
scan where the scan is acquired using an external radionuclide point source with the patient in 
scanning position. CT attenuation correction (CTAC) is used on PET/CT scans as it’s faster, 
contains more data and produces less statistical noise (Kinahan et al., 1998). This comes at a 
cost as CTAC can compromise the accuracy of PET data as respiratory motion can cause 
misalignment between CTAC and PET scans as they are acquired at different times and speeds. 
This can result in artefacts around the dome of the liver and the lung on AC PET images in some 
cases (Bacharach, 2006). There has been significant work to overcome this issue including 
averaging CT data over respiratory cycles (Pan et al., 2005; Chi et al., 2007), and respiratory 
gating CT and PET data (Nehmeh et al, 2004; McQuaid et al., 2011). 
1.1.6) PET Tracers for Oncology 
PET tracers are labelled with positron-emitting radionuclides which indirectly cause production 
of back-to-back γ rays. The most common radionuclides in PET imaging studies are oxygen-15, 
nitrogen-13, carbon-11 and fluorine-18. They have half-life’s (t½) of 2min, 10min, 20min and 
110min respectively making them suitable for imaging. Their t½’s are long enough to allow 
imaging to take place while being short enough to not give unnecessary doses of radiation to a 
patient. Radiotracers/radiopharmaceuticals for PET imaging are synthesised from positron 
emitting radionuclides which are usually produced in a cyclotron where stable elements are 
bombarded with protons or negative ions (Schleyer, 2004). Fluorine-18 is commonly the 
radionuclide of choice as it has an ideal t½ to allow time for imaging, produces a high positron 
yield (~97%) and low positron energy. However, it does have complicated radiochemistry and is 
not a complete, isotropic tracer as there is no natural fluorine in organic compounds. Therefore, 
Carbon-11 is of particular interest since carbon is heavily involved in the chemical structure of 
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organic compounds, however its shorter t½ of 20min limits the time available for synthesis, and 




F-FDG) is by far the most widely used tracer in PET imaging measuring 
glucose metabolism prevalent in fast growing cancer cells, however, undesirably, there is also 
normal physiological uptake in organs including the brain, kidneys and bladder (Warburg, 
1956). 
18
F-FDG also accumulates in areas of inflammation and infection and it shows relatively 
low uptake in some diseases such as prostate cancer, neuroendocrine tumours and 
hepataocellular carcinomas that may replace or compliment FDG (Mercer, 2007). This 
highlights the need for extensive ongoing research into other tracers. One of the most promising 





F-FLT) shows good correlation with tumour 
proliferation making it an ideal evaluation tool for therapeutic response (Shields et al., 1996; 
Shields et al., 1998; Reske and Deisenhofer, 2006). Another nucleoside analog is 2’-[18F]fluoro-









F-FET) also show uptake 
representing cell proliferation (Dunphy and Lewis, 2009). Choline kinase activity and 











F-FCH), are of 
potential future use (DeGrado et al., 2001; Pantaleo et al., 2008). 
 
Hypoxia tracers are another important area of research. Hypoxia has been found to increase the 
likelihood of tumour progression and failure of radiotherapy due to increased radioresistance of 
hypoxic cells compared with oxygenated ones (Vaupel and Mayer, 2007; Overgaard, 2007; 
















Cu-ATSM) (Lewis et al., 1999). Examples of other tracers 
being researched in PET imaging are 
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C-5-hydroxytryptophan for targeting amine 











Ga-DOTATOC) as a somatostatin receptor to image neuroendocrine tumours (Mercer, 2007). 
1.1.7) Clinical Applications of PET 
PET has a wide variety of applications in medical imaging. It was first used in neurology as 
early as the 1980s to investigate movement disorders such as Huntingdon’s disease and 
Parkinson’s disease (Kuhl et al., 1982; Raichle et al., 1984). Since then, it has also been used to 
study dementia (Alzheimer’s disease), brain tumours (gliomas) and epilepsy with a variety of 
tracers (Tai and Piccini, 2004). PET is used in cardiology to detect coronary artery disease 
(CAD), due to its higher spatial resolution and heart-to-background ratio when compared to 
single photon emission computed tomography (SPECT) (Knuuti, 2008). PET can also assess 
myocardial perfusion, blood flow, heart failure and identify plaque burden (Maisey, 2002; 
Schwaiger et al., 2005). 
 
PET is most widely used in oncology. Up to 90% of PET investigations are performed using 
18
F-
FDG for cancer imaging (Lonsdale and Beyer, 2010). Its huge growth in this area is due to its 
importance in cancer management in which it can be used to confirm suspected malignancies, 
determine staging and site of disease, diagnose recurring disease and assess response to therapy 
(Maisey, 2002). 
18
F-FDG PET is widely used clinically and has large practical usefulness in 
diagnosing head and neck and lung cancers, as well as staging lung, oesophageal, colorectal, 
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lymphoma, melanoma, and head and neck cancers. 
18
F-FDG PET also has the ability to detect 
recurrence in melanoma, colorectal, breast, ovarian and head and neck cancers. It is being 
increasingly used in these areas for other cancers such as pancreatic, uterine, testicular, thyroid, 
sarcoma and gastrointestinal stromal (Fletcher et al., 2008; Papathanassiou et al., 2009). A 
growing area of clinical PET/CT is identifying response to therapy in patients with a variety of 
different cancers, particularly lymphomas, non-small cell lung cancer (NSCLC), breast, 
colorectal and oesophageal cancers (Ben Haim and Ell, 2009). 
 
18
F-FDG PET is also useful for the investigation of primary lesions of unknown cancer, which 
occurs in 2-4% of all cancer patients (Jerusalem et al., 2003). While 
18
F-FDG PET is very useful 
for imaging many cancers including gastric carcinomas, bronchialveolar cell carcinomas, 
mucosa-associated lymphoid tissue lymphomas, small lymphocytic cell lymphoma, carcinoids 
and renal cell carcinomas do not take enough 
18
F-FDG to be used accurately (Lucignani et al., 
2004). 
18
F-FDG PET has been shown to have a positive and significant impact on therapeutic 
management of cancer patients in oncology (Zafra et al., 2008). 
 
PET has been highlighted as a useful tool in drug development and pharmacology as it can 
detect early signs of drug success or failure and could provide the most superior and early 
assessment of drug efficacy in comparison to current methods (Kelloff et al., 2005). The main 
benefit of PET is that it can show, very early, the effectiveness of a given drug while also being 
useful in pre-clinical imaging for better translation of animal models to clinical human patients 
(Pien et al., 2005). 
18
F-FDG PET has been used to assess traditional chemotherapy agents in 
breast cancer, colorectal cancer and melanoma, as well as novel agents such as epidermal growth 
factor receptors, successfully detecting response within the first few weeks of treatment 
(Hammond et al., 2003). It can also measure the uptake of a drug to evaluate its bioavailability 
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i.e. whether the tumour takes up enough concentration of a drug to kill cancer cells whilst most 
normal tissue remains unharmed.  
 
Recent research has shown increased use of PET in areas including paediatric oncology and 
radiotherapy planning where images can be registered and segmented to establish a gross tumour 
volume (GTV) to be irradiated (Nestle et al., 2009; Bussink et al., 2010; London et al., 2010; 
Portwine et al. 2010, Lucignani and De Palma, 2011; De Ruysscher et al., 2012). Another 
clinical application of PET is its emerging use in combination with magnetic resonance imaging 
(MRI), an imaging modality which images the nuclei of atoms using magnetic fields and 
radiowaves. PET/MRI offers benefits over PET/CT including more reliable image registration 
and lower radiation exposure, although there are limitations in its development including issues 
with AC and in what areas it may be of best use (Schiepers and Dahlbom, 2011). 
1.1.8) PET Imaging Protocol and Quality Control 
The standard protocol for clinical whole body imaging with 
18
F-FDG PET starts with an 
injection of ~370MBq of 
18
F-FDG. The patient is then left to rest for a period of ~1h to allow for 
tracer uptake. Images are acquired in 5-9 bed positions of ~15cm, taken sequentially for 2-5min 
per section (Marsden and Sutcliffe-Goulden, 2000). Imaging protocols can differ depending on 
factors including breath holding, contrast agents, CT operating parameters, PET scan time, and 
optimal injected dose. In monitoring response to therapy in clinical studies, care must be taken to 
make sure these factors are as similar as possible in each scan to enhance repeatability.  
 
A documented quality control (QC) assurance program should be carried out at all institutions 
for PET scanners including annual/monthly testing of hardware/software and daily maintenance 
checks for detector performance (using a transmission scan) and image uniformity (Zanzonico, 
2008). There are a number of defined measurement standards which can be followed for 
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performance measures for spatial resolution, sensitivity, scatter fraction, count losses and image 
quality e.g. National Electrical Manufacturers Association (NEMA) NU 2-2001 PET 
performance measures (Daube-Witherspoon et al., 2002). For clinical trials it is normally 
expected that a full QC program is completed and properly documented, particularly for multi-
centre trials (MCTs) where different scanning procedures are likely to increase variation in 
SUVs (Takahashi et al., 2008). At St Thomas’ Hospital, QC procedures are based on those of the 
American College of Radiology Imaging Network. This requires making sure the specified 
technical scanner specifications and acquisition and reconstruction protocols are used, and 
nominating people responsible for scanning and QC at each institution to ensure that QC tests 
are conducted. In addition, correct data transfer methods and anonymisation of patient data are 
required. The PET Imaging Centre at St Thomas’ Hospital is the main base for the National 
Cancer Institute Research clinical trials network in the UK.  
 
1.2) Response Assessment in PET 
1.2.1) Introduction to Response Assessment 
18
F-FDG PET was first studied in assessing response in the early 1990s in a group of breast 
cancer patients undergoing chemohormonotherapy (Wahl et al., 1993). Further studies have 
shown that PET can identify whether treatment is working after days to weeks, rather than weeks 
to months compared with CT imaging (Wieder et al., 2005). This has resulted in PET/CT being 
increasingly used to investigate response to therapy in a number of different cancers, particularly 
lymphoma (Brepoels et al., 2007; Ben Haim and Ell, 2009). Comparing a pre-therapy scan with 
a post-therapy scan within a few weeks of treatment can accurately predict response to 
chemotherapy (Kostakoglu et al., 2002). Identifying whether tumours will respond within the 
 36 
first few weeks of treatment is of great clinical importance as it means non-responding patients 
do not have to undergo unsuccessful therapy reducing side effects and cost (Weber, 2005). 
 
Many criteria have been devised to assess response, mainly for anatomical measurements on CT, 
but criteria for metabolic changes on PET are now being included due to the disadvantages of 
anatomical imaging modalities and growing evidence that 
18
F-FDG uptake is a predictor of 
tumour response (Larson and Schwartz, 2006). Qualitative visual interpretation is used in the 
clinical environment along with semi-quantitative measures including standardised uptake 
values (SUVs) to quantify the amount of 
18
F-FDG uptake in a lesion. Semi-automated 
techniques for identifying response are of interest, as is research into analysing scans. A robust, 
accurate and easy to use method could potentially be a huge benefit in clinical studies and for 
diagnostic use. 
1.2.2) Qualitative Methods 
1.2.2.1) Visual Assessment 
Visual interpretation of 
18
F-FDG PET images is used clinically and has been shown to 
adequately identify patients who are likely to respond to current therapies (Miller et al., 2003). A 
study assessing 161 pulmonary nodules showed that visual assessment was as accurate as semi-
quantitative methods at distinguishing between positive and negative lesions with only faintly 
positive lesions showing better evaluation when using quantifiable SUV values (Nomori et al., 
2005). Despite its simplicity, observer variability in the reporting of PET scans is seen as an 
issue as it is not quantifiable. Semi-quantitative methods, such as SUVs, are considered more 
robust and reliable measures at predicting response in lymphoma (Lin et al., 2007), however, 
visual analysis is still used clinically and has the advantages of more intelligent interpretation of 
images. While SUVs may quantify changes in uptake, an experienced oncology clinician will 
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always be more valuable when assessing response as they can recognise where FDG uptake is 
likely to be physiological, if new lesions have appeared, and whether changes in uptake in some 
anatomy are more meaningful than in other areas. 
 
1.2.2.2) Anatomical Guidelines 
In 1981, the World Health Organisation (WHO) proposed a set of guidelines, primarily designed 
for use with X-ray and CT, suggesting the use of bidimensional measurements for identifying 
tumour response. Bidimensional measurements are obtained by taking the longest diameter of 
each tumour in one direction and multiplying this with the longest perpendicular diameter, the 
product of these measurements for each tumour can then be used to compare pre- and post- 
therapy results (Miller et al., 1981). Other groups, such as the South West Oncology Group 
(SWOG) in the United States (Green and Weiss, 1992), concurred with the WHO guidelines in 
terms of tumour measurements but suggested subtle differences in terms of response criteria, 
such as using different changes in volume to determine response categorisation. WHOs 
bidimensional method of measurement has been criticised, as the process of measuring in two 
dimensions and calculating the products is arduous and still has potential for error (Oh Park et 
al., 2003). New guidelines were introduced by the Response Evaluation Criteria in Solid 
Tumours (RECIST) Group in the late 1990s which attempted to update and simplify the WHO 
methods, most notably by proposing unidimensional measurements of tumours, taking the 
maximum 2-dimensional (2-D) diameter of each tumour in a 3-dimensional (3-D) image 
(Therasse et al., 2000).  
 
Studies have shown that RECIST correlates well with the WHO criteria, validating the more 
simplistic method of measurement as a time saving measure (James et al., 1999; Trillet-Lenoir et 
al., 2002). Other changes in the criteria have seen the percentage changes needed in tumour 
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volume (TV) for different categories of response modified, meaning that there can be 
discordance between different criteria (Julka et al., 2008) (Table 1.1). There have also been 
criteria developed for specific cancers, for example, the International Working Group criteria 
(IWC) for non-Hodgkin’s lymphoma (NHL) (Cheson et al., 1999). 
Response WHO SWOG RECIST 
Complete 
Response (CR) 
Disappearance of all 
known disease 
Complete disappearance of 
all measurable disease 
Complete disappearance of all 
target and non-target lesions 
Partial 
Response (PR) 
Decrease of  >50% in TV, 
no new lesions found 
Decrease of  >50% in TV, 
no new lesions found 
Decrease of  >30% in TV, no 
new lesions found 
Stable Disease 
(SD) 
Decrease of <50% or 
increase of <25% in TV 
Decrease of <50% or 
increase of <50% in TV 
Decrease of <30% or increase 
of <20% in TV 
Progressive 
Disease (PD) 
Increase of >25% on 
smallest measurement of 
TV or new lesion(s) found 
Increase of >50% or 
>10cm
2
 in TV or new 
lesion(s) found 
Increase of >20% over smallest 
sum of the max diameter or 
new lesion(s) found 
Table 1.1: Comparison of Anatomical Response Criteria 
WHO, SWOG and RECIST criteria have the same four categories for CR, PR, SD and PD with slight 
differences in what % changes in tumour volume (TV) warrants each type of response. 
 
The most recent adaptation of anatomical response criteria, RECIST 1.1 (Eisenhauer et al., 
2009), proposes reducing the number of lesions used for calculating total TV from a maximum 
of 10 to 5, improving simplicity without significantly affecting response categorisation. While 
all aforementioned anatomical response criteria may have developed better, more substantial and 
easier to follow guidelines over time, they all suffer from the same flaws when it comes to 
assessing response. Firstly, they rely heavily on observers measuring lesions accurately, a task 
which can result in significant inter- and intra- observer variability potentially causing 
inconsistency and incorrect interpretation of tumour response (Thiesse et al., 1997; Erasmus et 
al., 2003). Secondly, they do not take into account metabolic processes including necrosis, 
cavitation and fibrosis which can occur in tumours often meaning that a reduction in size is slow 
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or non-existent (Hicks, 2005). Finally, they do not consider metabolic imaging techniques, such 
as PET, which could potentially solve these issues. 
 
An increasing number of drugs in development do not kill cells like traditional cytotoxic 
treatments, but stop tumour cell growth (cytostatic treatment). This results in a constant tumour 
size, even if therapy is successful, meaning that anatomical TV measurements cannot be used 
accurately as an indicator of response (Tuma, 2006). PET can show changes in cell growth faster 
than anatomical imaging modalities and, therefore, is gradually being used more to identify 
response. A CT criteria based on both tumour size and density, based on Hounsfield numbers on 
contrast enhanced CT, has been suggested as a possible solution to account for changes in 
tumour density and provide similar results to PET response (Choi et al., 2007). However, it is 
clearly unlikely to compete with PET on a long term basis as PET has more functional imaging 
capabilities. 
 
1.2.2.3) Metabolic Guidelines 
The continuing use of PET/CT in clinical situations along with a wide range of literature proving 
its success at identifying response to therapy, in a variety of different cancers, has meant that 
anatomical guidelines need to be updated for PET/CT (Avril et al., 2009; Ben Haim and Ell, 
2009; Hutchings and Barrington et al., 2009; Krause et al., 2009; Schöder et al., 2009; Schwarz 
et al., 2009). The increased use of PET has led to criteria being redesigned for PET/CT imaging, 
for example, revised IWC integrating 
18
FDG-PET for response assessment in NHL (Juweid et 
al., 2005), and new criteria being developed for assessing and categorising response to therapy 
using PET. The first criteria for PET imaging was developed by the European Organisation for 
Research and Treatment of Cancer (EORTC) PET study group and made recommendations on 
patient preparation, scanning procedure and timings as well as response categories (Young et al., 
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1999) (Table 1.2). Other studies have continued to make recommendations on standards for PET 
imaging (Shankar et al., 2006; Delbeke et al., 2006; Boellaard et al., 2010). However, the only 
other guidelines to specifically look at response are the PET Response Criteria for Solid 
Tumours (PERCIST) (Wahl et al., 2009). The criteria use the same four response categories as 
EORTC criteria but are slightly updated to represent developments over the decade since 
EORTC were developed (Table 1.2). 
 




Complete resolution of FDG uptake 
within TV (Tumour Volume) 
Complete resolution of FDG uptake 
within measurable target lesion, 
indistinguishable from background levels 
Partial Metabolic 
Response (PMR) 
A reduction  >15% in tumour SUV 
Reduction of a >30% in SULpeak, absolute 
drop must be >0.8 units 
Stable Metabolic 
Disease (SMD) 
Increase in tumour SUV of <25% or 
decrease of <15% and no visible 
increase in uptake 
No more than a 30% increase or decrease 




Increase in tumour SUV of >25%, 
viable increase of uptake (20% in 
longest dimension) or uptake in a new 
lesion(s) found 
Increase of >30% in SULpeak, absolute 
increase >0.8 units. Alternatively, a 
visible increase in overall uptake (>75% 
change in TV) or new lesion(s) found 
Table 1.2: Comparison of Metabolic Response Criteria 
EORTC criterion and PERCIST have the same four categories of response: CMR, PMR, SMD and PMD. 
However, like anatomical criteria, each has differences in how change is measured and what warrants 
which response. SUL = SUV normalised using lean body mass rather than body weight. 
 
The PERCIST criterion has many similarities to RECIST as it uses similar data analysis 
methods, such as analysing up to five tumours, however, it does highlight the limitations of 
categories of response and claims that data is intrinsically continuous and should be treated as 
such. The main differences come in the guidelines for the PET scan itself and methods of 
quantification used in determining response to therapy which are different to the anatomical 
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measurements in RECIST. The maximum SUV in the tumour (SUVmax) is recommended as the 
main quantitative measure to assess response but SUVpeak, an average SUV of a small spherical 
volume around the maximum pixel/voxel, and metabolic tumour volume (MTV) measures 
combined with SUVs are suggested as possible measures for the future. The criteria also 
suggests SUV should be corrected for lean body mass (SUL) rather than body weight. The 
invention of PERCIST is a clear sign of the need for specific PET guidelines to analyse response 
to therapy. The standardisation of PET scanning to minimise variability of SUVs and produce 
reliable results relates heavily to this and is a major issue in quantification and response and is 
discussed in more detail in 1.2.6.  
1.2.3) Semi-Quantitative Methods 
Semi-quantitative methods measure the uptake of tracer in a PET image so values are relative to 
radionuclide concentration. Quantification of uptake can be calculated in an image in which 
pixel values are proportional to Bq/ml. This can be taken one step further by obtaining 









 and parameters relating to 
receptor properties such as density and occupancy (Marsden, 2004). It has been shown that for 
assessing FDG uptake in tumours, using semi-quantitative measures on static scans is adequate 
and avoids unnecessary blood sampling (Minn et al., 1993).  
 
Over two decades ago, Di Chiro and Brooks (1988) argued that quantification was not as 
important as many deemed it and that visual inspection was more accurate (Di Chiro and 
Brooks, 1988). PET imaging and related technologies have progressed since and it has been 
suggested that although quantification is not a necessary tool, it can provide useful information 
for newer observers of images to make a decision on whether a lesion is benign or malignant 
(Coleman, 2002). It has been stated that a key role of quantitation is identifying response to 
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therapy as it can be a useful tool to the oncologist in deciding whether a tumour is responding to 
treatment (Graham, 2002). Accurate quantitative analysis needs PET images which have had 
emission data corrected for random and scatter coincidences, attenuation, differences in detector 
efficiencies and detector geometry and dead-time effects (Visvikis et al, 2004). 
 
1.2.3.1) Tumour to Background Ratio 
The tumour to background ratio (T/B) ratio is an index which can be calculated from a static 
PET scan. It is a comparative guide which uses normal tissue, such as the liver or mediastinum, 
as a background measure to distinguish areas of high activity and possible tumours. However, as 
a result of using background values, it is subject to being affected by changes in normal tissues 
and is therefore regarded as an unreliable index compared to other semi-quantitative methods 
(Castell and Cook, 2008). It is rarely seen as an index for assessing response in current research, 
however, one study using contrast ratios of the brain and lung compared to tumours, found them 
to provide better results compared to SUVmax (Nomori et al., 2005). Highest activities in the 
tumour (T) and background (B), using either the lung or brain, were measured and the contrast 
ratio was calculated as (T-B) / (T+B) in each nodule as an index for uptake. 
 
1.2.3.2) Standardised Uptake Values 
The Standardised Uptake Value (SUV), also referred to as the Differential Uptake Ratio (DUR) 
or Dose Absorption Ratio (DAR), is the most popular method of quantification and is expressed 
as:  
                       [1.3] 
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where Q is radiotracer concentration (MBq/l), Qinj is injected activity (MBq) and W is body 
weight (kg) (Woodard et al., 1975). 
 
SUVs can either be taken as the mean value (SUVmean), or the SUVmax in a region or volume of 
interest (ROI/VOI) of the tumour, segmented manually or by automatic methods such as 
thresholding. SUVmax is operator independent and will almost always have the same value 
regardless of the technique used to draw the VOI. However, random errors can distort individual 
pixels so values may not be a good representation of the tumour as a whole. Due to this, SUVmean 
is used in some investigations but this causes problems as segmentation of the VOI by the 
operator is very subjective and the value will depend on the VOI selected (Berkowitz et al., 
2008). Therefore, SUVmax is usually used clinically, and in most studies, although SUVmean 
values are often recorded too.  
 
The PERCIST criteria suggest the use of the SUVpeak parameter which aims to reduce the 
potential distortion of SUVmax by taking a VOI around it. It has been thought to be a more robust 
parameter to noise than SUVmax (Lodge et al., 2012). However, there are issues in defining the 
small volume around the SUVmax as the method for doing so can vary the result considerably 
(Vanderhoek et al., 2012). A typical, normal tissue SUV is ~1. However, some organs including 
the brain and liver actively take up more FDG and will therefore have SUVs greater than this 
(Hallett et al., 2001). Equally, tissues including the lung and adipose tissue have less of a need 
for glucose and so have SUVs of <1, while most cancers will have SUV >1. A SUV of ~2.5 has 
been commonly used as a cut-off point to separate benign and malignant processes (Hicks, 
2005). 
 
SUV does not require any blood sampling and can give values that can be used to aid diagnosis. 
As a result of not requiring blood sampling, SUV needs the injected dose to be calibrated and 
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measured accurately and makes the assumption that plasma clearance will remain the same, 
which is not always the case. This is a particular issue when comparing pre and post therapy 
SUVs as plasma clearance of FDG may change after therapy due to varying uptake in other 
tissues potentially affecting the relationship between uptake at a specific time and the 
administered dose (Lammertsma et al., 2006). SUV has been claimed to be a flawed quantitative 
method as it is subjected to many sources of variability, which is particularly an issue when 
comparing SUVs over different institutes where there can be variability of up to 25% (Fahey et 
al., 2010). However, SUVs are highly reproducible on the same scanner and using the same 
protocols (Nahmias and Wahl, 2008), although there is more of an issue in tumours with low 
18
F-FDG uptake (de Langen et al., 2012). The most notable sources of variability are patient 
size, measurement times i.e. time from injection of the tracer to the start of the scan, plasma 
glucose levels, the partial volume (PV) effect and the position of the VOI. These potential 
limitations to quantification are discussed further in 1.2.3.4 to 1.2.3.8.  
 
1.2.3.3) Volumetric Measures 
The use of volumetric measures for assessing response to therapy has become popular over the 
last few years (Roedl et al., 2009; Everaert et al., 2011; Gulec et al., 2011). Using a volumetric 
parameter combining TV with the intensity of uptake within it was first introduced by Larson et 
al. (1999) and defined as total lesion glycolysis (TLG) (Larson et al., 1999). The TLG for each 
tumour can be added together to calculate a TLG value for the disease. The change between 
these parameters between pre- and post- therapy scans can be used to measure response and is 
defined as the δTLG or the Larson-Ginsberg Index (LGI): 
            [1.4] 
where 1 and 2 are pre- and post- therapy scans, respectively. 
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Other studies have used very similar measures of TV and SUVmean, differing only by 
segmentation methodology of TV, subtle corrections and terminology. The TLG has also been 
termed the effective glycolytic volume (EGV), total glycolytic volume (TGV) and metabolic 
tumour burden (MTB) or metabolic burden (MB) (Nakamoto et al., 2002; Francis et al., 2007; 
Berkowitz et al., 2008). Methodology can change slightly between studies. For example, while 
Larson et al. (1999) used a fixed ROI placed by an observer on the PET image to define TV 
(Larson et al., 1999), Berkowitz et al. (2008) used a manual segmentation on the CT and used 
the recovery coefficient (RC) to correct for the PV effect (Berkowitz et al., 2008), calculating 
MB as:   
                           [1.5] 
where VCT is the segmented CT volume and SUVmean CT is the SUVmean within the CT volume 
on the PET image. 
 
1.2.3.4) Limitations of SUV due to Scanner Issues 
SUV has become the most used semi-quantitative measure because of its normalisation and 
simplicity. However, it has a number of limitations which can cause variation in values.  With 
regards to the PET scanner itself, noise and image resolution have been shown to have a 
substantial impact (up to 50%) on SUVs in phantom simulations, however, SUV ratios used for 
response monitoring are not affected as much, implying SUVs may be better equipped to deal 
with identifying response (Boellaard et al., 2004).  
 
Differences in SUV of up to 40% between high (7mm) and low (10mm) resolution images have 
been reported (Westerterp et al., 2007), corresponding with similar results when reconstructing 
data with less iterations than normal, although there has been no significant differences found 
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between measured and segmented AC methods (Jaskowiak et al., 2005). Significant differences 
in SUV were found when using different numbers of iterations and subsets in OSEM and FBP 
reconstruction algorithms (Visvikis et al., 2001; Ivanovic et al., 2004), although no statistical 
differences between SUVs on OSEM and FBP reconstructed images have been reported (Krak et 
al., 2005). The effect of the PET/CT hardware used and the positioning of the subject has little 
effect on SUVs (Doot et al., 2007), however, sufficient calibration of the PET scanner should be 
conducted before obtaining images for quantification to establish accuracy of at least 10% 
(Geworski et al., 2002). 
 
1.2.3.5) Limitations of SUV due to Physiology 
Body weight is commonly used to normalise body concentration for SUVs, however, it can be 
inaccurate because it does not give a specific volume and can be variable. This is particularly 
true in patients with a high body mass index (BMI) who have higher SUVs than they should 
because of the low uptake of FDG in adipose tissue. Due to this, other normalisation methods 
have been suggested. SUL (or SUV-lean or SUVLBM) replaces body weight with lean body mass 
(LBM) for normalising SUV (Zasadny and Wahl, 1993). Similarly, SUVBSA replaces body 
weight with body surface area (BSA) for normalising SUV (Kim et al., 1994), and has been 
found to correlate with kinetic modelling methods better than SUV normalised by body weight 
(Graham et al., 2000). 
 
However, a study has shown that the method of estimating LBM for SUVs can cause substantial 
error in comparison to accurate dual-energy X-ray absorptiometry (DEXA) (Erselcan et al., 
2002). In addition, these methods only improve characteristics of SUVs over the population as a 
whole, as identifying abnormal uptake requires estimation of normal values which depend 
entirely on the patients in the study (Hallett et al., 2004). A weight index (SUVm) has been 
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proposed to reduce variability where the coefficient of variation of SUVs was below a third 
(Thie et al., 2007). This approach means population averages are dimensionless unlike SUVLBM 
or SUVBSA. 
 
The amount of blood glucose is another psychological factor which can cause variation in SUVs 
as SUV can be reduced if there is more glucose to compete with FDG. This has been studied in 
head and neck cancer patients and in bronchial carcinomas (Langen et al., 1993; Lindholm et al., 
1993). Both investigations found differences in SUVs and this has led to corrections for blood 
glucose (SUV x glucose) being used in calculating SUVs, however, these have not always led to 
better results (Diederichs et al., 1998; Hallett et al., 2001). There are conflicting results with 
regards to the effect of glucose on SUV. One study has shown that SUVs for lung tumours in 
diabetic patients (with elevated glucose levels) were not significantly different to those from 
non-diabetic patients (Gorenberg et al., 2002). However, it has been suggested that this may be 
due to differences in tumour type and glucose transporter expression (Hallett, 2004). Generally, 
none of the correction methods mentioned have been fully validated and a study using different 
methods of correcting SUV for blood glucose, tumour size and BSA/LBM in lung nodules 
showed no improvement in accuracy compared to traditionally calculated SUV (Menda et al., 
2001). 
 
Other physiological factors which can affect SUV include patient breathing or motion and 
inflammatory processes (Erdi et al., 2004; Boellaard et al., 2008). Patient breathing and motion 
can cause resolution loss and artefacts and when imaging the lungs, changes in motion of 10mm 
have been found to cause SUV changes of 20% (Erdi et al., 2004). SUVs can be affected by 
tense patients and uncomfortable conditions which can cause increased FDG uptake in muscle 
and brown fat which will have an effect on the image, and therefore the SUV (Boellaard et al., 
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2008). Finally, inflammatory processes can also cause FDG uptake, and if this occurs around 
tumour areas there can be false positive results (Boellaard et al., 2008). 
 
1.2.3.6) Limitations of SUV due to Partial Volume Effect 
The PV effect describes what happens when signal intensities mix near the boundaries of tissues 
causing loss of intensity in small objects such as tumours (Figure 1.4). The effect arises from 
limited spatial resolution which can produce inaccurate and blurred images. This is of a 
particular problem in PET studies where resolution is not as high as other modalities including 
CT or MRI. The PV effect has been shown to underestimate small lung lesion phantoms by up to 
91% (Feuardent et al., 2005). 
 
 
Figure 1.4: Partial Volume Effect in a Phantom Image 
The phantom contains a number of cylinders of the same activity but the measured activity decreases 
depending on the size of the cylinder due to the PV effect (Taken from Barrington, 2006). 
 
PV corrected images can give better T/B ratios and improve quantitative image analysis. There 
have been many differing approaches to PV correction including noise models and geometric 
transform matrix (GTM) models (Rousset et al., 1998; Aston et al., 2002; Frouin et al., 2002), 
which incorporate popular use of high resolution magnetic resonance (MR) images in 
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combination with the known point spread function (PSF) of the imaging system (Bencherif et 
al., 2004; Quarantelli et al., 2004). 
 
Kessler et al. (1984) introduced the RC, a ratio of observed intensity to true intensity that can be 
seen in an image (Kessler et al., 1984). This ratio can be used to boost observed intensities up to 
the true values and has been used in a number of studies (Uemura et al., 2000; Asselin et al., 
2004; Teo et al., 2007). It has been stated that PV correction of SUV produces a more accurate 
assessment of disease activity and will help in prognosis (Basu and Alavi, 2007), however, until 
an accepted method of PV correction is available care must be taken to standardise acquisition 
and analysis (Soret et al., 2007). Although correction for PV may improve the estimation of 
uptake, most techniques are so sensitive to object size, shape and heterogeneity there is a limit to 
how much they can achieve (Hallett, 2004). For any object smaller than about two times the full 
width half maximum (FWHM), typically less than 15-20mm, there is no accurate and precise 
method for correction available (Boellaard et al, 2008).  
 
SUVs of small lesions (<2cm) have been corrected for the PV effect by using CT data to 
measure the lesion and calculating a corrected SUV using this lesion size (Hickeson et al., 
2002). This is defined as: 
        [1.6] 
where background activity = activity / volume in background * (region’s volume – lesion’s size 
on CT cm
3
). This calculation of SUV corrects for the understimation of true metabolic activity of 
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a lesion caused by resolution (by subtracting background activity) and partial volume effects (by 
using the lesion size on CT). The problem with this technique is it assumes that anatomical CT 
TV and PET MTV are the same and this is not always the case.  
 
1.2.3.7) Limitations of SUV due to Imaging Time 
The time between the injection of FDG and the start of the scan can cause variation in SUV as 
concentrations of FDG take time to reach a plateau before imaging. In patients with lung cancer, 
an approximate 60min wait was found to underestimate SUV significantly in most tumours, as 
FDG uptake continues past 60min and does not reach 95% plateau until, on average, 298min 
pre-treatment and 154min post-treatment (Hamberg et al., 1994). These findings have been 
supported by further evidence showing increases in SUV of up to 30% and greater tumour 
detectability depending on the time delay between FDG injection and the start of scanning 
(Hustinx et al., 1999; Lodge et al., 1999; Stahl et al., 2004). Although these findings suggest a 
longer waiting time before scanning would be beneficially, practically it is usually not feasible. 
An imaging time of between 50-70min after injection is considered both optimal and practical by 
the EORTC, PERCIST and other studies (Lowe et al., 1995; Young et al., 1999; Wahl et al., 
2009).  
 
1.2.3.8) Other Limitations of SUV 
SUVs can be affected by inaccurate measurement of FDG administration. Errors can arise due to 
inaccurate cross-calibration between the PET scanner and dose calibrator for measuring patient 
dose, unaccounted for residual activity in the syringe (or other administration system), and the 
use of injection time in calculations instead of dose calibration time (Boellaard et al., 2008). 
SUVs can also be affected by respiratory motion (Goerres et al., 2002a), the presence of metal 
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implants or prostheses (Goerres et al., 2002b; Goerres et al., 2003b; Kamel et al., 2003), and the 
use of CT contrast agents such as Iodine and Barium (Antoch et al., 2003; Cohade et al., 2003). 
All can cause artefacts and over- or under- estimate tracer concentration activity, affecting SUVs 
by ~5% in regard to contrast agents (Dizendorf et al., 2003). Respiration artefacts can be limited 
by using breathing protocols, such as free breathing and normal expiration, during image 
acquisition but these do not produce perfect results (Goerres et al., 2003a).  
 
One of the major problems with SUVs is that comparing values from different institutes is 
problematic because of all the limitations noted. Any cut-off values designed to estimate, for 
example, whether a tumour is malignant or benign are often institute specific, particularly if they 
are affected by differences in acquisition protocols, reconstruction algorithms and ROI definition 
(Lammertsma et al., 2006). This is one of the reasons why standardisation is required, to 
minimise fluctuations so that semi-quantitative analysis techniques can be used across 
institutions in MCTs. It is important to note that despite these limitations SUVs are still reliable 
and reproducible within an institute, as has been shown in a number of studies (Minn et al., 
1995; Nakamoto et al., 2002; Paquet et al., 2004). 
1.2.4) Full Quantitative Methods using Kinetic Models 
1.2.4.1) Kinetic Modelling 
Kinetic modelling links measured activity levels in functional scans with physiological 
parameters such as the metabolism of glucose by tumours, organs, and tissues, mathematically 
describing the movement of FDG in cells (Basu et al., 2007). Modelling was first used to 
calculate glucose utilisation in the brain (Sokoloff et al., 1977; Reivich et al., 1979; Phelps et al., 
1979). FDG enters glucose-consuming cells via glucose transporters (GLUTs) where it is 
 52 
phosphorylated by hexokinases. Unless dephosphorylation occurs, phosphorylated FDG remains 
trapped in the cell (Castell and Cook, 2008). 
 
1.2.4.2) Nonlinear Regression 
Nonlinear Regression (NLR) analysis is the most complex method of quantification used in PET 
studies. It has been adapted for use outside of the brain to evaluate glucose metabolism in 
specific lesions, for example, in liver tumours (Okazumi et al., 1992). A generalised version of 
the compartmental model used to achieve this is shown in Figure 1.5. 
 
 
Figure 1.5: Three Compartmental Model of FDG Behaviour 
The model uses rate constants to evaluate glucose metabolism (Taken from Basu et al., 2007). 
 
NLR uses an algorithm which fits values to rate constants, typically by nonlinear least squares, 
using a two or three compartmental model with an arterial plasma input to measure the net influx 
rate constant for FDG (Castell and Cook, 2008). This can be defined as:  
                                                      [1.7]  
where MRglu is the glucose metabolic rate (MRglu), Cp is the plasma glucose concentration, K1 
and k2 are rate constants for forward and reverse transport of FDG respectively, Ki is the net rate 
of influx and LC is the lumped constant (Basu et al., 2007). There are now many different 
versions of this technique, from even more complex methods involving two ROIs and six 
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compartments (Wu et al., 1995), to time saving variants including the simplified kinetic method 
(SKM) which requires just one venous blood sample (Hunter et al., 1996), and the Sadato 
method which estimates Ki based on its relationship with SUV (Sadato et al., 1998). The most 
widely used simplified method is Patlak analysis. 
 
1.2.4.3) Patlak Analysis 
Patlak analysis is a simplified method of NLR and was originally developed for evaluating 
transfer constants from blood to brain (Patlak et al., 1984). It is a linearisation of the NLR model 
and still needs dynamic scanning and an arterial input function (AIF) for worthwhile results, but 
is a more rapid and robust method and produces results which correlate well with NLR 
(Cheebsumon et al., 2011). Simplifications mean there is no separation between GLUTs and 
hexokinases, and dephosphroylation is assumed to be negligible, making it less accurate in 
comparison to NLR. However, Patlak analysis does allow the possibility of generating functional 
images of metabolism using pixel level calculations (Lammertsma, 2001). 
 
Less invasive methods of blood sampling have been suggested for Patlak analysis. A population-
based arterial blood curve using data from 10 patients has been developed (Takikawa et al., 
1993), as has image derived input functions (IDIFs) for non-invasive quantification of the 
cerebral metabolic rate (Chen et al., 1998). Both techniques show good correlation with real 
arterial input, making them worthwhile alternatives but further validation is required and they 
will still lack the accuracy of blood sampling. Patlak separates out metabolised and 
unmetabolised FDG in blood and intracellular spaces of the cell and by using arterial sampling, 
the integral under the AIF can be used for more accurate normalisation in compared to SUV 
(Freedman et al., 2003). 
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1.2.4.4) Limitations of Kinetic Modelling 
While NLR provides one of the most accurate estimates of tumour glucose use, it comes at the 
cost of time and inconvenience as it needs arterial blood sampling (Dimitrakopoulou-Strauss et 
al., 2002). Due to this, it is rarely used in clinical settings as absolute quantification is not 
usually necessary and limited statistical data can lead to errors in fitted parameters. More 
simplified modelling approaches, such as Patlak analysis, also have similar issues (Hallett, 
2004). Although there is a need for these techniques, the complexity and time taken to conduct 
them makes it impractical in a clinical context. As a result, these techniques are not explored 
further as the clinical data that will be investigated are static scans with no arterial sampling so 
kinetic modelling would not be possible. Therefore, the main focus will be on SUVs and other 
semi-quantitative methods, such as volumetric measures. 
1.2.5) Comparison of Quantitative Methods 
Quantitative methods have correlated well with each other in a number of studies with NLR 
being used as the gold standard (Graham et al., 2000; Wu et al., 2001; Hoekstra et al., 2002; 
Kroep et al., 2003; Krak et al., 2003; Brenner et al., 2004). SUVs are the simplest form of 
quantitative measurement but results suggest that despite their limitations they are reliable and 
can be used successfully. While NLR and Patlak analysis provide greater accuracy and have the 
ability to give exact biological values for specific processes, SUVs offer a reliable method of 
identifying response to therapy in a clinical environment where kinetic modelling is not possible. 
Despite positive correlations, discrepancies can be found between methods and these must be 
considered (Freedman et al., 2003). 
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1.2.6) Imaging Recommendations for Response Assessment and Quantification 
To produce accurate and reproducible data a number of reports have described standardised 
methodology and protocols for PET scanning for accurate quantification of images and 
identifying response to therapy. They include the EORTC guidelines (Young et al., 1999), 
National Cancer Institute (NCI) consensus recommendations (Shankar et al., 2006), Procedure 
Guideline for Tumor Imaging 1.0 (Delbeke et al., 2006), PERCIST (Wahl et al., 2009), and 
European Association of Nuclear Medicine (EANM) procedure guidelines for tumour imaging 
(Boellaard et al., 2010), the latter being heavily drawn from the Netherlands protocol (Boellaard 
et al., 2008).  
 
There are differences between the guidelines but they mostly agree on specific standards in PET 
imaging (Table 1.3). These include: (i) Patients should be fasting for at least 4-6h before a PET 
scan, (ii) patients should be well hydrated, (iii) patients should not have done any strenuous 
exercise before the scan, and (iv) plasma glucose levels should be <200mg/dl. Before the scan, 
patients should be resting in a warm, dimly lit, quiet room and should urinate before the start of 
the scan. There should be ~1h wait between the injection of 
18
F-FDG and the start of the scan 
with this time gap made standard for all scans. The timing of the post-treatment scan should be 
between 10-14 days after the start of treatment. The aspect of the guidelines which differs most 
is the way images should be analysed, with varying standards suggested in terms of correction of 
SUVs, response measurements and how TV should be obtained. 
 
Overall, the guidelines are very similar and are designed to get the most reproducible 
18
F-FDG 
uptake and SUV measurements possible, preventing variations between scans. This is of 
particular importance in MCTs where camera calibration, image reconstruction and data 
analysis/settings can mean a variability of more than 50% on SUVs (Boellaard et al., 2009). 
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Changes in SUV of up to 25% are possible due to instrument and analysis factors from different 
centres, however, this is reducible by using a central reading from one institute and performing 
rigorous quality control procedures (Fahey et al., 2010). Inter-institution calibration and a 
standardised scanning methodology along with strict quality control measures are vital to the 
success of MCTs and strict standardisation of PET imaging is of the utmost importance 
(Boellaard et al., 2010).  
 
Currently, improvement in this area is needed as recent reports by eight imaging response 
assessment teams, funded by the NCI, showed there were major areas of variation in 
18
F-FDG 
dose, uptake time, handling of diabetic patients, duration of fasting and acquisition protocols 
used (Beyer et al., 2011; Graham et al., 2011). This is why a standardised and globally accepted 
procedure of 
18
F-FDG PET/CT imaging is needed in all quantitative studies both in research and 
clinical, diagnostic practice (Boellaard et al., 2011). Factors affecting quantifying tracer uptake 
and ways to correct issues such as calibration errors are being investigated (Doot et al., 2010; 
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Mentions the use 




delineation using  
thresholding 
Table 1.3: Comparison of Guidelines for 
18
F-FDG PET Response Assessment  
The five guidelines compared are (i) EORTC criteria (Young et al., 1999), (ii) Consensus 
Recommendations in NCI trials (Shankar et al., 2006), (iii) Procedure Guideline for Tumor Imaging 1.0 
(Delbeke et al., 2006), (iv) PERCIST (Wahl et al., 2009), and (v) EANM Procedure Guidelines for 
Tumour Imaging (Boellaard et al., 2010). Specific guidelines compared are (a) minimum amount of time a 
patient should fast before a scan, (b) recommendations for the hydration and exercise of the patient before 
a scan, (c) the plasma glucose levels that are expected and the maximum level over which a scan would be 
cancelled, (d) guidelines for patient preparation, (e) the scanning start time from 
18
F-FDG injection, (f) the 
time between the first treatment of the patient and the post-therapy scan, and (g) guidelines for image 
analysis. GL = Glucose Level. N/A = Not Applicable. SUVLBM = SUL. 
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1.3) Image Analysis for Identifying Response to Therapy 
1.3.1) Overview of Image Analysis for Identifying Response 
Identifying response to therapy can involve many methodologies for categorising and scoring 
response between pre- and post- therapy images. Qualitative techniques, including visual 
analysis by trained consultants, are predominantly used in the clinical environment but there is a 
great deal of interest and research in quantitative methods (Tomasi et al., 2012; Lambin et al., 
2012). Image analysis techniques can produce quantitative measurements, including SUVs and 
TVs, which could be of great benefit in early response assessment and in MCTs where 
qualitative methods are flawed due to a lack of comparability and reproducibility (Tomasi et al., 
2012). Image analysis can come in many different forms but in terms of medical imaging, and 
PET studies in particular, some of the main tools are the ability to register images, segment 
tumours and extract intensity data such as SUVs and histograms. Other techniques such as 
quantifying texture and shape in an image by analysing the spatial distribution of voxels and 
their intensities could also be useful in identifying response in pre- and post- therapy PET/CT 
studies. While there has been a great deal of research in the use of SUVs, assessing response to 
therapy using TV, TLG, intensity volume histogram (IVH) parameters and texture analysis is 
gaining a lot of interest in research (Tomasi and Rosso, 2012). These methods may provide more 
information, related to the size, variation, and pattern of intensity within a tumour rather than 
just a maximum value, and this is very appealing for assessing response. 
1.3.2) Image Registration 
The goal of image registration is to match two images so that corresponding features are aligned 
with one another. This can mean registering different patients, different modalities, scans at 
different times, including differences in motion between scans within a few minutes of each 
other, or a combination of all three. To achieve this, a spatial transform is obtained which maps 
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the points on one image to those on another. Registration techniques can be classified in various 
ways. Rigid registration describes techniques which involve the rotation and translation of one 
image to match a target image, while non-rigid registration not only allows rotation and 
translation but also stretching and deformation of images in order to match them. This is often 
needed due to image acquisition or biological differences, including differing image protocols 
and patient positioning (Crum et al., 2004). A registration algorithm is usually made up of three 
components. A similarity measure which dictates how well the two images are matched, a 
transformation model which specifies how the source image is changed to match the target and 
an optimisation process which varies transformation parameters in order to get the best 
registration (Crum et al., 2004). Registration is rarely used routinely in a clinical environment 
but is widely used in research, particularly rigid algorithms for registering brain images.  
 
Registration of PET/CT studies is occasionally done clinically to allow a clinician to align pre- 
and post- therapy scans with each other to aid visual analysis. This is usually done using simple 
manual registration or by a computationally efficient rigid algorithm as precise and accurate 
registration is not of critical importance in this scenario. For more quantitative purposes, more 
accurate registration is required and different techniques are applied. For assessing response to 
therapy, the most interesting prospect for registered pre- and post- therapy PET/CT images is the 
use of parametric or subtraction images to characterise tumour change. This concept was first 
investigated in 15 patients with lung cancer and has since been used to successfully predict 
RECIST-based response on CT scans performed 5-8 weeks after initial post-therapy PET/CT 
scans in 28 patients with colorectal cancer (Necib et al., 2008; Necib et al., 2011). Parametric 
images were obtained by rigidly registering CT images and applying the transformation to the 
PET component of the PET/CT scans. Bi-parametric graphs of tumour voxels in the pre- therapy 
PET scan can be plotted against the voxels of the subtracted PET image (pre-therapy – post-
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therapy) (Figure 1.6). It is claimed that the volume affected by changes in intensity and mean 
change in SUV within this volume can be used to identify response to therapy.  
 
Figure 1.6: Bi-parametric Graph using a Subtraction Image 
The graph plots voxels from a liver tumour on the subtraction image (pre-therapy PET – post-therapy 
PET) with the pre-therapy image to see if changes in intensities can be identified (Taken from Necib et al., 
2011). 
 
1.3.3) Tumour Volume and Total Lesion Glycolysis  
TV and TLG are being increasingly used in quantifying response in pre- and post- therapy PET 
scans (Francis et al., 2007; Berkowitz et al., 2008; Benz et al., 2008; Roedl et al., 2009; Everaert 
et al., 2011; Gulec et al., 2011). While the basis of these metabolic measurements remain the 
same, methodology changes slightly depending on the type of cancer investigated, correction 
factors used and, principally, the segmentation method used for obtaining TV. Table 1.4 
illustrates the differing use of TLG, and its many other terminologies, in a number of PET 
studies using TV and TLG.  
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Study Type of Cancer Term Used Segmentation(s) Used 
Larson et al. (1999) 
Lung, rectal, esophageal 
and gastric 
TLG 40% of SUVmax 
Akhurst et al. (2000) Renal TLG Manual Segmentation 
Bural et al. (2006) 
Atherosclerosis in the 
aorta 
Atherosclerotic 
burden / MTB 
Manual Segmentation 
Francis et al. (2007) Mesothelioma TGV 
GRAB algorithm - uses 
SUVmean and BG based 
threshold 
Benz et al. (2008) Soft tissue Sarcoma TLG CT segmentation 
Berkowitz et al. 
(2008) 
NHL MTB 
CT segmentation or 40% of 
SUVmax 
Boucek et al. (2008) Phantom Study TGV 
50% of SUVmax, BG adapted 
and GRAB algorithm 
Costelloe et al. (2009) Osteosarcoma TLG Manual Segmentation 
Roedl et al. (2009) 
Esophageal 
adenocarcinoma 
TLG Fixed 2.5 SUV threshold 
Lee et al. (2010) Mesothelioma TLG 
PERCIST criteria: liver BG + 
2 S.D 
Nowak et al. (2010) Mesothelioma TGV GRAB algorithm 
Arslan et al. (2011) Small cell lung cancer TLG 
Fixed 2.5 SUV and 50% of 
SUVmax 
Everaert et al. (2011) Rectal adenocarcinoma TGV 
2.5 SUV threshold in Manual 
Segmentation  
Gulec et al. (2011) 
Colorectal cancer in liver 
metastases 
TLG Threshold of liver SUVmax 
Hatt et al. (2011) Oesophageal TLG 
FLAB probability method and 
adaptive threshold. 
Abd El-Hafez et al. 
(2012) 
Oral cavity squamous cell 
carcinoma 
TLG Fixed 3 SUV threshold 
Chen et al. (2012) NSCLC TLG 50% of SUVmax 
Chung et al. (2012) Ovarian TLG 40% of SUVmax 
Dibble et al. (2012) Oropharyngeal squamous 
cell carcinoma 
TGA 
Gradient-based method and 
38%, 50% and 60% of SUVmax 
Lim et al. (2012) TLG 42% of SUVmax 
Im et al. (2012) Osteosarcoma TLG 
Various fixed thresholds of 
SUV 
Liao et al. (2012) NSCLC TLG Gradient-based method 
Sharma et al. (2012) Lymphoma (Paediatrics) MTB 
% of SUVmax dependent on CT 
tumour length 
Zhang et al. (2012) NSCLC TLG Gradient-based method 
Table 1.4: Comparison of Literature using Tumour Volume and Total Lesion Glycolysis in PET 
Comparison of PET studies investigating TV and TLG showing different terminology, segmentation 
methods and types of patients. All definitions of TLG, TGV, MTB and total glycolytic activity (TGA) 
were calculated as TV * SUVmean within TV. The exception being a study by Larson et al. (1999) in which 
SUVmean was taken as a large 2-D ROI around the SUVmax rather than the whole segmented TV (Larson et 
al., 1999). Segmentation methods are discussed in 1.3.4. BG = Background. 
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Table 1.4 includes some studies using TV and TLG on just pre-therapy scans rather than a 
comparison between pre- and post- therapy scans but the methodology for obtaining the 
measures is the same. Studies used typical SUV measurements with a few exceptions which 
used SUL (Costelloe et al., 2009), SUV corrected for plasma glucose levels (Larson et al., 
1999), and the use of RC on small tumours (Berkowitz et al., 2008). Success of using TV and 
TLG measures to predict response to therapy has been mixed. While some studies show they 
perform more favourably than measures such as SUVmax (Francis et al., 2007; Berkowitz et al., 
2008; Roedl et al., 2009; Hyun et al., 2010; Lee et al., 2010), others have found the reverse 
(Benz et al., 2008; Costelloe et al., 2009; Everaert et al., 2011). There is enough evidence of 
success to suggest these methods require further investigation and differing results are likely due 
to different types of cancer and segmentation methods, the latter being an increasingly prominent 
area of image analysis in PET studies in its own right. As the terms TLG, TGV, TGA, and MTB 
all refer to the same calculation of the product of TV and SUVmean within the TV, to avoid 
confusion this measurement will be defined as TLG. 
1.3.4) Image Segmentation 
The aim of segmentation is to accurately delineate a particular object from the rest of the image 
whether this is an anatomical landmark on an MRI image, a tumour on a CT image or high areas 
of uptake on a PET image. The segmentation of disease on a PET image is needed to assess TV 
and TLG and is also necessary for other methods of analysis. An obvious method of 
segmentation, used often in radiotherapy planning, is visual contouring of a tumour on 
individual 2-D slices, over a 3-D image, by an experienced physician (Avril et al., 1997). The 
main limitation with this technique is there is a degree of observer variability, as each physician 
will segment lesions differently. Many user-defined protocols have been constructed to try to 
reduce this variability with some success (MacManus et al., 2007). However, observer 
variability will always be an issue when using user defined contouring to segment tumours on 
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PET images and this had led to the development of a number of semi-automated and automated 
methods for segmenting PET lesions. 
 
Semi-automated threshold contouring allows the segmentation of a PET lesion based on a 
threshold, whereby all voxels in the tumour area are included if they are above the threshold 
value. Typical region growing algorithms would ‘grow’ from a user defined starting point placed 
somewhere in the tumour and include all connected voxels above the threshold to create a TV. 
There are a number of ways to choose a threshold including taking a percentage of the SUVmax 
(Erdi et al., 1997), using a fixed SUV (Paulino and Johnstone, 2004), or by using a calculation 
which takes into account background intensity in the image (Boellaard et al., 2004). Using a 
fixed SUV as a cut off for segmentation is useful for many reasons. Its simplicity makes it easy 
to implement and for physicians to understand what has been segmented and an SUV of 2.5 has 
been shown to be useful for separating benign and malignant tumour (Paulino and Johnstone, 
2004). It should be noted that some disease can have a SUV of <2.5 while many active 
inflammatory processes can have SUVs higher than this (Hicks, 2005; Kinahan and Fletcher, 
2010). The main limitation with using a fixed SUV threshold is that there are no ‘normal’ SUVs 
as they are too easily affected by bias and so using a fixed value, particularly from different 
scanners or centres, is unrealistic as SUVs are likely to be inconsistent (Boellaard, 2009). 
 
Taking a percentage of the SUVmax does not face the same problem as using a fixed SUV, in that 
it does not rely on the same SUV for all tumours/images and, therefore, does not suffer from a 
dependence on consistent SUVs, as there can be significant variation (Boellaard et al., 2004). It 
does suffer from the fact that the optimal percentage is often so different for each individual 
lesion on each image that a fixed percentage is unlikely to be the best threshold to obtain the 
correct SUV for segmenting the tumour. Different percentages of SUVmax for tumour 
segmentation are often used for different studies (Erdi et al., 1997; Boellaard et al., 2004; 
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Boucek et al., 2008; Dibble et al., 2012), the percentage used seemingly dependent on the data 
in question and the author’s discretion. It is acknowledged there is no one appropriate percentage 
of SUVmax which can be used as an optimal threshold (Biehl et al., 2006). Rather than use 
SUVmax, region growing techniques can use SUVmean of a region to calculate a fixed threshold 
(Black et al., 2004), or continually adapt the threshold to a percentage of SUVmean as the region 
grows (Green et al., 2008). These methods eradicate the problem of finding an optimal threshold 
% of SUVmax but only take into account the tumour and not the intensity of the background 
around it. 
 
The source-to-background (S/B) ratio in PET images can be an important factor in obtaining the 
correct TV and this has lead to segmentation methods which use a background VOI rather than 
tumour values (Zasadny et al., 1998; Wahl et al., 2009; Gulec et al., 2011). PERCIST guidelines 
suggest segmentation should be based on a threshold equal to normal-liver mean, based on a 
ROI of 3cm in diameter, plus two standard deviations (S.D.) (Wahl et al., 2009). This 
calculation was originally proposed by Zasadny et al. (1998), adding three S.D. to the mean 
rather than two. Another study investigating TLG measurements used a background value equal 
to the SUVmax in the liver to segment disease (Gulec et al., 2011). The combination of 
background and SUVmax to determine the threshold for segmentation has been used with a 
threshold based on 50% of the background and SUVmax (Boellaard et al., 2004). 
 
Many methods have investigated the relationship between tumour SUV, background SUV, T/B 
ratios and tumour size (Daisne et al., 2003; Yaremko et al., 2005; Davis et al., 2006; Drever et 
al., 2006; Van Dalen et al., 2007; Jentzen et al., 2007; Nehmeh et al., 2009). Two of these 
algorithms use a threshold based on the background added to a certain percentage of a SUVmax 
background corrected value (SUVmax – background), where the percentage is determined by the 
contrast level and/or tumour size based on phantom experiments (Davis et al., 2006; Drever et 
 65 
al., 2006). Other methods use a similarly constructed methodology and formula but continually 
adapt the percentage or relative threshold level (RTL) to iteratively calculate the correct RTL 
until it does not deviate significantly from the last iteration (Van Dalen et al., 2007; Jentzen et 
al., 2007; Nehmeh et al., 2009). The issue with these types of methods is by using phantom 
measurements and parameters specific to a particular PET scanner, the methodology is not easily 
transferable from one PET system to another (Lee, 2010). 
 
Similar methods have also used SUVmean of a tumour rather than SUVmax along with background 
to define a threshold. Two studies investigating the relationship between the optimal threshold 
and tumour SUVmean and background came up with similar calculations for a threshold for 
segmentation based on the SUVmean, background and constant variables (Nestle et al., 2005; 
Nestle et al., 2007). Additionally, an adaptive region growing segmentation method has been 
described which uses both SUVmean and background to segment PET tumours (Boucek et al., 
2008), a modification of the algorithm using just SUVmean (Green et al., 2008). The disadvantage 
of using background uptake in segmentation methods is the background region is likely to vary 
depending on how the VOI is obtained, particularly if it needs user input as it means there will 
be intra- and inter- observer variability. This means that the segmentation will not be 
reproducible as the threshold will change depending on the background region used. Threshold 
based segmentation methods are summarised in Table 1.5. 
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Study Segmentation Type Segmentation Methodology 
Avril et al. 
(1997) 
Manual Delineation 





Fixed Threshold based 
on SUV 
Fixed 2.5 SUV threshold 
Erdi et al. 
(1997) Threshold using % of 
SUVmax 
3-D isocontour of ~40% of SUVmax 
Boellaard et 
al. (2004) 
3-D isocontour of 50% of SUVmax 
3-D isocontour of 70% of SUVmax 
Threshold using 
SUVmax and BG 
3-D isocontour with threshold halfway (50%) between BG 
and SUVmax i.e. 0.5(Max + BG) 
3-D isocontour with threshold 70% of BG and SUVmax  
i.e. 0.7(Max + BG) 




Threshold = 0.307 * SUVmean + 0.588. Based on linear 
regression function from phantom experiments 




Adaptive region growing method which uses a % of the 
SUVmean, which changes with each iteration 
Zasadny et 
al. (1998) 
Threshold using BG Threshold = mean of normal liver + 3 S.D 
Wahl et al. 
(2009) 
Threshold using BG 
Threshold = mean of normal liver + 2 S.D., based on a VOI of 
3cm in diameter in the right hepatic lobe of the liver 
Gulec et al. 
(2011) 
Threshold using BG Threshold = SUVmax in the liver 
Davis et al. 
(2006) 
Threshold using 
SUVmax and BG 
Threshold = BG + Relative Threshold (SUVmax – BG), 
relative threshold based on phantom measurements 
Drever et al. 
(2006) 
Threshold using 
SUVmax and BG 
Threshold  = Contrast Level (%) * (SUVmax – BG) + BG, 
based on phantom measurements 
Nestle et al. 
(2005) 
Threshold using 
SUVmean and BG. 
Threshold = (0.15 * SUVmean) + BG where SUVmean is taken 
from 70% of SUVmax segmentation 
Nestle et al. 
(2007) 
Threshold using 
SUVmean and BG. 
Threshold = (0.7 * SUVmean) + (0.5 * BG) where SUVmean is 
taken from 70% of SUVmax segmentation 
Boucek et al. 
(2008) 
Threshold using 
SUVmean and BG. 
Adaptive region growing method which uses a threshold 
called maximum normal level (MNL) = BG + 3 S.D. and 
SUVmean to create a VOI of the tumour 
Jentzen et al. 
(2007) 
Iterative Thresholding 
Iteratively calculates the optimal threshold based on signal-to-
background threshold-volume curves derived from phantom 
measurements 
Van Dalen et 
al. (2007) 
Iterative Thresholding 
Iteratively calculates threshold using relative threshold level 
(RTL) = (Threshold – BG) / (SUVmax – BG) where RTL is 




Iteratively calculates the optimal threshold based on target-to-
background ratio and lesion volume using a Monte Carlo 
based mathematical model 
Table 1.5: Comparison of Threshold Based PET Segmentation Methods 




There are more sophisticated methods of PET tumour segmentation than thresholding methods. 
Traditional region growing techniques have been combined with dual active contours and have 
shown success at delineating tumours in PET phantom studies (El Naqa et al., 2007; Li et al., 
2008).  Gradient-based segmentation attempts to identify changes in the gradient in an image to 
detect borders of tumours. A gradient-based algorithm, applying the watershed transform and 
cluster analysis, has shown initial success on phantom studies (Geets et al., 2007). Probability 
based methods have been found to be accurate in segmenting PET tumours using a fuzzy locally 
adaptive Bayesian (FLAB) approach, showing good initial results and continued success on 
more data (Hatt et al., 2009; Hatt et al., 2010). Recent studies have investigated the use of 
artificial intelligence, in the form of neural networks, and possibility theory in delineating 
tumours on PET (Sharif et al., 2010; Dewalle-Vignion et al., 2011). While all these methods 
may provide a better solution to the problem of segmenting PET tumours in time, their 
development is at the early stages and they are difficult to implement into clinically based 
software. Table 1.6 summarises these more advanced segmentation methods. 
 
Study Segmentation Type Segmentation Methodology 




Gradient based method which uses the watershed transform 
and hierarchical cluster analysis 
El Naqa et al. 
(2007) 
Dual Active Contours 
Uses dual active contours to identify edges of tumour and 
background to compute tumour delineation 
Li et al. 
(2008) 
Thresholding + Dual 
Active Contours 
Uses adaptive thresholding based on volume changes at 
SUVmax %s and then applies dual active contours 




Uses probability theory in the form of a Fuzzy Locally 
Adaptive Bayesian (FLAB) based method 




Artificial neural networks are used in the wavelet domain to 
segment PET lesions 
Dewalle-




Uses possibility theory to avoid the use of binary values for 
edge voxels in a volume, using fuzzy c-means clustering to 
determine volume delineation 




The issue of PET segmentation is made particularly problematic due to the lack of a clearly 
identified gold standard to compare delineation methods to. Segmentations are compared to 
phantom images, simulated data, segmented CT volumes and histopathology but all of these 
come with their own problems. Testing algorithms against spheres and phantoms, with well-
defined homogenous uptake, may provide accurate results but cannot produce more realistic, 
heterogeneous lesions which are likely to occur in clinical data. While comparing PET 
segmentation to CT segmentation has the advantage of being applicable to clinical data, there is 
no way of knowing the accuracy of the CT segmentation itself or if it accurately represents the 
functional PET volume. 
 
Histopathology measurements are the most accurate method for obtaining reliable TV 
measurements. However, histopathology does not give a perspective of whether the 
segmentation is in the correct position or shape in an image as well as often being impractical to 
obtain and in small samples when available. Simulated data, often using real clinical data as a 
starting point, is a favourable and practical way of testing segmentations. It can at least try to 
represent clinical data and there is a definite true TV before blurring and noise is added to the 
image, however, it is still only a simulation. Defining the ‘best’ segmentation method is always 
going to be flawed. Equally, the best segmentation method for one type of tumour, or disease, 
may not be the same for another. Segmenting smaller, homogeneous tumours in some types of 
lymphoma is going to be a very different task to segmenting larger areas of more heterogeneous 
disease in cancers such as mesothelioma. It may mean that different segmentation methods are 
needed for each. It has also not been fully investigated to what extent the segmentation method 
affects response measures. 
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1.3.5) Intensity Volume Histograms (IVH) 
Image histograms are often used in image analysis and show intensity distribution over an 
image. Studies have used histograms to try and predict response using just pre-therapy PET 
scans and  the comparison between pre- and post- therapy PET scans (El Naqa et al., 2009a; El 
Naqa et al., 2009b; Tixier et al., 2011; van Velden et al., 2011; Vaidya et al., 2012). The first 
study to use parameters from histograms to assess response used a generalisation of the dose-
volume histogram, named the intensity volume histogram (IVH) (El Naqa et al., 2009a). The 
IVH plots SUV against fractional volume of the VOI analysed, typically a tumour in the patient, 
and determines what volume of the tumour is over a given SUV. It effectively summarises the 
intensity information into a single curve for a particular area of disease (Figure 1.7). 
 
Parameters of interest can be extracted from the IVH in an attempt to predict response such as 
percentage of TV above a given intensity. These parameters can be of potential use as they show 
intensity data which could be beneficial to the prediction of response which is not apparent using 
SUVmax alone. For example, a tumour with a high SUVmax and high SUVs in surrounding voxels 
may have a poorer response than a tumour with a high SUVmax with lower SUVs in surrounding 
voxels, as the latter case could represent a less aggressive tumour. While the SUVmax will remain 
the same in both these scenarios, parameters from a IVH would show this difference. IVH 
statistics have had promising initial results (El Naqa et al., 2009a; El Naqa et al., 2009b), but due 
to low patient numbers it is difficult to draw any real conclusions from the work. It has led to the 
use of IVH measures in other PET studies although their use in predicting response is still under 





Figure 1.7: Example of an Intensity Volume Histogram (IVH) 
In this example, the clinical target volume (CTV) (manually delineated by a physician) and the GTV 
(delineated using a 40% of SUVmax threshold, established for radiotherapy planning in a patient), are 
plotted (Taken from El Naqa et al., 2009a).  
 
1.3.6) Texture Analysis 
Texture analysis is a growing area in identifying response to therapy in PET studies and analyses 
texture properties of a tumour to see if changes can predict patient outcome (El Naqa et al., 
2009a; El Naqa et al., 2009b; Tixier et al., 2011; Vaidya et al., 2012). This novel method of 
analysis highlights the pattern of uptake in a tumour, rather than intensity, and this can be highly 
specific and predictable in distinguishing between inflammatory uptake and disease (Hofman 
and Hicks, 2010). The most commonly used texture analysis method is the grey-level co-
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occurrence matrix (GLCM), from which features such as contrast, energy, entropy, homogeneity 
and correlation can be extracted to assess response (Haralick et al., 1973). 
 
The GLCM is a matrix defined as the distribution of co-occurring values at a given offset, 
originally designed to develop a set of features for classifying pictorial data (Haralick et al., 
1973). Texture was defined to be the overall, or ‘average’, spatial relationship and distribution of 
grey tones over an image. If there is no pattern to an image, the variation of grey tones is wide 
and this results in a fine texture, whereas an image with more of a pattern has a coarser texture. 
Texture information of an image is specified by a set of grey-tone spatial-dependence matrices 
computed at various angular relationships and distances between neighbouring pixels. The co-
occurrence matrix of a 2-D image can be defined as: 
                                 [1.8] 
where C is the co-occurrence matrix, ∆x and ∆y are the offsets, n and m are the size of the image 
(i.e. the image is n x m pixels) and p and q are an image pixel in the n x m image. The values can 
be binary or a given type of greyscale (e.g. 8-bit, 16-bit or 32-bit colour).  
 
The GLCM is constructed using four variables. The intensity values of the reference pixel (i) and 
neighbourhood pixel (j), the distance or offset of each neighbouring pixel (d) and the angle used 
(in °) from the reference pixel (a). For each angle and distance an i-by-j probability matrix can 
be obtained. The co-occurrence matrix is set out as a symmetrical grid of the number of grey 
levels in the image, so, for an image with 8 grey levels, it would be a 8-by-8 (i by j) matrix 
usually averaged for each of the four angles (Figure 1.8). Each distance would have a different 
matrix. Images often undergo quantisation to reduce the number of grey levels in them to make 
the GLCM more computationally efficient.   
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Figure 1.8: Possible Angles for Calculation of GLCM  
In 2-D, a pixel has 8 neighbours opposite to it at different degrees. At 0° and 180° are pixels 1 and 5, at 
45° and 225° are pixels 8 and 4, at 90° and 270° are pixels 7 and 3, and at 135° and 285° are pixels 6 and 
2 (Taken from Haralick et al., 1973).  
 
From these GLCMs, different parameters can be obtained which can represent texture features in 
the image. The most relevant are deemed to be energy, contrast, variance, correlation, entropy 
and the inverse difference moment/homogeneity (Baraldi and Parmiggiani, 1995). The GLCM 
was originally designed for 2-D images but with medical images predominantly being in 3-D a 
number of methodologies have been developed for computing the GLCM in 3-D images (Kurani 
et al., 2004; Tsai et al., 2007; Tesař et al., 2008). The GLCM has previously been used to assess 
texture in other medical imaging modalities, such as MRI, ultrasound and mammography (Garra 
et al., 1993; Lerski et al., Mudigonda et al., 2000; Mahmoud-Ghoneim et al., 2003; Alvarenga et 
al., 2007). More recently, it was used on the CT component of PET/CT scans as a potential 
marker for survival and correlated well with SUVmax and SUVmean measurements in patients with 
oesophageal cancer and tumour survival in patients with NSCLC (Ganeshan et al., 2012a, 
Ganeshan et al., 2012b). 
 
Other texture analysis measures useful for medical imaging include transform methods, which 
analyse the image in a different space, computationally exhaustive model-based methods, and 
other statistical approaches, such as gradient and run length matrices (Castellano et al., 2004). Of 
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these, grey level run lengths have been used to try and identify response in PET studies (Tixier et 
al., 2011). Grey level run lengths compute the number of times the same intensity is present 
along a run of pixels in an image at a specific angle resulting in a similar matrix to the GLCM 
from which parameters can be extracted (Galloway, 1975). 
 
There are issues with using texture analysis to identify response in pre- and post- therapy PET 
scans as there are variations in results depending on image parameters, such as acquisition 
protocol and reconstruction parameters, which can affect most texture features by up to >30% 
(Galavis et al., 2010). However, a study comparing textural features between baseline PET scans 
just four days apart showed that some texture features, such as homogeneity and entropy, were 
very reproducible and that many texture features were as reproducible as SUVmax and SUVmean 
(Tixier et al., 2012). Producing a reproducible methodology for texture analysis is difficult. 
Applying a fixed cubic VOI in the tumour will result in intra- and inter- observer variability, 
while using a semi-automated segmentation may eradicate this, an unsymmetrical VOI makes 
the computation of the 3-D GLCM more problematic. Despite these issues with reproducibility, 
there is a lot of interest in texture analysis in PET studies because of its success at distinguishing 
malignant and benign lesions (El Naqa et al., 2009a; El Naqa et al., 2009b; Tixier et al., 2011; 
Chicklore et al., 2012; Vaidya et al., 2012).  
1.3.7) Shape Analysis 
Just as texture analysis can distinguish between benign and malignant lesions so can shape 
(Adams et al., 1991; Rangayyan et al., 1997; O’Sullivan et al., 2003; O’Sullivan et al., 2005; 
Eary et al., 2008; El Naqa et al., 2009a). Studies of breast lesions on MRI and mammography 
images have shown more spherical and symmetric lesions are likely to be benign (Adams et al., 
1991; Rangayyan et al., 1997). The success of shape analysis in these studies has led to its use in 
PET. Studies on sarcoma patients employed shape analysis using a measure based on the 
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difference between tumours from an idealistic elliptical sphere to characterise heterogeneity of 
tumours on PET images (O’Sullivan et al., 2003; O’Sullivan et al., 2005; Eary et al., 2008). It 
proved to accurately predict patient outcome in >200 patients. Different shape based features, 
including measurements for eccentricity, solidity and extent, were used to try and predict patient 
outcome on head and neck and cervix cancer patients (El Naqa et al., 2009a). Results in this 
study were variable with low patient numbers, but some shape analysis measures were more 
accurate than texture features. This is still an untested image analysis tool in identifying response 
to therapy, however, there is potential for it to be useful at predicting patient outcome. 
1.3.8) Conclusion to Image Analysis in Response to Therapy 
Image analysis has the potential to play a prominent role in analysing response to therapy in 
PET/CT studies. Unlike visual analysis, image analysis tools can provide quantitative and 
reproducible indices, which can be useful in predicting patient outcome, aiding clinician’s 
reports and for standardising measurements in clinical trials. Research into using image analysis 
to extract quantitative features in images has been defined as ‘radiomics’ (Lambin et al., 2012). 
The growth of radiomics has led to the use of measures such as TV, TLG, IVH parameters, and 
texture and shape analysis on PET/CT studies as they may provide more information than 
SUVmax or SUVpeak values. 
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2) Software for Identifying Response to Therapy 
2.1) Introduction to PETTRA Software 
Identifying response to therapy between pre- and post- therapy PET/CT scans can be 
investigated using SUVs and volumetric measures, including SUVmax, SUVpeak, SUVmean, TV and 
TLG. Additionally, more experimental methods such as IVHs, texture analysis and registered 
pre- and post- therapy subtraction images can also be used. Commercial software is available, 
including HERMES Volume Display and General Electric’s (GE) Advantage Workstation, 
which can do some of these tasks. However, a tool to view and analyse PET scans specifically 
for analysing response would be advantageous. This led to the development of PET Therapy 
Response Assessor (PETTRA), a software tool designed using commercial software package 
MATLAB
®
 2012b (The MathWorks Inc., Natick, MA, 2000). PETTRA was custom built for 
analysing PET scans and extracting parameters for identifying response to therapy. This chapter 
assesses the development of PETTRA, the tools it offers and how it operates. PETTRA is 
capable of showing 3-D PET, CT and PET/CT images in all three planes (coronal, sagittal and 
transverse), segmenting PET images and calculating SUV, TV, TLG, and IVH parameters. 
2.2) PETTRA Interface and Viewing Tools 
2.2.1) PETTRA Interface 
Software analysing any type of medical image needs to have a graphical user interface (GUI) to 
view the image in all planes, and the ability to navigate through them to see the full image. 
Rarely is analysing an image an automated process so it is important that an interface the user 
can interact with is accessible. PETTRA’s GUI was created using the GUI Design Component 
(GUIDE) of MATLAB
®
 software, allowing the designer to create an interface with text, labels, 
buttons, axes and other utensils to allow users to analyse PET images with ease (Figure 2.1).
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Figure 2.1: PETTRA User Interface
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2.2.2) Viewing Images in PETTRA 
Most medical imaging software tools allow the user to configure how they want to view and 
analyse images, allowing changes in image properties, and the way images are viewed. PETTRA 
displays data in the dimensions it is stored in, i.e. it does not interpolate data to fit the interface. 
The reason for this is that for assessing response to therapy, it is important that values are not 
affected by changes caused by interpolation. PETTRA has fixed axes in which data can be 
displayed, changing the height of the axis to keep the image in the right aspect ratio. PETTRA 
displays three axes, one for each of the coronal, sagittal and transverse planes. The coronal and 
transverse planes normally have the same image dimensions and are displayed together with the 
coronal plane in the centre of the display because this was the most viewed orientation during 
visual analysis for most image consultants. The transverse plane is typically square and so 
appears smaller on the viewer and is placed in the top corner to allow room for GUI components. 
 
In PETTRA, users can click on any of the axes to select a specific voxel, highlighted by the 
green cursor lines on all three planes. The co-ordinates and intensity of the voxel are displayed. 
These co-ordinates can be changed by typing in new co-ordinates to highlight a voxel rather than 
clicking on the axes or using the arrow keys on the keyboard to go through the current axes slice 













Figure 2.2: PETTRA 3-D Display and Navigation 
The PETTRA GUI allows the user to navigate through the image by clicking the mouse on the axes, going 
through slices using the arrow keys on the keyboard. Green crosshiars show the position of the 3-D image 
in other planes. 
 
Medical images are often viewed in a variety of different colour scales over different ranges of 
values, particularly when interpreting the intensity of tumours. Software should allow the user to 
customise the way the image is displayed. PETTRA allows the user to display the image in a 
number of different colour scales. The default is the reverse greyscale colour scale which is the 
preferred scale for most commercial imaging software, including HERMES. However, the user 
may choose to view the image in other colour scales including greyscale, hot, bone and jet 
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(Figure 2.3). Should a user want a specific colour scale, MATLAB
®
 has functionality to create 




Figure 2.3: Colour Scale in PETTRA 
Coronal view of a PET image displayed in (A) reverse greyscale, (B) greyscale, (C) hot, (D) bone, and (E) 
jet. The user can select the colour scale they want using a drop down box on the PETTRA interface (F). 
Colour range for all images is 0-5 SUV.  
 
 
As well as colour scale, a user may also want to change the range of intensity in an image to aid 
image interpretation. By setting minimum and maximum values on a colour scale, all values 
over the maximum will be set to the specified maximum value and all values under the minimum 
will be set to the minimum value. This can be useful as it means that a user can, for example, 
modify background in an image by setting the minimum value to 1 SUV or set the maximum 
value to 2.5 SUV if it is believed that disease is >2.5 SUV. This allows the user to see 
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differences between background and disease in greater detail (Figure 2.4). The default setting for 






Figure 2.4: Colour Range in PETTRA 
Coronal view of a PET image displayed in minimum to maximum SUV ranges of (A) 0 – 35.1 (SUVmax in 
the image), (B) 0 – 10, (C) 0 – 5, (D) 0 – 2, (E) 0.5 – 2, and (F) 1 – 5. The colour scale used is displayed 
on the PETTRA GUI with editable textboxes for changing the minimum and maximum values used (G). 
PETTRA’s default display of images is in a reverse greyscale with a colour range of 0-5 SUV. PET 
images are displayed in this format in other figures unless otherwise stated. 
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2.2.3) Image Formats and Information 
Medical images come in a variety of file formats from the universal Digital Imaging and 
Communications in Medicine (DICOM) standard to more specific formats designed for 
particular use at different institutions, such as the Guy’s Image Processing Lab (GIPL) format. St 
Thomas PET Centre uses HERMES software which primarily stores images in Interfile 3.3 and 
DICOM. PETTRA is customised to deal with these file formats ahead of others. Interfile 3.3 is 
the preferred file format, although there has been development of software for loading both 
DICOM and Mayo Analyze formats too (Figure 2.5). 
 
Figure 2.5: Loading Images in PETTRA 
PETTRA can load images in Interfile 3.3, DICOM and Analyze file format selected by the user. 
 
 82 
Analysis was performed on images in Interfile 3.3 format, however, as DICOM is the most 
common file format across many institutions and Analyze was used to register images with 
IRTK, these formats were considered when developing the software. It is possible to develop 
PETTRA to load in other formats if necessary. Along with the image, information in the image 
header file is also loaded into PETTRA as the information is vital in calculating SUVs and 
volumes. Header files contain information such as what institution the image is from, acquisition 
details, patient information and sizes/dimensions. This information can be important to the user 
and thus it is useful to display it if requested by the user. PETTRA can do this and the 
information shown can be easily adapted (Figure 2.6). 
 
 
Figure 2.6: Image Information Table in PETTRA 
PETTRA displays patient information, image measurements and other parameters if requested by the user. 
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2.2.4) Viewing Modes in PETTRA 
PETTRA has several different modes for viewing images. The user can load up to two PET 
images and two CT images to analyse from the initial opening GUI. They can then choose to 
view images in a viewer for one image, two images, or two images and their resulting 
subtraction image (Figure 2.7). The subtraction image is most useful when two images are 
registered to allow voxel-by-voxel comparison. These viewing modes are designed with 
particular focus on the main aim of the tool, to assess response in pre- and post- therapy images, 
allowing two images to be viewed at once can aid this process. There is also a volume extractor 
tool for creating subvolumes of the image. 
 
Figure 2.7: PETTRA Welcome GUI for Choosing Viewing Mode and Loading Images 
User must load one PET image but can also load a second PET image and corresponding CT images. They 
can then view the image(s) in a viewer for just one scan, two scans, or two scans with a subtraction image. 
Additionally, the user can use a volume extractor for reducing image size for analysis or registration.  
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2.2.4.1) Viewing Pre- and Post- Therapy PET Images 
The PETTRA two scan viewer allows pre- and post- therapy PET scans to be analysed side by 
side (Figure 2.8). The software is designed for two images with the same dimensions and voxel 
sizes to allow voxel-by-voxel comparison. Pre- and post- therapy PET/CT scans should ideally 
be acquired on the same scanner using the same protocol so the dimensions and, particularly, 
voxel size should be the same. There are cases where the dimensions are not the same and there 
are more slices in one image than the other, usually in the transverse plane. In this case, slices 
can be removed to allow images to be viewed. If the voxel sizes of the two images are different, 
interpolation can be done in MATLAB
®
 so the images can be viewed in the software. 
 
2.2.4.2) Viewing Pre- and Post- Therapy PET and Subtraction Images 
The PETTRA two scan and subtraction image viewer shows both pre- and post- therapy images 
and their subtraction image (pre-therapy – post-therapy). The subtraction image can highlight 
areas in which a patient has responded, particularly if the post-therapy image has undergone 
registration. Parameters can be extracted from the subtraction image which could potentially be 
useful in identifying response. Figure 2.9 shows this viewing mode, where a patient has clearly 
responded between the pre-therapy and post-therapy image and this is visualised on the 
subtraction image where areas of black between liver and spleen show the change in disease. 
However, it should be noted that some of the changes are likely to be down to changes in 
physiological uptake and registration error. The default grey colour shows areas where no 




Figure 2.8: PETTRA Two Scan Viewing Mode 
Two scan viewing mode, primarily designed to view pre- and post- therapy PET images together in one viewer. As with the one scan viewer, parameters for 
viewing can still be changed and images can be segmented and parameters for response extracted such as SUVmax, TV and IVH parameters. 
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Figure 2.9: PETTRA Two Scan and Subtraction Image Viewing Mode 
The two scan viewer with subtraction image is best used with registered images for voxel-by-voxel analysis. All the features of the one scan viewer are available. 
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2.2.4.3) Viewing PET and CT Images 
While the viewer is primarily designed for analysing PET images, it can also display CT images, 
either individually or with corresponding PET images (Figure 2.10). CT images can be 
interpolated into the same image space as PET scans and overlaid in the viewer to allow the user 
to see where uptake on the PET scan corresponds, anatomically, on the CT scan. This is similar 
to the display in HERMES. For the analysis of data herein, PET images were viewed alone after 
areas of disease were segmented with the aid of a clinician using the more familiar HERMES 
software. 
 
2.2.4.4) Subvolume Selection Tool 
PETTRA allows the user to create subvolumes of pre- and post- therapy PET/CT images to 
focus on a specific VOI, such as a tumour, for analysing PET images or registering PET/CT 
datasets (Figure 2.11). The tool allows users to select two points in the images with the 3-D 
volume between the two points taken as the subvolume. The images can be saved in interfile 
format with the header file copied from the original images with the size of the image and new 
number of slices replaced to match any changes. These images can then be used for registration 
of subvolumes or analysis in PETTRA. Pre- and post- therapy PET scans are displayed together 
and the same subvolume is taken to ensure that registration can occur on images of the same 
dimensions and that a region can be taken which covers the main areas of interest on both 





Figure 2.10: CT Scan Viewed in PETTRA 
In addition to PET images, CT images can be viewed in PETTRA in the same visual display. 
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Figure 2.11: PETTRA Subvolume Selection Tool 
The user can select two separate voxels in the images and the volume between these two points is taken as the subvolume, highlighted as the area encapsulated 
within the green and yellow lines on the images, both of which can be changed by the user. The blue crosshairs represent the voxel currently highlighted.
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2.3) PETTRA Segmentation 
2.3.1) Introduction to PETTRA Segmentation 
With PET images displayed in PETTRA, one of the most important steps to allow assessment of 
response is the segmentation of areas of disease for analysis. PETTRA allows segmentation of 
disease using a number of methods, ranging from simple measures, such as placing a cubic 
volume over a region, to more complicated threshold methods which use SUVmean of the tumour 
and a background region to adapt the threshold. The user can choose from a list of segmentation 




Figure 2.12: PETTRA Segmentation Methods 
The user can choose from a list of segmentation methods (A) and adapt the parameters of them, such as 
dictating the size of a cubic region (B) and setting the threshold for a fixed threshold method (C).  
 
The segmentation algorithms are all programmed to produce a binary mask of the image with the 
voxels included in the segmentation marked as true (value of 1) and those voxels not included as 
false (value of 0). An array of voxels in the segmentation is also included with the co-ordinates 
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in each plane recorded along with the intensity of the voxel, allowing the maximum, mean and 
standard deviation (S.D.) of the VOI to be calculated easily. Multiple segmentations can be 
performed on an image if there are multiple areas of disease with binary masks accumulated in a 
multidimensional array and voxels included added to the array list. PETTRA can combine the 
image with segmented VOIs to show the different areas of the image which have been 
segmented, with different colours representing multiple segmentations (Figure 2.13). 
 
Figure 2.13: Visual Display of Segmentations of Disease on a PET Image 
The PET image is combined with binary masks of segmented areas, represented by different colours to 
show different segmentations. The image with VOIs highlighted is shown in sagittal and coronal planes. 
As previously mentioned, images are displayed in a reverse greyscale colour scale and with a colour range 
of 0-5 SUV unless otherwise stated. 
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2.3.2) Segmentation of a Cubic Volume 
One of the simplest segmentation methods implemented in the software creates a small cubic 
volume, typically used to segment a small area of tumour (Figure 2.14). This is useful in 
assessing distribution of voxels in an area of tumour using texture analysis, or similar measures, 
rather than for obtaining tumour volume (TV). The user can define the size of the cube based on 
how many voxels it uses from the initial, central voxel. For example, if three voxels are chosen 
in the coronal direction then the volume will include three voxels either side of the starting 
voxel, making a total of seven voxels. The user can select the displacement in all three planes 
using either voxels or mm. If mm are chosen rather than voxels, PETTRA will round up to the 
nearest mm which is a product of voxel size.   
 
Figure 2.14: Visual Display of a Cubic Volume Segmentation 
The user can choose the number of voxels included from the central, starting voxel in each plane in either 
voxels or mm. By pressing ‘Update’, PETTRA will display the values for the other units. If mm are used, 
they are rounded to the nearest multiplicative of voxel size. 
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2.3.3) Segmentation using a Fixed Threshold 
Segmentation of PET images can be done using a fixed value of intensity to separate those 
voxels included in the VOI and those that are not. A fixed 2.5 SUV has been used to distinguish 
malignant and benign lesions (Paulino and Johnstone et al., 2004). PETTRA can create a VOI 
where all the voxels in an image over a certain fixed threshold value, editable by the user, are 
included and those under the threshold are not (Figure 2.15). The advantage of applying this 
threshold over the whole image is that it will pick up any area of disease, no matter how small, if 
it is over the threshold. The disadvantage is that unwanted areas of physiological uptake such as 
the brain, heart, liver, kidneys and bladder will be included and will need to be removed if the 
VOI is to be used for analysis. 
 
 
Figure 2.15: Visual Display of a Fixed 2.5 SUV Threshold Segmentation over an Image  
In the coronal plane of the image, segmented areas show voxels >2.5 SUV. While most of this is disease, 
there is physiological uptake in the brain included. 
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Rather than perform a fixed threshold over the whole image, a region growing algorithm can be 
used to make sure that only voxels connected to a tumour are included in the VOI.  Region 
growing starts from an initial voxel and then ‘grows’ a region over voxels connected to each 
other if they are over the threshold. This means a tumour can be segmented independently from 
the brain, unlike in Figure 2.15, unless the tumour and brain are connected by voxels over the 
threshold. Region growing continues to add voxels connected to those in the VOI which are 
above the threshold until no more can be added and the algorithm finishes.  
 
Region growing is implemented in PETTRA and is used for several segmentation algorithms 
which use thresholding, including the fixed threshold method. Region growing starts with a seed 
point, selected as the current chosen voxel in PETTRA, determined by the user. This seed voxel 
is included in the VOI and its connected voxels are checked to see if they are over the given 
threshold. If they are, they are included in the VOI. If connected voxels are added to the VOI, 
their connected voxels are also checked to see if they are over the threshold and this process 
continues until all voxels have been checked. If no more connected voxels are above the 
threshold, the algorithm terminates (Figure 2.16).  
 
The connected voxels to a voxel in the VOI can be defined in three different ways. Voxel 
connectivity can either use 6-connected voxels, 18-connected voxels or 26-connected voxels for 
a 3-D image (Figure 2.17). 6-connected voxels are those which touch the face of a voxel, 18-
connected touch the face or edge of a voxel, and 26-connected voxels touch a face, edge or 
corner. PETTRA can perform region growing using 6-connected, 18-connected or 26-connected 
voxels, depending on the input of the user. The default is set to 6-connected voxels to avoid 









Figure 2.16: Flowchart for Region Growing in PETTRA  
Region growing continues until the continue variable is left set to false after all the connected voxels have 
been checked to see if they are above the threshold. If no more connected voxels are above the threshold 








Figure 2.17: Voxel Connectivity for Region Growing Segmentation 
The three types of voxel connectivity: (A) 6-connected, (B) 18-connected, and (C) 26-connected are 
illustrated over three slices of a 3-D image where the middle voxel in black is the one which voxels are 
connected to. Connected voxels are highlights in grey while non-connected voxels are white.  
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2.3.4) Segmentation using SUVmax 
One of the most common segmentation methods in PET studies is using a percentage of SUVmax 
in a tumour as a threshold for delineation. The percentage used varies amongst PET studies with 
percentages from 40% to 70% used to segment PET tumours (Erdi et al., 1997; Boellaard et al., 
2004). A region growing segmentation method using a percentage of SUVmax has been 
implemented in PETTRA, allowing the user to choose the percentage. To ensure the user does 
not have to choose the maximum voxel as the seed point, the tumour is first delineated using a 
region growing algorithm with a fixed 2.5 SUV threshold. When this VOI has been established, 
the maximum voxel is identified and threshold calculated as a percentage of it. The region 
growing algorithm is performed again using the new threshold. Figure 2.18 shows segmentations 
using the region growing algorithm with thresholds of 42% of SUVmax and 2.5 SUV. 
 
 
Figure 2.18: Visual Display of Region Growing Segmentations using Different Thresholds 
The segmentations use thresholds of (A) 42% of SUVmax and (B) fixed 2.5 SUV. Both segmentations are 
of the same tumour and are done using region growing with 6-connected voxels. 
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2.3.5) Segmentation using SUVmean 
Rather than use a percentage of SUVmax, a linear relationship between the optimal SUV 
threshold and SUVmean can be used to calculate a threshold based on phantom studies (Black et 
al., 2004). Using a linear regression function, the optimal SUV threshold was calculated as: 
     [2.1] 
where SUVmean is the mean uptake in the tumour and 0.307 and 0.588 are constant variables 
relating the SUVmean to the threshold. A drawback of this method is the constant variables are 
likely to change depending on the scanner, and coming up with a SUVmean for a TV of which 
volume is not know becomes a circular problem. However, this has been implemented in 
PETTRA by using a starting fixed threshold of 2.5 SUV and then continually modifying this 
threshold based on the calculation until it reaches a point where the change in TV is <1% or 
there have been at least 10 iterations.   
 
An alternative segmentation method using SUVmean uses a modified region growing method 
which continually adapts the threshold depending on the current SUVmean of the VOI (Green et 
al., 2008). This region growing algorithm works differently to the standard region growing 
algorithm illustrated in Figure 2.16. Firstly, the algorithm is passed through twice, once to get an 
initial VOI to obtain the SUVmax and a second time with the SUVmax as the seed point for the 
algorithm. The threshold is recomputed each iteration as the SUVmean from the current VOI is 
used to adapt the threshold throughout the algorithm (Figure 2.19). The percentage of SUVmean 
used to calculate the threshold is user defined, but a percentage of 85% was found to segment 
tumours best in comparison with manual delineation by an experienced clinician. However, 
these were on images from a gamma camera for SPECT imaging so other percentages may be 
more appropriate for PET segmentation. 
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Figure 2.19: Flowchart for Adaptive SUVmean Region Growing Algorithm  
The algorithm computes the threshold during each iteration (Taken from Green et al., 2008). 
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Implemented in PETTRA, the region growing algorithm is adapted to match the flowchart in 
Figure 2.19 and the user can choose the percentage used to calculate the adaptive threshold. It is 
worth noting that other algorithms mentioned so far are all 100% reproducible, no matter where 
the user defines the starting point of the algorithm. The adaptive SUVmean threshold can 
potentially yield different volumes depending on the starting point as the SUVmean can be 
different depending on where the algorithm starts from. However, this is unlikely to be the case 
as the mean will no doubt end up being similar and segment a similar tumour volume with the 
same SUVmax which will then be used as the starting point for the second run through the 
algorithm. Both segmentation methods involving the SUVmean are shown in Figure 2.20. 
 
 
Figure 2.20: Visual Display of Region Growing Segmentations using SUVmean 
The segmentations use (A) Threshold = 0.307 * SUVmean + 0.588 (Black et al., 2004), (B) Adaptive 85% 
SUVmean (Green et al., 2008) and (C) Adaptive 50% SUVmean (Green et al., 2008). It may be that a lower 
percentage threshold for the adaptive SUVmean may yield more accurate segmentation for PET images, as 




2.3.6) Segmentation using Background Uptake 
Some segmentation methods choose to use thresholds based on background activity, such as the 
method proposed in PERCIST criteria (Wahl et al., 1999). The guidelines state that for 
measuring TLG, TV should be obtained using a threshold based on the normal mean of the liver, 
calculated as:  
                         [2.2] 
where Background is a spherical VOI with a 3cm diameter in the right hepatic lobe of the liver. 
For particularly active tumours, the S.D. may be multiplied by 3 rather than 2. The segmentation 
method is implemented in PETTRA using the formula in [2.2], and can be applied using region 
growing or over the whole image (Figure 2.21). The background region can be obtained using 
methods described in 2.3.10. 
 
Other studies have used very similar segmentation methods based purely on background in an 
image (Zasadny et al., 1998; Gulec et al., 2011). PET segmentation using the PERCIST formula 
multiplied by 3 S.D. rather than 2 (Zasadny et al., 1998), and using SUVmax in the liver have 
both been proposed as thresholds for segmentation (Gulec et al., 2011). These methods can be 
applied in PETTRA as well as the PERCIST method. PETTRA allows the multiplication factor 
of the background S.D. in the PERCIST formula to be changed by the user and can use the fixed 
threshold method discussed in 2.3.3 to perform segmentation with a threshold equal to the 
SUVmax in the liver (Figure 2.21). 
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Figure 2.21: Visual Display of PERCIST Segmentations 
PERCIST segmentation over the whole image (A) and on a single tumour using region growing (B) with 
background value/mean and S.D. for calculation chosen by the user. The multiplying factor, also editable 
by the user, defines multiplication of S.D. in the PERCIST formula so either method of calculating 
background + S.D. can be used (Zasadny et al., 1998; Wahl et al., 2009). Connectivity was set to the 
default 6-connected voxels for the region growing algorithm. 
 
2.3.7) Segmentation using SUVmax and Background Uptake 
Segmentation methods can use a background region along with SUVmax to calculate a threshold. 
A threshold based on 50% or 70% of the combination of SUVmax and a background region has 
been suggested (Boellaard et al., 2004), calculated as: 
     [2.3] 
where ‘SUVmax’ is the maximum voxel in the tumour and ‘Background’ is a mean value taken 
from a background region in the image. The advantage of this method is the higher the uptake in 
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the background, the higher the threshold will be for segmentation, with the aim to ensure that 
segmentation does not spill into areas of background around the tumour. This segmentation 
method is implemented in PETTRA using region growing and a fixed 2.5 SUV segmentation is 
used to obtain the SUVmax of the tumour.  The percentage (50%, 70% or another percentage) and 
background mean are chosen by the user. Experimentation with different percentages may be 
useful on clinical data as the formula was devised on phantom experiments (Figure 2.22). 
 
 
Figure 2.22: Visual Display of SUVmax and Background Segmentations 
Segmentations are on the same tumour for (A) 50%, (B) 70% and (C) 30% of SUVmax + Background 
 
Another segmentation method proposes using a background corrected SUVmax calculation to 
obtain a suitable threshold (Davis et al., 2006). The threshold is defined as: 
    [2.4] 
where ‘SUVmax’ and ‘Background’ are as described before and the Relative Threshold is a fixed 
percentage of background subtracted SUVmax, dependent on the size of the tumour/object. In a 
phantom study, for spheres with diameters >12.5mm, a relative threshold of 0.41 (41%) was 
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found to be most accurate for segmenting volume (Davis et al., 2006). However, thresholds 
varied for those with diameters <12.5mm. For tumours where the diameter was >12.5mm, the 
SUVmax was taken as the mean of the highest 10% of adjacent pixels, similar to a SUVpeak 
measure.  
 
Implementation of the algorithm in PETTRA is similar to the previously described SUVmax and 
background segmentation (Boellaard et al., 2004). The user chooses the background and relative 
threshold value while SUVmax is taken from a fixed 2.5 SUV segmentation from the initial seed 
voxel. In the study by Davis et al. (2006), an algorithm to determine the volume of the lesion is 
used to customise the relative threshold used according to phantom measurements (Davis et al., 
2006). This has not been implemented in PETTRA, however, if phantom measurements are 
available, a tumour volume size can be obtained using an initial segmentation and the relative 
threshold changed to match these results. Once again, experimentation with relative thresholds 
may be useful on clinical data as the formula was devised primarily on phantoms (Figure 2.23). 
 
Figure 2.23: Visual Display of Background Subtracted SUVmax Segmentations  
Relative thresholds of (A) 41%, (B) 30% and (C) 50% are used on the same tumour. 
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Other investigations have studied the relationship between SUVmax/SUVmean and background 
with both tumour size and T/B ratio (Daisne et al., 2003; Yaremko et al., 2005), and these can be 
related to formula [2.4] (Davis et al., 2006). A study by Drever et al., (2006) uses the same 
formula but with the relative threshold changed depending on contrast rather than tumour size 
(Drever et al., 2006). Some studies have used iterative thresholding to segment PET images 
using similar formulas and phantom experiments, but using algorithms which continue to 
recalculate the threshold value and tumour size and/or contrast ratio until there is no significant 
change in values (Jentzen et al., 2007; Van Dalen et al., 2007; Nehmeh et al., 2009). While these 
segmentation methods could all be implemented in PETTRA, they are heavily related to the 
threshold calculation in [2.4] and all these methods use phantom data which is unlikely to be 
available in many cases. Therefore, addition of these sorts of methods in PETTRA seems 
redundant. 
2.3.8) Segmentation using SUVmean and Background Values 
Rather than using SUVmax, segmentation based on tumour and background intensities can use 
SUVmean of the tumour (Nestle et al., 2005; Nestle et al., 2007; Boucek et al., 2008). Nestle et al. 
(2005) defined a threshold for segmentation as: 
       [2.5] 
where SUVmean is the mean of the tumour segmented using an isocontour of 70% of SUVmax, 
Background is the SUVmean of a ROI placed over a relevant background structure, and 0.15 is a 
constant based on phantom measurements. The background VOI is advised to be placed over an 
anatomic entity, such as mediastinum or liver, adjacent to the tumour but a far enough distance 
away to ensure no disease is included in the VOI. The highest uptake of the background regions 
should be used to ensure the threshold is high enough to avoid spillover into other areas of 
physiological uptake, such as the liver, spleen, kidneys, bowel and bladders.  
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Once again using phantom measurements with further testing on clinical data, Nestle et al. 
(2007) revised the method for calculating the threshold through this technique (Nestle et al., 
2007), with the new threshold being defined as: 
    [2.6] 
where SUVmean is the mean of the tumour segmented using an isocontour of 70% of the SUVmax, 
Background is the SUVmean of a ROI of 20 - 60cm
3
 in the mediastinum and 0.5 and 0.7 are 
constant variables based on phantom measurements. 
 
Another segmentation method, named the GRAB algorithm, is based on an iterative region 
growing algorithm using a percentage of SUVmean (Boucek et al., 2008). GRAB uses both 
SUVmean and background to calculate a threshold to use to segment the tumour. It uses a product 
of the SUVmean in the tumour and a threshold factor, which uses the maximum normal level 
(MNL) to define the threshold. The MNL is based on the equation used for obtaining a threshold 
in the PERCIST segmentation [2.2], but uses a multiplying factor of 3 rather than 2 for S.D. The 
MNL is combined with the SUVmean to provide the threshold factor. 
                             [2.7] 
          [2.8]
                          [2.9] 
 
Calculations in [2.5] and [2.6] are implemented in PETTRA in the same way as the method by 
Black et al. (2004), starting with a segmentation of a fixed 2.5 SUV threshold and iteratively 
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using the relevant calculation until it reaches a point where TV changes is <1% or there has been 
at least 10 iterations. The GRAB segmentation method uses the same coding in MATLAB
®
 as 
the algorithm by Green et al. (2008) but changes the threshold calculation to use the threshold 
factor (Green et al., 2008), calculated by the MNL (Figure 2.24).  
 
Figure 2.24: Visual Display of Segmentations using SUVmean and Background 
Segmentations using (A) Threshold = (0.15 * SUVmean) + BG (Nestle et al., 2005), (B) Threshold = (0.7 * 
SUVmean) + (0.5 * BG) (Nestle et al., 2007), and (C) GRAB algorithm (Boucek et al., 2008), on the same 
tumour. BG = Background. 
 
2.3.9) Restricting Segmentation 
On a PET image, there can be many areas of physiological uptake that can interfere with 
segmentations. Region growing algorithms are designed to not ‘spill’ over from segmenting 
tumour and include areas of physiological uptake but sometimes this is inevitable. For example, 
a segmentation of mesothelioma can include the heart through no fault of the segmentation 
method, as both the heart and disease can have areas of high uptake and are connected by 
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adjacent voxels (Figure 2.25A). Semi-automated segmentation methods are designed to have 
user input and therefore this will be noted when segmenting the image. However, the user needs 
a method to remove the area of physiological uptake or to avoid segmenting it initially. 
 
PETTRA has two functionalities that allow the user to customise the segmented VOI. Firstly, the 
user can remove segmented regions as well as adding them. Removing a region takes all the 
voxels in the newly segmented region and subtracts them from any previously segmented VOIs 
and the list of voxels included in the VOI is updated. This allows the user to segment disease and 
then remove any physiological uptake. Secondly, PETTRA allows the restriction of 
segmentation within the boundaries of a given set of co-ordinates. By doing this, after the 
segmentation has been performed, any voxels selected outside the restricted region will be 
subtracted from the VOI. Therefore, the segmentation of a lesion can be confined within a 
specific area or segmentation of physiological uptake can be confined within a set of co-
ordinates and then removed from a segmentation of disease. The latter technique is how the heart 
has been removed in Figure 2.25B, with the initial segmentation using a fixed 2.5 SUV threshold 
has included the heart and another segmentation constrained to a VOI placed around the heart, 





Figure 2.25: Visual Display of a Segmentation where the Heart is removed from Disease.  
(A) User segments all the disease in the first image using fixed 2.5 SUV threshold but physiological 
uptake in the heart is included. (B) Physiological heart uptake is removed by using another fixed 2.5 SUV 
threshold restricted to the region between the co-ordinates 62-76 in the x-direction/coronal plane, 61-79 in 
the y-direction/sagittal plane and 140–168 in the z-direction/transverse plane. This segmentation of the 
heart is then removed from the initial segmentation so only disease is left. 
 
2.3.10) Obtaining Background Regions in PETTRA 
Obtaining a background region in PETTRA is important in many of the segmentation methods 
implemented in the software. There are two user input boxes for background mean and S.D. 
which are subsequently used in segmentation algorithms (Figure 2.24). These can be filled with 
values chosen by the user or, alternatively, the user can navigate to a voxel in the background 
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region and select ‘Calculate Background Region’ which autofills the input boxes with the mean 
and S.D. of the selected voxel and its 26-connected neighbours. If a larger background region is 
desired, the cubic volume segmentation can be used to obtain a volume in an area of background 
of a given size (this is described in more detail in 2.3.2). The mean and S.D. from this region can 
be used in the input boxes and, therefore, be used for segmentation. 
2.3.11) Segmentation Methods not included in PETTRA 
Segmentation methods discussed in 1.3.4 which have not been included in the PETTRA 
software include gradient based methods (Geets et al., 2007), dual active contours (El Naqa et 
al., 2007; Li et al., 2008), probability and possibility based methods (Hatt et al., 2009; Dewalle-
Vignion et al., 2011), and AI methods (Sharif et al., 2010). In the majority of cases, the reasons 
why these segmentation methods have not been implemented is due to a combination of 
complexity and lack of testing on clinical data. While a lot of methods have potential to provide 
more accurate TVs than threshold based methods, they are at early stages of development and 
have not been fully tested on a range of clinical data. Most of the methods are more complex to 
program compared to threshold techniques and, therefore, these methods have been omitted from 
PETTRA. However, implementation of additional segmentation methods in the future is 
possible. Adaptive thresholding methods, discussed in 1.3.4 and 2.3.7, which rely on phantom 
measurements of T/B or a priori estimates of tumour size have also not been implemented in 
PETTRA (Jentzen et al., 2007; Van Dalen et al., 2007; Nehmeh et al., 2009). This is because 
there is no evidence to suggest they are more beneficial in comparison to the threshold 
techniques already implemented in the software and they rely on measurements which are 
unlikely to be available for many datasets when assessing response. 
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2.4) Quantification in PETTRA 
2.4.1) Implementation of SUV 
SUVs are generally regarded as the best, practical semi-quantitative measure to quantify PET 
images (Stahl et al., 2004; Nahmias and Wahl, 2008). Images are usually stored in intensities of 
Bq/cc, meaning there is no normalisation of tracer uptake with regards to radioactivity and 
patient volume e.g. body weight. Therefore, software must use patient weight, dose, 
radiopharmaceutical injection time and scanning start time to correct for radiotracer activity and 
patient volume to convert Bq/cc to SUV. These values are obtained from information from the 
image header file. Different image formats can use different header parameters and names, so 
coding a function which converts an image into SUV can be challenging. Even the same image 
format can store information differently depending on the institution and software used.  
 
PETTRA’s function for converting an image from Bq/cc to SUV starts by searching through the 
image file for radiopharmaceutical injection time, scan start time, administered dose to the 
patient, patient body weight, and isotope half life, slope and intercept on a logarithmic plot of the 
radioactive half life of the isotope. Without these seven parameters, SUV can not be calculated. 
If the function can not find these parameters in the header files it may ask the user to input the 
values manually. Knowing these inputs, the gap between the start of the scan and 
radiopharmaceutical injection time can be calculated and dose at the start of the scan can be 
derived. SUV can then be calculated using the following equation: 
  [2.10] 
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2.4.2) Implementation of SUV Variations 
As well as being able to convert images into SUV, PETTRA can also convert images into 
variations of SUV, including SUL, or SUVLBM, and SUVBSA (Zasadny and Wahl, 1993; Kim et 
al., 1994). Both are similar parameters to SUV and are calculated in the same way but instead of 
normalising by patient weight, SUL uses lean body mass (LBM) and SUVBSA uses body surface 
area (BSA), otherwise formula [2.10] remains the same. Both are used throughout literature as 
better methods of normalisation than body weight (Graham et al., 2000; Hallett et al., 2004), and 
SUL is recommended as standard in PERCIST criteria (Wahl et al., 2009). Both SUL and 
SUVBSA require patient height and weight, and SUL also uses the sex of the patient for 
calculation. These can be obtained from the image’s header file like the other parameters. The 
equation for LBM is: 
              [2.11] 
where BW = body weight (kg) and H = Height (cm). 
 
BSA is calculated as: 
   [2.12] 
where BW = body weight (kg) and H = Height (cm). While LBM in SUL and patient weight in 
SUV are multiplied by 1000 to convert from kg to g, BSA is multiplied by 10000 to convert to 
cm
2
/cc for calculation of SUVBSA. In PETTRA, the default setting converts the image(s) into 
SUV, however, the user can toggle the setting to convert the values into SUL, SUVBSA or their 
original Bq/cc values (Figure 2.26). SUV, SUL, and SUVBSA values from PETTRA have all 
been compared with those from HERMES viewing system and they match perfectly. 
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Figure 2.26: Different Units of Quantification in PETTRA 
The same image displayed in (A) SUV, (B) SUL, (C) SUVBSA, and (D) Bq/cc in PETTRA. The value of 
the highlighted voxel in the image is illustrated, as is the toggle for selecting what format the values are 
displayed in and the colour scale and range used for viewing the image. 
2.4.3) Obtaining SUVmax  
For assessing PET images, obtaining the SUVmax in an image or within a tumour is important in 
software such as PETTRA and there are buttons to find SUVmax in an image or within a VOI. 
The SUVmax is also given out in the display of details from a VOI. 
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2.4.4) Obtaining SUVpeak 
SUVmax can be sensitive to noise in an image and so using SUVpeak is recommended in the 
literature (Wahl et al., 2009; Lodge et al., 2012). The methodology used to define SUVpeak, a 
small volume of the most intense uptake in a tumour, can cause results to vary considerably 
(Vanderhoek et al., 2012). PERCIST recommends that the SUVpeak is a 1cm
3
 sphere with a 
1.2cm diameter centered on the hottest point in the tumour. The hottest point will typically 
contain the SUVmax but does not always. The implementation of SUVpeak into imaging software 
can be complicated depending on how it is achieved. 
 
Images can be interpolated into a format where a sphere with a 1.2cm diameter and 1cm
3
 volume 
can be produced and the largest peak can be searched for throughout the image or VOI. This 
makes the task easier but also changes the original values of the PET image, something which is 
not advisable and which PETTRA refrains from. With no interpolation used, implementation of 
SUVpeak has to define a volume closest to 1cm
3
 with a 1.2cm diameter, if following PERCIST 
guidelines (Wahl et al., 2009). If a PET image has a voxel size of 97.80mm
3
 (5.47mm x 5.47mm 
x 3.27mm), then 10 voxels are needed to get as close to 1cm
3
 as possible, with a volume of 
0.978cm
3
. If the PET image has voxel sizes of 71.85mm
3
 (4.69 x 4.69 x 3.27) and needs 14 
voxels are needed to get as close as possible to a 1cm
3
, with a volume of 1.006cm
3
. This means 
that the shape of the SUVpeak in images with different voxel sizes is likely to be different. In 
addition, the shape constructed using different methodologies and software can result in different 
shapes, and therefore values, of SUVpeak as they will not be fully spherical. 
 
For example, if a SUVpeak with a volume of 2mm
3
, rather than 1cm
3
, was required, only two 
voxels would be needed. These two voxels would be different values depending on which plane 
the neighbouring voxel was searched for in, i.e. a 2-voxel volume along the coronal plane will 
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yield a different result to one along the sagittal plane, to a different one along the transverse 
plane. Simple rectangular VOIs for 2-voxel (2 x 1 x 1), 4-voxel (2 x 2 x 1), 12-voxel (3 x 2 x 2), 
16-voxel (4 x 2 x 2) and 18-voxel (3 x 3 x 2) SUVpeak-like measurements can be constructed with 
the difference in SUVpeak dependent upon which plane the VOI is in and results can vary by ~8% 
(0.3 SUV) (Table 2.1, based on the data of a group of mesothelioma patients in chapter 4.2). 
This may not seem significant but maximum differences of up to 38% (4.2 SUV) for 2-voxel 
VOIs and 24% (3.3 SUV) for 4-voxel and 16-voxel VOIs are possible which could have a 
considerable effect on the reproducibility and variability of SUVpeak between studies. The lowest 
differences are seen in volumes with a higher number of voxels and with more symmetrical 
shapes (the 16-voxel SUVpeak has larger differences, ~10%, but this is because the cubic volume 
is more elongated with dimensions of 4 x 2 x 2). 
 
The data herein show that even at a fundamental level, SUVpeak is prone to variation and matters 
are further complicated when different shapes or connected voxels can be used, as well as 
different directions. For example, if a spherical SUVpeak is constructed of 1cm
3
 (10 voxels) with 
a 1.2cm diameter (2 voxels in coronal or sagittal plane or between 3-4 voxels in the transverse 













Mean Diff Mean Diff (%) Max Diff Max Diff (%) 
2-voxel SUVpeak (2 by 1 by 1) 0.682 (0.831) 7.55 (7.56) 4.198 37.39 
4-voxel SUVpeak (2 by 2 by 1) 0.550 (0.578) 6.29 (6.18) 2.989 24.77 
12-voxel SUVpeak (3 by 2 by 2) 0.396 (0.476) 4.62 (4.19) 2.514 19.82 
16-voxel SUVpeak (4 by 2 by 2) 0.612 (0.701) 7.33 (5.74) 3.288 24.10 
18-voxel SUVpeak (3 by 3 by 2) 0.360 (0.461) 3.90 (3.98) 2.106 16.41 
ALL 0.520 (0.609) 5.94 (5.53) 4.198 37.39 
Table 2.1: Mean and Maximum Differences of Rectangular SUVpeak in Different Planes 
Mean and maximum difference of SUVpeak measurement when taken in different planes in all three 
directions (i.e. x-plane value – y-plane value, x-plane value – z-plane value and y-plane value – z-plane 
value) over 27 images with a voxel size of 97.80mm
3
in a dataset of mesothelioma patients (see chapter 4.2 
for details). Absolute and percentage differences are shown. S.D. (Standard Deviation) in brackets. Diff = 
Difference. 
 
SUVpeak in PETTRA was implemented by joining the 6-connected neighbours (then 18-
connected and then 26-connected) in a systematic and logical order, with voxels added on the 
coronal plane, then the sagittal plane and finally the transverse plane. Using 10 voxels for 
SUVpeak, PETTRA would use the shape in Figure 2.27A. However, more symmetrical and 
sphere-like shapes in Figures 2.27B and 2.27C could represent the SUVpeak of a lesion more 
accurately. However, these methods would have a length/‘diameter’ of ~16mm (3 x 5.47mm), 
while the shape in Figure 2.27D would be closer to the PERCIST recommended 1.2cm diameter, 
at 10.94mm (2 x 5.47mm). Similarly to the difference in direction, the difference in shape used 
can affect the SUVpeak in the region of 3-4% (Table 2.2). All the different shapes and planes 
could be used to search for the highest region. However, this is more computationally exhaustive 
and is likely to be different depending on the exact methodology and software. 
 
To create more spherical VOIs with diameters closer to 1.2cm, taking partial voxels can be used 
rather than using whole voxels, e.g. using half voxels to produce more spherical like VOIs while 
using half the intensity of the whole voxel to calculate the intensity. However, computing a 
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SUVpeak using such a methodology is more intricate. While this was not investigated in this 
study, it would be interesting to discover the affect this technique would have on SUVpeak. It is 
worth noting that this is another factor which could cause variation in SUVpeak. 
 
 
Difference in SUVpeak Value 
Diff (SUV) Diff (%) 
Mean 0.329 3.19 
S.D. 0.483 3.55 
Min 0.002 0.06 
Max 2.626 17.74 
Table 2.2: Mean Difference of SUVpeak using Different Shapes of 10 Voxels 
Mean difference in SUVpeak using shapes B, C and D in Figure 2.27 over all 27 images with a voxel size of 
97.80mm
3
. Absolute and percentage differences are shown. S.D. = Standard Deviation. Diff = Difference. 
 
There are also significant differences in SUVpeak values depending on the size of the VOI and 
whether it is in 2-D or 3-D (Vanderhoek et al., 2012), however, even if a fixed 3-D volume is 
taken this does not always mean the results will be the same as has been shown with the results 
in Tables 2.1 and 2.2. While these variations need to be considered, as long as the method uses 
the same volume and methodology it is unlikely to vary enough to cause significant differences. 
For example, over the 27 images with voxel sizes of 97.80mm
3
, the default PETTRA SUVpeak 
shape A correlated extremely well with shapes B, C and D (Figure 2.27), with Pearson 
Correlation Coefficients (pcc) of 0.998, 0.996 and 0.990 respectively (p-value > 0.0001). 
 
In PETTRA, SUVpeak in a segmented VOI is obtained by calculating the SUVpeak for each voxel 
in the VOI with the highest value representing the SUVpeak in the VOI. This does mean that the 
SUVpeak may include voxels outside the segmented VOI, however, this would be unlikely, 
especially in large TVs. SUVpeak was also obtained from HERMES software, which tries to 
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follow the PERCIST recommendations but often takes a lower volume, presumably to take into 
account the SUVpeak diameter measure. 
 
Figure 2.27: Potential Shapes for SUVpeak using 10 Voxels 
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2.4.5) Obtaining SUVmean, Tumour Volume and Total Lesion Glycolysis 
Once disease has been segmented, parameters such as SUVmean, TV, TLG and S.D. can all be 
obtained from a tumour and are useful in assessing response along with SUVmax and SUVpeak 
parameters. PETTRA will automatically display the SUVmax, SUVmean and volume parameters 
for the combined segmented areas in the viewer and in addition will show all these parameters, 
and SUVpeak, for each VOI in a table upon the request of the user (Figure 2.28). 
 
Figure 2.28: Visual Display of VOI Statistics in PETTRA  
Details of VOIs segmented by the user are automatically displayed on the PETTRA GUI, including the 
starting voxel of the last segmentation (A). A pop-up table is displayed after ‘VOI Details’ is selected 
which shows full details of each individual segmentation in the image and the combined total (B). Each 
row represents a different individual segmentation with the last row being the SUVmax and SUVpeak over 
all the segmentations and the combined total of SUVmean, number of voxels, volume, TLG and S.D. The X, 
Y and Z co-ordinates on each row represent a voxel from within the segmented region. 
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The volume of each VOI is listed in ml and is the result of the number of voxels multiplied by 
the voxel size, obtained from information in the header file of the image. TLG is the product of 
the SUVmean and the volume (SUV * ml, or g). 
2.4.6) Implementation of Intensity Volume Histograms and Related Statistics 
As discussed in 1.3.5, histograms can provide more information about a VOI than simply 
SUVmax and SUVpeak. PETTRA has implemented a ‘Statistics’ button which brings up a new 
GUI which presents the user with a wealth of graphs and parameters that can be used for 
identifying response to therapy including several histograms which can be a useful visual aid and 
which parameters can be extracted from. Firstly, typical histograms plotting the number of 
voxels against intensity, with different binning of voxel intensities, are displayed (Figure 2.29). 
 
 
Figure 2.29: Histograms of Number of Voxels against Intensity in a Segmented VOI 
(A) MATLAB constructed histogram of voxels against intensity and (B) a customised version of the 
histogram with data binned into units of 0.2, 0.5 and 1 SUV. 
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The intensity volume histogram (IVH) is a modified version of the histogram which plots 
volume as a function of image intensity over a given intensity. A number of metrics can be 
extracted from the IVH, the six used in studies looking at response are I10, I90, I10-90, V10, V90 and 
V10-90 (El Naqa et al., 2009a; El Naqa et al., 2009b). Ix is defined as the ‘minimum intensity to 
x% highest intensity volume’ while Vx is defined as the ‘% volume having at least x% intensity 
value’ (El Naqa et al., 2009a). These have been implemented in PETTRA as I10 (or I90) is the 
minimum intensity in the highest 10% (or 90%) of the volume subtracted from the minimum 
intensity in the VOI, while V10 (or V90) is the volume in the VOI having at least 10% (or 90%) of 
the SUVmax. I10 and V10 are therefore calculated as: 
 
        [2.13] 
                          [2.14] 
 
To show the principle of these equations, an example from the dataset investigated in chapter 5 
is shown. Table 2.3 lists the intensity of the 17 voxels in a TV on a response scan. For this 
example, I10 would be the minimum intensity of 4.6 and 4.5, as just two voxels would make up 
10% of the volume. These subtracted from the minimum intensity of 2.6 would give a I10 of 1.9. 
V10 would result in a volume of 100% because all the voxels would be over 10% of the 
maximum intensity of 4.5. However, V90 would give a volume of 17.64% as there are three 
voxels greater than 90% of the SUVmax (0.9 * 4.6 = 4.14) and three divided by the number of 
voxels in the VOI (17) gives 17.64%.  
 
4.6 4.3 3.9 3.7 3.3 3.1 3.0 2.7 2.6 
4.5 3.9 3.8 3.5 3.1 3.0 2.9 2.6  
Table 2.3: List of Voxel Intensities from a Tumour Volume in a Response Scan 
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The concept of these IVH parameters is that they describe more about the distribution and 
intensity of data than SUVmax and SUVpeak and take into account the tumour intensity unlike TV. 
For example, I10 is taking into account a specific intensity range which does not involve the 
SUVmax  or the top 10% of intensities in the image, but the intensity range after they are 
removed. This eliminates the possibility of noise affecting these values considerably and 
estimates whether the tumour is still very active if the highest values in the tumour are removed. 
If a tumour still has a high intensity after the highest intensities have been removed, it is likely to 
have more, intense cancer cells and, theoretically, be more immune to therapy and less likely to 
respond. The IVH and related statistics, including volumetric data for a VOI, are displayed in 
PETTRA as shown in Figure 2.30. 
 
 
Figure 2.30: Intensity Volume Histogram and Related Statistics for a Segmented VOI 
The IVH is displayed on the left while statistics on the right show related parameters to the IVH and 
statistics taken from the VOI. 
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3) Registration of Pre- and Post- Therapy PET/CT Scans 
for Assessing Response to Therapy 
3.1) Introduction to Registration of Pre- and Post- Therapy PET/CT Scans 
3.1.1) Motivation for Registration of Pre- and Post- Therapy PET/CT Scans 
There are several reasons for obtaining registered pre- and post- therapy PET/CT images, 
particularly for assessing response to therapy. Qualitatively, image registration can allow an 
observer to see lesions in both scans in the same anatomical space, potentially aiding the 
interpretation of pre- and post- therapy images and the determined response. Quantitatively, 
accurate registration can allow computation of subtraction images of pre- and post- therapy 
images from which it may be possible to obtain new parameters. Tumour volumes (TV) from 
pre- therapy scans can be used on post- therapy scans to analyse changes in the size, shape and 
texture of lesions, potentially aiding the development of volumetric measures such as total lesion 
glycolysis (TLG). If registration is accurate enough, new methods of quantitative response 
assessment employing voxel analysis techniques, such as statistical parametric mapping, could 
be used, as they have been in studies of the brain (Jeong et al., 2005; Lee et al., 2008; Amorim et 
al., 2010; Hsieh et al., 2012). These methods have the potential to improve response assessment 
and predict the success of therapy. Therefore, a robust and accurate method for registering pre- 
and post- therapy PET/CT studies could be of significant benefit. In this chapter, three methods 
for registering pre- and post- therapy PET/CT images are investigated and evaluated in respect 
of their accuracy and robustness. The effect of the registration methods on SUVs and TVs will 
also be studied. 
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3.1.2) Registration of Pre- and Post- Therapy PET/CT Scans 
PET images are far from ideal to register, as they have low spatial resolution meaning that the 
best possible registration can still only be within the region of 4-6mm and the metabolic nature 
of imaging means that anatomical (or other) landmarks cannot be selected for use in registration 
easily. Intensities in the image are likely to change significantly to mark a response to treatment 
ruling out the possibility of using them for registration. For these reasons, registering one PET 
scan to another becomes problematic. Registration of pre- and post- therapy PET images has 
been attempted using a non-rigid algorithm which uses position dependent rigidity to stop areas 
of high tracer uptake changing shape or intensity (De Moor et al., 2006). Registration was found 
to be accurate and made visual therapy response assessment easier and faster, however, there 
was no thorough evaluation into how accurate the registration was or how it may help assess 
response assessment other than promising visual images and clinician feedback. 
 
While PET-PET registration is a plausible method for registering PET/CT scans, using the CT 
component for registration appears to be a more practical, easier and justifiable method of 
registration. CT images have a high resolution and are not as likely to change dramatically over 
time, particularly when compared to PET where drastic changes in tumour uptake are expected 
shortly after therapy. Although changes in tumour size and density are seen on CT images, they 
are not usually as sizeable after a few weeks of therapy (Wieder et al., 2005), and therefore, 
registering pre- and post- therapy CT images and applying the resulting transformations to the 
respective PET images appears to be a more suitable method. A similar methodology was used 
to register PET/CT studies of lung tumours, using a multilevel nonlinear registration to align 
pre- and post- therapy CT data to be used in the registration of PET images (Ouksili et al., 
2007). This study showed promising results, although it was only tested on synthetic data, and 
not clinical data. 
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Most other studies investigating PET/CT registration opt for rigid registration methods (Necib et 
al., 2011; Zsoter et al., 2011). Rigid registration does not use non-rigid deformations to register 
tumours, therefore eliminating the possibility that the size and shape of a tumour on the 
registered post-therapy image will be changed drastically in an attempt to match it to the pre-
therapy image. Changes in tumour size from pre- to post- therapy CT images, the potential effect 
of these changes on registration and the affect of all this on the transformed PET images are yet 
to be full studied. Despite these potential issues, non-rigid registration is likely to register images 
more accurately than rigid registration and has been shown to be very accurate in aligning head 
and neck PET/CT scans for radiotherapy planning (Ireland et al., 2007). However, the most 
recent studies on the subject use rigid registration techniques. A hextuple registration method 
using a unique similarity measure showed good accuracy and speed in registering simulated pre- 
and post- therapy PET/CT scans but this has not yet been applied to clinical data (Zsoter et al., 
2011). Necib et al. (2011) computed parametric images by registering pre- and post- therapy 
PET/CT scans and obtained promising results in terms of predicting response, suggesting 
registration must have been successful for this methodology to work, however, the accuracy of 
registration was not thoroughly investigated (Necib et al., 2011). 
3.1.3) Registration of PET and CT Scans 
PET/CT scanners allow acquisition of both modalities within the same image space allowing 
automatic co-registration. However, there are limitations due to differences in imaging time, 
which can result in errors in registration due to patient movement and breathing. During a 
PET/CT scan, the CT scan is acquired at the beginning of the imaging protocol and the more 
time consuming PET after. This means the CT image is from a relatively fixed position within 
the breathing cycle and of a still patient, while the PET image will be over the whole breathing 
cycle and is likely to be affected by a patient’s movement on the bed. These differences between 
the acquisition of the PET and CT scans can cause errors in registration (Veit et al., 2006). If 
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common acquisition and reconstruction methods are used, images should still be very well 
registered in space and in time. PET and CT images from PET/CT scanners can be registered 
with an unprecedented accuracy compared with separate imaging (Coleman et al., 2005; Weigert 
et al., 2008).  
 
In some PET/CT scans there is the possibility of non-rigid misalignment artefacts due to 
respiration (Shekhar et al., 2005), although these can be minimised to dimensions comparable to 
the spatial resolution of most PET scanners (Goerres et al., 2002a). Statistically significant 
differences between PET and CT images are common but are of a modest nature and are usually 
in the limits of PET resolution (Nakamoto et al., 2003). A study measuring distance between 
fiducial markers on concurrent PET and CT scans found differences between 1.6mm to 3.1mm 
(Somer et al., 2007), within the range of PET resolution. Therefore, it appears acceptable to 
apply transformations obtained from registering pre- and post- therapy CT scans to concurrent 
pre- and post- therapy PET scans. However, it should be noted that differences in PET and CT 
acquisition can cause misalignment and registration of concurrent PET and CT scans could be 
used to improve registration of pre- and post- therapy PET/CT studies further. 
 
3.2) Methodology for Registering Pre- and Post- Therapy PET Scans 
3.2.1) Proposed Registration Algorithms for Registering PET Images 
CT-CT registrations are intra-modality and intra-subject class problems, meaning that the 
modality and subject remain the same with the only differing factor being the time of the scan. 
This makes voxel intensity based similarity measures for registration a favourable and fast 
measure to use. The sum of squared differences (SSD) is a measure which uses the difference, or 
lack of, from one image to another in terms of intensity values to guide registration. This is the 
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most common measure for registering images of the same modality and has been used for 
registering serial MR scans (Hill et al., 2001). Other intensity based similarity measures such as 
cross correlation (CC) and normalised mutual information (NMI) will be tested but are more 
suited to inter-modality registration problems i.e. scans from different modalities. Other 
registration techniques, such as using landmark or surface/edge-based measures, have been 
disregarded because there are no fiducial markers in the images. Identifying anatomical 
landmarks would be time consuming and not as accurate as the aforementioned methods as 
intensity values across the whole CT image hold the most information and rarely change 
drastically. 
 
There has been limited research on longitudinal pre- and post- therapy PET-PET or CT-CT 
registration. Designing new methods and algorithms would be wasteful when current techniques 
and software may be adequate. For this reason, the Image Registration Toolkit (IRTK), which 
provides an environment in which many types of medical images can be registered to one 
another using both rigid and non-rigid algorithms, was used for registration (Rueckert et al., 
1999; Studholme et al., 1999; Schnabel et al., 2001). IRTK has been shown to be one of the best 
nonlinear deformation registration methods for registering MRI brain images (Klein et al., 
2009). The IRTK library is flexible and allows parameters to be modified to ensure the best 
registration for a particular task, in this instance, registering longitudinal pre- and post- therapy 
CT scans of lymphoma patients using rigid and non-rigid techniques. 
 
Both customised rigid and non-rigid IRTK registration algorithms were used to register pre- and 
post- therapy CT studies with parameters such as resolution levels, blurring, number of 
iterations, step size, step length, interpolation mode and optimisation method experimented with 
to find robust and accurate registration methods suitable for the purpose of registering pre- and 
post- therapy CT scans. Initial experimentation took place on five patients, from a dataset of 20 
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patients with lymphoma. The full 20 patient dataset was used to validate the registration methods 
in a more thorough assessment. In the initial experimentation, visual interpretation of pre- 
therapy and registered post- therapy images, both overlaid in greyscale and in the form of 
subtraction images, was used to assess which parameters provide the most accurate, efficient and 
robust algorithms for rigid and non-rigid registration. Subtraction images subtract the intensity 
values of one image from the other allowing the observer to see differences between them and 
the changes in intensity. More accurately registered post-therapy images are likely to produce 
subtraction images with less difference in intensity values. 
 
Patient alignment between pre- and post- therapy scans is usually relatively close in the coronal 
and sagittal planes as the patient is placed in the same position along the width of the bed. 
However, the misalignment in the transverse plane is often much greater as the patient 
positioning along the length of the bed is more variable. Patients should be aligned within 3cm, 
in either direction, of a marker used to guide patient positioning along the length of the bed to 
ensure that misalignment between scans is no larger than this. This is the case in the dataset used 
herein acquired at the St Thomas’ PET Centre but also, a similar standard of positioning should 
be used in other institutes. This still means PET-CT images can be misaligned by up to 6cm in 
the transverse plane before any registration is performed. Initial experimentation of changing 
parameters in registration algorithms found large misalignments of this degree to be problematic 
causing significant modifications of IRTK parameters. A method involving calculating the 
centre of mass (COM) of each scan and aligning these in image space showed promise in 
aligning images in a computationally fast manner and was tested along with IRTK rigid and non-
rigid methods. 
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3.2.2) Centre of Mass Registration Algorithm 
In an attempt to register images initially in a computationally efficient way, a COM registration 
method was implemented to try and perform a simple but very fast alignment. The COM of an 
image, I, is defined as:  
                                                                                              [3.1] 
where pi = position of each voxel and mi = mass of each voxel.  
 
Calculating COM of both pre- and post-therapy images in all three axes, the two can be aligned 
approximately by converging them together in all three planes. This was achieved using 
MatLab
®
. The difference in COM in each plane was calculated in voxels and then converted to 
mm so it could be corrected for on IRTK R-view software, a visual viewing tool for looking at 
registered images. This technique is very efficient, taking ~5-20s to calculate the COM on the 
two images and can potentially give a good initial starting point for finer algorithms to start 
from. 
3.2.3) Rigid Registration Algorithm 
Default IRTK input parameters for rigid registration assume the two images are already aligned 
relatively well, using low step lengths i.e. small movements in the region of mm rather than cms, 
to try and match the source image to the target image. Due to the possibility of considerable 
original misalignment, particularly in the transverse plane, input parameters were modified to 
allow successful alignment of all images. The customised algorithm uses three resolution levels 
with the first using very large step lengths and a high number of iterations to ensure the images 
are aligned to within a few cm. This allows even the most misaligned images to converge to an 
extent where finer registration can take place, increasing the robustness of the algorithm. 
 130 
SSD is used as a voxel similarity measure, gradient descent as an optimisation method and 
default values for blurring and resolution of the images were kept at 1.6mm and 3.2mm 
respectively at the finest registration level. The blurring and resolution parameters are set to 
dictate to what degree the images are blurred defining the amount of detail in the images that 
stands out, and to set the voxel size of the images during the registration process. At the most 
coarse registration level, blurring and resolution are set to 6.5mm and 13mm respectively but 
with a large step length, number of steps and iterations to ensure convergence from poorly 
aligned pre- and post-therapy scans. The algorithm uses linear interpolation, as it is balances 
accuracy and speed (using more complex methods of interpolation at least tripled the time taken 
for registration). Nearest neighbour interpolation is not ideal in terms of getting a more detailed 
transformation and more complicated sinc and cubic methods increase computation time greatly 
with little significant difference in registration accuracy when viewing subtraction images. 
3.2.4) Non-Rigid Registration Algorithm 
Rather than use a non-rigid method that starts on unregistered images, it is more appropriate to 
use a rigid registration transformation as a starting point for a non-rigid method. The IRTK non-
rigid method uses the IRTK rigid registration transformation as a starting point due to the 
considerable initial misalignment that can be found between some pre- and post- therapy scans. 
While the deformations applied by the non-rigid algorithm are likely to have an effect on the 
accuracy of registration at a fine level, they are unlikely to change transformations at the 
beginning of registration when initially aligning two images cm apart, and so applying them 
after the rigid algorithm appears to be a logical method. The IRTK non-rigid algorithm uses 
three resolution levels like the rigid registration algorithm, but with shorter step lengths, number 
of steps and number of iterations in an attempt to achieve finer alignment, all set to default IRTK 
settings. Like the IRTK rigid algorithm it uses SSD as a similarity measure and gradient descent 
as an optimisation method. A typical IRTK non-rigid registration takes ~1h to run but this is 
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variable depending on the exact size of the images/subvolumes being registered. While rigid 
registration allows only translations and rotations to align images, non-rigid algorithms perform 
affine registration changes, such as scaling and shearing of images so lengths and angles are not 
preserved, and non-linear deformations to register the source image to fit the target. The IRTK 
non-rigid method uses free-form deformation based on b-splines to transform images (Rueckert 
et al., 1999).  
 
Non-rigid registration is likely to improve registration accuracy of images, although which 
method will be better for looking at response to therapy is unclear as non-rigid registrations 
could cause unwanted changes to tumours on PET images. This will be an important factor in 
this study and is evaluated in 3.4. The non-rigid method takes between 45-111min (mean: 
80min), depending on the size of the image or subvolume, compared to ~3-4min for the rigid 
method in comparison (on a Lenovo Thinkpad R61 with 3GB of RAM and an Intel® Core™ 2 
Duo CPU T8100 @ 2.10GHz). 
3.2.5) Dataset for Evaluating Registrations 
All three registration algorithms were performed on 20 pre- and post- therapy PET/CT studies on 
patients with lymphoma (11 male, 9 female; median age, 30 years; age range, 18-73 years). The 
time between pre- and post- therapy scans in this study was approximately 3 and a half months 
(median, 96; days, range, 55-263 days). CT image dimensions were 512 x 512 x 223, 267 or 311 
(with voxel sizes of 0.98mm x 0.98mm x 3.27mm) while PET image dimensions were 128 x 128 
x 223, 267 or 311 (with voxel sizes of 4.69mm x 4.69mm x 3.27mm). In the transverse plane, 
the number of slices was 267 slices 25 times, 223 slices 13 times and 311 slices twice over the 
40 images from the 20 datasets. All PET images underwent AC. Injected activity of 
18
F-FDG for 
each PET scan ranged from 294-377 MBq. Both PET and CT scans used free breathing 
protocols and CT scans were low dose, non-contrast enhanced scans. Images were acquired on 
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GE Discovery ST or GE Discovery VCT PET scanners (Waukesha, WI). Response to therapy on 
CT only was measured by a radiologist using the IWC (Cheson et al., 1999). PET/CT response 
was scored by two physicians from the PET Imaging Centre at St Thomas using the Deauville 
criteria (Meignan et al., 2009). 
 
The three registration algorithms were tested on subvolumes of each image, selected from below 
the pelvis to the base of the skull in the transverse plane, the complete torso in the coronal plane 
(with arms removed) and from the front to the back of the thorax in the sagittal plane. This 
subvolume was chosen as it was thought that it would allow registration to take place on a 
specific area of the body, as would be expected in research scenarios when registering just 
diseased areas of the patient. Equally, this area should give enough information for both visual 
and landmark analysis. On average, volumes were 335 x 230 x 630mm. Subvolumes were used 
for performing all registrations and for visual and landmark analysis. It is hoped that the 
algorithms used will work on both smaller and larger VOIs and even whole body images as well. 
However, for this study it was important to keep analysis to an area large enough to assess 
registration success while being small enough to ensure it was a practical investigation and 
computationally efficient. All the registration methods use CT data to perform registrations and 
the resulting transformations are then applied to corresponding PET images with the assumption 
that there was no, or limited, patient movement between the PET and CT acquisition. No 
noticeable misregistrations between PET and CT were found during inspection of the 
registrations.  
3.2.6) Reason for Chosen Registration Evaluation Methods 
Analysing image registration algorithms can be difficult to achieve, not least because it can be 
challenging to differentiate between registration inaccuracies and actual physical differences 
between images (Zitova et al., 2003). Qualitative assessment, where experienced image analysts 
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assess the images visually, can be a valid method but there are issues with how much 
misalignment can be detected by human evaluation. Wong et al. (1997) investigating human 
perception of registration accuracy in 3-D brain 
18
F-FDG PET to MRI images showed five 
observers could all detect translational misregistration of up to 2mm along the x- and y- axes, 
and 3mm in the z-axis (Wong et al., 1997). Rotational misregistration could be detectable by all 
observers by up to 2° in z-axis, 3-4° in the y-axis, and 2° in the x-axis for positive rotation and 
4° for negative rotation. A similar experiment on MR and CT brain images showed that 
differences of >2mm are usually spotted by experienced observers (Fitzpatrick et al., 1998a). 
This evidence suggests that visual assessment can be a worthwhile method of testing registration 
algorithms. There are clear differences between the degrees of detection that can be made 
between whole body CT-CT images in comparison to MRI brain images but it is still likely that 
any translations of several mm or significant rotation will be noticed.  
 
Quantitative methods of assessing registration accuracy are less subjective and provide a result 
which can quantitatively estimate how accurate registration is. One method of quantitatively 
assessing registration accuracy is to use a voxel-based similarity measure to calculate how well 
aligned images are with each other. As this technique has been used to register images, it would 
be expected to show excellent results, but it is a circular argument to prove the method works 
using the same technique used to achieve the registration in the first place. An alternative 
method is to assess how close fiducial or anatomical landmarks are to each other on the two 
images by calculating the distance between them. Fiducial markers can be placed in or around a 
patient during scans. While this is ideal for quantitative assessment, fiducial markers are not 
used routinely in a clinical environment so the dataset does not have such markers available. 
Rather than using artificially placed fiducial markers, anatomy in images can be used. An 
anatomical landmark registration assessment is more practical but not ideal as there are likely to 
be differences in where markers are placed on images, for example, due to intra- and inter- 
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observer variability. Factors including patient breathing, movement and positioning can 
potentially have an impact on the accuracy of an observer locating these markers. 
Although using anatomical landmarks has some operator variability, it can be an excellent 
measure of registration as it can test whether the algorithm meets the clinical needs of the 
observer (Hutton et al., 2002). Reliably identifying anatomical landmarks requires a high 
resolution of anatomy so while landmark analysis on CT images is plausible, on low resolution 
functional PET images, this sort of analysis is not really possible. Non-rigid algorithms are 
harder to assess than rigid ones as the extent of non-rigid misalignment can be greatly different 
from case to case, therefore no single validation method can be used confidently (Hutton and 
Braun, 2003). Despite this visual assessment has been proven to be successful at validating and 
comparing non-rigid registration and there is no evidence to suggest that quantitative methods 
such as anatomical landmark measures would not provide useful analyse (Meyer et al., 1997). 
3.2.7) Proposed Methods for Registration Evaluation 
Both qualitative visual assessment and quantitative landmark analysis were used to evaluate 
registration accuracy on 20 pre- and post- therapy PET/CT datasets of lymphoma patients. Each 
of the 20 datasets were grouped into sets of five images, each comprising of a pre-therapy image, 
an unregistered post-therapy image and three post-therapy images with each of the registrations 
applied – COM registration, IRTK rigid registration and IRTK non-rigid registration. For each 
dataset, the pre-therapy image was assigned as image A while the others were randomly 
assigned as images B, C, D and E to blind observers from the registration method applied on 
each post-therapy image. PET and CT datasets were treated as different entities so random 
assignment of images B, C, D and E was different for PET and CT components for each dataset. 
 
For qualitative visual analysis, three researchers with experience of working with PET/CT 
images analysed the PET and CT images independently from each other and from the other 
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imaging modality. For each dataset, each researcher ranked images B-E in order of how 
successfully registered they were with image A and gave each a quality score from 5 (poor) to 1 
(excellent) to define the quality of registration according to a defined scoring system (Table 3.1). 
Rankings were done based on the quality score i.e. the better the quality score, the better the 
ranking. For images with the same quality scores, ranking was based on the observer’s 
judgement on which was more accurately aligned. The study was completed using HERMES 
Hybrid Viewer software (Nuclear Diagnostics AB, Stockholm, Sweden) which allowed each 
observer to view overlay images of each set of pre- and post- therapy scans and make spatially 





Almost perfect fit, no misalignment noticeable, almost like looking at the 
original baseline image. 
2 
Very small misalignment is just detectable but generally all the main 
organs and anatomy are very well aligned. 
3 
Some misalignment of organs and anatomy is noticeable in certain areas 
but generally everything is aligned to a suitable standard. 
4 
Misalignment of organs and anatomy is clear but the body is generally 
aligned. 
5 (poor) Misalignment of the entire body. 
Table 3.1: Quality Score Criteria for Judging Registration Accuracy 
 
CT registration was validated by a quantitative anatomical landmark study by one observer on 
the same groups of images for the 20 datasets. A number of anatomical landmarks were located 
on the pre-therapy (image A) and post- therapy (images B-E) images to measure the distance 
between corresponding points (Table 3.2). The difference in voxels and mm was measured 
between anatomical landmarks on the pre- therapy image and the same landmark on the post-
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therapy image, in each plane, to estimate registration error. The distance between two anatomical 
locations on a target image and a registered image can be referred to as the target registration 
error (TRE) and this will be used to estimate the accuracy of registration methods (Fitzpatrick 
and West, 2001).  
 
When using anatomical landmarks, TRE is affected by observer error in identifying each 
landmark so the accuracy of the observer for selecting the voxel for each landmark will have to 
be taken into account. The observer was asked to select the voxel for an anatomical landmark on 
five pre- and post- therapy images, five different times, to estimate observer error in locating 
each anatomical landmark. When dealing with fiducial markers, the distance between a given 
localised point and the actual, real unknown fiducial position of the point is referred to as the 
fiducial localisation error (FLE) (Fitzpatrick et al., 1998b). For the anatomical landmark 
analysis, the FLE is defined as the error in the observer locating a single fiducial marker, or in 
this case an anatomical landmark. 
 
Tip of the tail of the spine 
Tip of the left hip/coxal bone 
Tip of the right hip/coxal bone 
Central point of the 5th lumbar vertebrae 
Central point of the 11th thoracic vertebrae 
Central point of the 7th thoracic vertebrae 
Medial point of the left scapula 
Medial point of the right scapula 
Central point of the manubrium 
Tail of the sternum 
Superior tip of the left lung 
Superior tip of the right lung 
End of the trachea 
Medial inferior tip of the left lung 
Medial inferior tip of the right lung 
Lateral inferior tip of the left lung 
Lateral inferior tip of the right lung 
Superior tip of the liver 
Inferior tip of the liver 
Superior tip of the left kidney 
Inferior tip of the left kidney 
Superior tip of the right kidney 
Inferior tip of the right kidney 
Superior tip of the spleen 
Table 3.2: Anatomical Landmarks for Quantitative Registration Accuracy Analysis 
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3.3) Results of Registering Pre- and Post- Therapy PET/CT Scans 
3.3.1) Initial Visual Assessment of Registered Images 
A brief visual assessment of overlay and subtraction images gives an idea of the success of 
registration for each algorithm. It becomes apparent that while the COM method has great 
success on some individual datasets, it is not robust enough over the 20 datasets to be used 
usefully as in some cases it is no better aligned than the unregistered image. The IRTK rigid and 
non-rigid methods show much better success over the 20 datasets, demonstrating more robust 
algorithms and promising registrations upon visual inspection. The non-rigid algorithm shows 
more accurate registration when viewing overlay and subtracted images. This is illustrated in 
Figure 3.1, a subtraction image of dataset 1’s pre- and post- therapy CT images, and Figure 3.2, 
an overlay image of dataset 3’s pre- and post- therapy CT images. The COM registration works 
well on dataset 3 but poorly on dataset 1 where IRTK rigid and non-rigid algorithms appear well 
aligned on both. It is worth noting the difference in initial misalignment in the transverse plane 
which is small in dataset 1 (Figure 3.1A) but substantial in dataset 3 (Figure 3.2A). 
3.3.2) Anatomical Landmark Analysis Results 
3.3.2.1) Fiducial Localisation Error for Anatomical Landmark Analysis 
Whole body anatomical landmark analysis, or even registration, is rare in literature. Therefore, 
with little information or recommendations on what landmarks could be used outside of the 
brain, a degree of trial and error was used to choose suitable anatomical points (Table 3.2). 
Typically, it has been shown that between 8-16 landmarks are enough to produce good results 
for validating images using landmark based techniques (Hill et al., 1993; Strasters et al., 1997; 
Hawkes, 1998). However, with the suitability of potential landmarks unknown, a number of hard 




Figure 3.1: Subtraction Images for Registrations on Dataset 1 
The four images show the pre-therapy CT scan minus the post therapy CT scan with (A) no-registration, 




Figure 3.2: Overlay Images for Registrations on Dataset 3 
The four images show the pre-therapy CT scan overlayed with the post-therapy CT scan with (A) no-
registration, (B) COM registration, (C) rigid registration only, and (D) non-rigid registration applied. 
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The initial 24 anatomical landmarks (Table 3.2) were located over the first five datasets of pre- 
and post- therapy CT images, five separate times by the same observer, with a sufficient time 
gap between each attempt to locate the same landmark. The FLE was defined as the average 
error in distance between the observer-located voxels. FLE was calculated for each landmark for 
each 2-D plane and as a 3-D distance incorporating all planes in the image. The mean FLE for 
each landmark over the five scans is shown in Table 3.3. Landmarks which had a high mean 3-D 
distance FLE of >5mm were removed from the study, leaving the remaining landmarks suitable 
for assessing registration accuracy. 
 
Table 3.3 shows six anatomical landmarks proved much harder to reliably identify than the 
majority of others (landmarks 2, 3, 14, 15, 16 and 17). This could be due to a number of factors 
including unclear instructions on how to identify the landmark, difficulty in accurately 
identifying the location of the landmark and variability between scans and patients making a 
landmark harder to locate. The decision was made to remove these six landmarks as there was a 
great deal of unreliability in locating them consistently, illustrated by a mean 3-D distance FLE 
of >5mm. The remaining 18 landmarks were found to have a mean 3-D distance FLE of <5mm 
and were allocated for use in the study. The mean FLE of the selected 18 landmarks was 
1.57mm in the x-plane, 0.93mm in the y-plane and 0.33mm in the z-plane. The mean 3-D 
distance measurement was just 2.01mm
2
. These results show that landmarks can be identified 
accurately and although there may be some FLE in the results, it should be minimal and 









No Landmark X Y Z 3D Distance Included 
1 Tip of the tail of the spine 2.42 0.90 0.94 2.90 Yes 
2 Tip of the left hip/coxal bone 10.74 9.02 10.86 20.11 No 
3 Tip of the right hip/coxal bone 11.60 7.03 10.43 19.16 No 
4 Central point of the 5th lumbar vertebrae 1.37 0.70 0.20 1.67 Yes 
5 Central point of the 11th thoracic vertebrae 1.48 0.62 0.43 1.70 Yes 
6 Central point of the 7th thoracic vertebrae 1.25 0.74 0.39 1.59 Yes 
7 Superior tip of the left clavicle 0.43 0.08 0.16 0.51 Yes 
8 Superior tip of the right clavicle  0.31 0.00 0.12 0.43 Yes 
9 Central point of the manubrium 2.58 1.33 0.70 3.21 Yes 
10 Tail of the sternum 1.25 0.86 0.59 1.89 Yes 
11 End of the Trachea 0.51 0.47 0.27 0.90 Yes 
12 Superior tip of the left lung 1.13 1.56 0.12 2.10 Yes 
13 Superior tip of the right lung 0.86 0.86 0.00 1.28 Yes 
14 Medial inferior tip of the left lung 13.24 6.80 2.70 15.44 No 
15 Medial inferior tip of the right lung 11.99 6.87 2.97 14.76 No 
16 Lateral inferior tip of the left lung 15.86 10.94 0.59 20.18 No 
17 Lateral inferior tip of the right lung 27.07 11.13 1.33 29.81 No 
18 Superior tip of the liver 0.94 0.55 0.00 1.15 Yes 
19 Inferior tip of the liver 3.91 2.19 0.51 4.86 Yes 
20 Superior tip of the left kidney 2.30 1.13 0.08 2.62 Yes 
21 Inferior tip of the left kidney 1.87 1.17 0.35 2.35 Yes 
22 Superior tip of the right kidney 1.84 1.41 0.47 2.45 Yes 
23 Inferior tip of the right kidney 1.37 0.78 0.12 1.64 Yes 
24 Superior tip of the spleen 2.42 1.37 0.59 2.93 Yes 
MEAN (ALL) 4.95 1.45 2.85 6.49 
 
S.D. (ALL) 6.67 2.93 3.57 8.36 
MEAN (18 LANDMARKS SELECTED) 1.57 0.93 0.33 2.01 
S.D. (18 LANDMARKS SELECTED) 0.91 0.26 0.53 1.08 
Table 3.3: Fiducial Localisation Error for Anatomical Landmarks 
Mean fiducial localisation error (FLE) in X, Y and Z planes and as a 3-D distance. Values are in mm 
worked out from voxel locations. Light grey values indicate those <5mm, grey between 5-10mm and dark 






3.3.2.2) Target Registration Error for Anatomical Landmark Analysis 
The 18 anatomical landmarks were identified on all 100 CT images of pre-therapy scans, 
unregistered post-therapy scans and registered post-therapy scans using all three registration 
methods. Occasionally, some landmarks could not be identified well enough to be deemed 
suitable for analysis in either one or more of the images. This was because they were considered 
to be too difficult to identify accurately or beyond the boundaries of the subvolume. In total, 301 
landmarks were used for assessing registration accuracy. For each dataset, there was at least 
11/18 landmarks selected (median: 15 landmarks). The difference in distance between the 
anatomical landmark on the pre-therapy CT image and on each of the four post-therapy CT 
images was calculated, in each direction and as a 3-D distance i.e. a combination of the 
difference in distance in all three planes (x, y and z planes), to provide an estimate of the TRE to 
assess the accuracy of registration. The TRE on each plane was taken as the distance from the 
voxel selected by an observer on the target image to represent a given landmark to the same 
voxel located on the registered image to represent the same landmark,. 3-D distance TRE was 
calculated as: 
                                     [3.2] 
where xi, yi and zi are the difference in distance between the landmark in the pre-therapy and 
post-therapy CT images, in mm, summed over n number of subjects. 
 
The mean TRE, in each plane and as a 3-D distance, for each anatomical landmark over the 20 
datasets for all registration methods is presented in Table 3.4. The mean TRE, in each direction 
and as a 3-D distance, for each dataset over the 18 anatomical landmarks for all registration 
methods is presented in Table 3.5. TREs are calculated for each of the four categories of 
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registered images: (i) no registration/unregistered, (ii) COM registration, (iii) IRTK rigid 
registration and (iv) IRTK non-rigid registration. The results show that prior to any image 
registration, the mean TRE between pre- and post- therapy CT scans was ~40mm (using 3-D 
distance measure). The non-rigid registration algorithm was the most accurate at registering CT 
images with a mean TRE of ~6.5mm between pre-therapy and non-rigidly registered post-
therapy CT scans. Rigid registration also showed a reasonable registration accuracy of ~10mm.  
 
Unregistered post-therapy images had a TRE of >8mm in all planes with particular misalignment 
in the transverse plane, with a mean TRE of ~33mm. Although COM registration has been 
shown to be very favourable on some occasions, it has also produced further misalignment 
compared to unregistered images on others. On average, COM proved to be only slightly better 
than no registration. It can be an efficient way of performing registration, but its lack of 
robustness means it is not a reliable option. Subvolume selection and field of view is potentially 
an issue with the COM method as pre- and post- therapy scans can show different areas of 
anatomy. There may be ways to improve this method for future use but the rigid registration 
method performs much better and is not much more computationally exhaustive. While 
registration as accurate as 1-2mm is common in the brain, patient movement and natural 
deformation can cause more issues when registering whole body images and so to accurately 
align images within 5-10mm, comparable with PET resolution, is a promising result. 
 
The anatomical landmark analysis shows variations in TRE when using different landmarks for 
rigid and non-rigid registration. Observer error is inevitable going to affect this but it’s worth 
noting landmarks such as the tip of the clavicles, tail of the spine and tips of the kidneys have 
larger TREs than landmarks on the vertebrae and in the lung. Differences in TRE between 
different landmarks on the same image may be because of differences in the registration 
accuracy in different regions of the body (TRE) or the ability of the observer to successfully 
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locate landmarks (FLE). However, with relatively low FLEs found between identifying 
anatomical landmarks (Table 3.3), it is likely these differences are primarily down to TREs, 
where some landmarks are not registered as well as others. For example, the tips of the clavicles 
and kidneys have much higher mean TREs than the three vertebrae, however, particularly for 
rigid registration, the tips of the clavicles and kidneys are less likely to be aligned in registered 
images in comparison to the centrally positioned (in comparison to the clavicles) and rigid (in 
comparison to the kidneys) vertebrae. Registration accuracy is fairly consistent throughout the 
20 datasets with only a few datasets with mean TRE 3-D distances >10mm. IRTK rigid and non-
rigid registration algorithms improved alignment in all 20 datasets with excellent improvement 
in the majority of datasets. To improve registration even further, a smaller subvolume of the 
image could be used when analysing a specific tumour, or a region of several tumours, as this 
reduces the possibility of misregistrations due to registration algorithms registering certain 
anatomy in the subvolume better than the actual area of interest. 
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   NO REGISTRATION COM REGISTRATION IRTK RIGID REGISTRATION 
IRTK NON-RIGID 
REGISTRATION 
# Landmark No X Y Z 3-D X Y Z 3-D X Y Z 3-D X Y Z 3-D 
1 Tail of the spine 12 4.88 11.31 30.79 37.31 5.62 6.51 14.99 19.37 3.17 2.60 3.27 6.40 2.69 2.36 6.27 8.29 
2 5th lumbar vertebrae 20 7.52 9.52 32.37 38.24 5.13 5.81 30.90 34.13 2.88 2.54 5.07 7.22 1.37 0.93 2.29 3.39 
3 11th thoracic vertebrae 20 5.91 11.33 33.03 39.13 4.49 6.15 31.07 34.62 4.25 2.10 4.74 8.06 1.37 1.07 4.58 5.65 
4 7th thoracic vertebrae 20 6.79 11.43 32.05 38.01 6.79 7.67 30.25 34.63 2.59 1.46 4.58 6.30 1.81 0.88 2.78 4.52 
5 Superior tip of the left clavicle 11 13.32 11.81 44.29 51.22 13.67 7.19 39.83 46.87 5.50 6.21 7.73 13.70 4.88 5.15 8.62 12.89 
6 Superior tip of the right clavicle 11 12.52 16.87 42.81 51.79 12.34 8.79 40.73 48.09 6.04 5.15 11.00 14.84 5.33 4.26 8.03 11.59 
7 Central point of the manubrium 20 8.98 9.23 34.01 38.65 10.74 6.69 29.92 35.64 3.56 2.44 5.07 7.27 2.39 1.46 2.29 4.36 
8 Tail of the sternum 17 9.59 6.95 32.32 37.22 6.89 4.31 21.16 24.66 6.03 2.76 4.23 8.94 2.70 2.41 4.04 6.28 
9 End of the Trachea 20 7.86 9.86 31.72 36.94 9.62 6.74 31.07 35.43 3.66 2.00 7.03 8.87 1.12 1.03 1.80 2.94 
10 Superior tip of the left lung 17 11.55 10.80 31.55 40.35 10.23 8.33 27.31 35.93 5.11 3.04 5.00 8.81 2.64 1.95 0.38 3.95 
11 Superior tip of the right lung 17 9.71 15.97 32.51 42.94 9.48 7.98 30.20 35.51 3.68 3.79 5.19 8.57 2.07 1.55 0.77 3.05 
12 Superior tip of the liver 19 8.89 11.00 30.63 38.45 7.35 7.25 24.78 29.37 7.61 5.50 7.06 13.45 3.44 2.67 0.69 4.97 
13 Inferior tip of the liver 9 13.02 9.55 31.61 39.68 13.56 10.09 27.25 35.57 7.27 6.84 8.36 15.48 7.81 2.28 7.27 11.75 
14 Superior tip of the left kidney 19 7.14 11.51 31.15 37.81 5.24 6.53 30.63 34.23 5.81 3.70 7.23 11.04 4.01 2.57 6.20 8.55 
15 Inferior tip of the left kidney 19 9.87 11.98 31.67 39.38 6.42 7.04 29.77 33.88 5.50 4.06 9.12 12.87 6.12 3.44 7.23 11.35 
16 Superior tip of the right kidney 20 7.28 11.04 35.48 42.31 6.79 6.64 31.23 35.55 5.47 3.76 6.21 10.14 3.91 3.08 6.21 9.05 
17 Inferior tip of the right kidney 20 8.94 7.76 37.44 43.13 7.18 5.57 34.17 37.35 4.69 4.44 8.18 11.50 4.20 3.52 5.72 8.75 
18 Superior tip of the spleen 10 10.35 9.67 20.60 29.40 10.55 17.87 14.72 31.57 5.37 2.64 6.21 11.31 3.03 2.93 0.65 4.74 
ALL 301 8.79 10.85 33.07 39.89 8.00 7.23 29.19 34.37 4.78 3.44 6.28 9.93 3.16 2.28 3.99 6.62 
Table 3.4: Target Registration Error for Anatomical Landmarks 
Mean target registration error (TRE) over the 20 datasets for the 18 anatomical landmarks for each registration method in X, Y and Z planes and as a 3-D 
distance. Values are in mm worked out from voxel locations. Light grey indicate those <5mm, grey between 5-10mm and dark grey are those >10 mm. 3-D 
distance are in mm. # = the number of the landmark used and No = the number of times that landmark was used in the analysis of the 20 datasets. Values in the 
ALL row are mean values apart from the number of times a landmark was used which is a total. 
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X Y Z 3-D X Y Z 3-D X Y Z 3-D X Y Z 3-D 
1 11 23.17 3.55 9.81 27.80 9.14 4.08 48.46 50.42 9.77 2.93 9.51 14.67 5.95 1.95 6.84 10.00 
2 17 5.11 3.62 6.73 10.32 5.11 2.87 9.62 12.21 3.96 2.99 2.50 6.90 3.04 3.04 2.50 5.79 
3 17 9.88 18.32 75.98 79.58 8.16 6.55 5.58 13.24 5.28 3.68 4.62 9.22 2.59 1.67 2.31 4.59 
4 17 13.50 10.17 12.50 22.86 13.90 12.93 17.89 32.16 9.71 5.86 16.35 22.02 6.84 3.33 12.70 16.39 
5 16 10.93 6.41 22.69 26.52 4.52 3.72 10.01 12.56 3.17 2.87 4.29 6.95 2.50 1.59 2.45 4.56 
6 16 11.66 18.13 5.31 23.35 4.64 5.55 17.99 20.08 3.85 3.11 5.93 8.97 2.81 1.65 2.86 5.42 
7 12 2.20 10.50 48.51 50.13 8.79 8.30 29.98 33.02 2.12 2.44 3.54 5.49 1.63 1.87 5.72 6.99 
8 14 3.77 11.58 78.25 79.75 2.44 8.30 97.63 98.18 3.63 4.81 5.61 9.20 3.14 1.95 1.87 5.05 
9 13 11.49 16.30 19.62 30.24 8.11 40.26 49.05 64.78 3.83 6.46 6.79 11.41 2.48 2.70 3.02 5.54 
10 15 8.98 6.12 38.15 40.48 9.96 7.42 13.52 20.55 7.88 3.52 7.85 13.16 3.71 2.08 5.67 7.96 
11 14 8.44 8.51 79.88 80.89 2.72 2.51 92.96 93.10 2.79 2.23 7.01 8.51 1.74 2.58 5.14 6.91 
12 17 7.58 18.32 15.20 26.14 11.09 4.88 6.54 14.89 4.83 2.53 5.58 8.58 2.59 1.67 2.89 4.67 
13 14 8.09 12.49 67.97 72.21 14.86 3.07 11.91 20.97 5.16 2.79 4.67 8.17 3.56 1.60 2.80 5.43 
14 17 8.33 8.67 6.16 15.57 8.16 5.51 6.16 13.14 4.37 2.47 5.96 8.88 3.45 2.41 2.69 6.10 
15 14 20.65 7.18 45.55 52.48 20.72 5.30 110.5 113.4 10.25 4.95 8.18 15.84 6.77 4.12 6.77 11.72 
16 14 5.51 2.93 6.31 9.91 7.11 2.37 35.27 36.28 4.53 2.23 2.34 6.47 2.09 1.46 1.87 4.00 
17 17 5.74 21.71 15.77 28.56 7.98 7.01 10.19 16.23 2.36 3.39 7.12 9.05 1.67 2.41 2.89 4.88 
18 17 2.76 2.36 62.52 62.69 3.45 2.41 10.77 12.24 1.15 1.95 3.65 5.38 1.15 1.26 2.31 3.63 
19 15 6.32 15.30 46.22 50.07 5.08 7.88 33.14 35.30 4.30 4.43 6.54 10.42 3.26 3.19 4.36 7.66 
20 14 5.30 11.65 6.54 16.59 5.16 7.88 7.01 13.24 3.77 3.35 7.71 9.91 2.93 3.14 3.04 6.20 
ALL 301 8.79 10.85 33.07 39.89 8.00 7.23 29.19 34.37 4.78 3.44 6.28 9.93 3.16 2.28 3.99 6.62 
Table 3.5: Target Registration Error for Each Dataset 
Mean target registration error (TRE) over the 18 anatomical landmarks for each of the 20 datasets for each registration method in X, Y and Z planes and as a 3-D 
distance. Values are in mm worked out from voxel locations. Light grey indicate those <5mm, grey between 5-10mm and dark grey are those >10 mm. 3-D 
distance are in mm. Landmarks Used = the number landmarks used in the analysis of that dataset. Values in the ALL row are mean values apart from the number 
of times a landmark was used which is a total. 
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3.3.3) Visual Assessment Results 
Results of the visual analysis study completed by three observers ranked the non-rigid registration 
method the highest 98% of the time on CT images and 82% of time on PET images. For both 
PET and CT, in cases where the non-rigid method was not ranked first, the rigid registration 
method was. The rigid and non-rigid registrations consistently got high quality scores with mean 
scores of 2.80 (CT) and 3.25 (PET) for rigid and 1.77 (CT) and 2.10 (PET) for non-rigid (Table 
3.6). Images with no registration had poor quality scores of 4.67 (CT) and 4.53 (PET), as did 
COM registration which performed only marginally better than no registration with average 
quality scores of 4.32 (CT) and 3.83 (PET). Registration accuracy was consistent over the 20 
patients with mean observer quality scores for each image between 1.34-2.67 (PET) and 1.34-3 
(CT) for non-rigidly registered images and from 2.34-3.34 (PET) and 2.34-4.34 (CT) for rigidly 
registered images. No registration saw a range of 3.34-5 (PET and CT) while COM registered 
images showed the most variability ranging from 2.34-5 (PET) and 3.34-5 (CT). 
 
Fleiss’ Kappa analysis, a statistic for measuring the agreement of a number of observers when 
giving categorical ratings, was used to measure observer variability between ranking and quality 
scores (Fleiss, 1971; Landis and Koch, 1977). PET and CT rankings have substantial agreement 
between observers (>0.600), while PET and CT quality scores have a fair agreement (>0.200) 
according to suggested criteria based on the opinions of the authors of the methodology (Landis 
and Koch, 1977), however, it should be noted that this criteria is purely based on opion and is not 
universally accepted. The effects of registration and the observer were explored using linear 
fixed-effects modelling to fit effects to data sampled from normal distributions through the 
MIXED procedure in SPSS Statistics Version 20 (IBM, Armonk, NY, USA). Registration was 
treated as a fixed effect while the observer was treated as a random effect. Both effects of 
registration and registration and observer interaction were found to be significant, F3,152.6 = 
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165.799 (p < 0.001) and F8,88.8 = 4.3 (p < 0.001) respectively. Non-rigid registrations were 
consistently given quality scores of 1-3 for 97% of the scans on PET and 98% on CT, showing 
good consistency and robustness of registration. However, the score they were given seemed to 
change depending on the observer, potentially down to each observer’s interpretation of the 
quality score criteria. Observers performed better when ranking images as shown by a substantial 




PET RANKING PET QUALITY SCORE 
MEAN MED MODE S.D. MEAN MED MODE S.D. 
NO REGISTRATION 3.73 4 4 0.48 4.53 5 5 0.68 
CENTRE OF MASS 3.13 3 3 0.57 3.83 4 4 0.99 
RIGID 1.95 2 2 0.59 2.80 3 3 0.58 
NON-RIGID 1.18 1 1 0.39 2.10 2 2 0.75 
ALL 
N/A N/A N/A 1.12 3.32 3 3 1.21 
FK = 0.611 (0.538 - 0.684) FK = 0.367 (0.298 - 0.436) 
METHOD 
CT RANKING CT QUALITY SCORE 
MEAN MED MODE S.D. MEAN MED MODE S.D. 
NO REGISTRATION 3.80 4 4 0.44 4.67 5 5 0.63 
CENTRE OF MASS 3.13 3 3 0.43 4.32 4 4 0.75 
RIGID 2.05 2 2 0.34 3.25 3 3 0.82 
NON-RIGID 1.02 1 1 0.13 1.77 2 2 0.77 
ALL 
N/A N/A N/A 1.12 3.50 4 5 1.35 
FK = 0.850 (0.777 - 0.923) FK = 0.280 (0.213 - 0.347) 
Table 3.6: Visual Analysis Results for CT and PET Scans for All Registration Methods  
Results are mean values of all three observers over all 20 datasets. Ranking is scored from 1 (best) to 4 
(worst) and quality scores are rated from 1 (excellent) to 5 (poor). MED = Median, S.D. = Standard 
Deviation, FK = Fleiss’ Kappa (with 95% confidence intervals). 
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3.3.4) PET/CT Response Criteria Results 
Successful registration was achieved in patients with a variety of responses on both PET/CT and 
CT (Table 3.7). Response was judged by using both anatomical and metabolic response criteria, 
as defined by the IWC on CT and Deauville criteria on PET (Cheson et al., 1999; Meignan et al., 
2009). Table 3.7 shows response assessment for both PET and CT criteria for each of the 20 
datasets. The degree of change in tumour size can potentially have an effect on the success of the 
registration of an image. Larger changes in the patient from one scan to another presents more of 
a challenge for the registration, and in terms of non-rigid registration can cause unwanted 
deformations in order to match changes in tumour size and shape. Changes in tumour size in this 
dataset can be quite drastic with CT measurements decreasing by up to 30mm in size (~70%). On 
average, IWC measurements were found to approximately half from a pre-therapy average of 
29mm to a post-therapy average of 13mm for each lesion. These changes are more drastic than 
anticipated. Despite the changes in metabolic activity on PET and nodal size on CT, registration 
comparable with PET spatial resolution can be achieved using the non-rigid registration method. 
 
It was hoped that changes of tumour size on CT would be small allowing accurate registration to 
take place. While changes on CT are greater than expected, changes on PET are still more drastic 
in comparison. To illustrate this, Figure 3.3 shows two datasets of corresponding PET/CT pre- 
and post- therapy images with different responses. For both datasets, there is reduction in 
measured tumour size on CT between pre- and post- therapy images, particularly on dataset 2. 




Dataset and Patient Information  Deauville (PET) IWC (CT) 
No Age Sex Weight (kg) Score Response Node Pre Post Difference (in %) Response 
1 27 F 63 2 Negative 1 44 13 31 (71) CRu 
2 55 M 82 1 Negative 
2 18.3 5 13.3 (73) 
CR 
3 16.3 5 11.3 (69) 
3 21 F 51 1 Negative 4 16.3 11 5.3 (33) PR 
4 21 M 80 1 Negative 
5 50 15 35 (70) 
PR 6 34 7 27 (79) 
7 19 7 12 (63) 
5 43 F 59 5 Positive 8 51 31 20 (39) PR 
6 39 F 83 4 Positive 9 70 46 24 (34) PR 
7 27 M 57 1 Negative 
10 15 5 10 (67) 
CR 11 20 5 15 (75) 
12 17 5 12 (71) 
8 19 M 76 1 Negative 
13 15 7 8 (53) 
PR 
14 40 21 19 (48) 
9 66 F 57 1 Negative 
15 18 6 12 (67) 
CR 16 17 5 12 (71) 
17 16 5 11 (69) 
10 63 F 82 4 Positive 
18 33 17 16 (49) 
PR 
19 34 9 25 (74) 
11 31 F 55 2 Negative 
20 29 13 16 (55) 
SD 21 37 27 10 (27) 
22 19 10 9 (47) 
12 28 M 77 1 Negative 
23 20 8 12 (60) 
CR 
24 17 5 12 (71) 
13 18 F 62 5 Positive 25 82 53 29 (35) PR 
14 49 M 90 1 Negative 
26 35 5 30 (86) 
CR 
27 23 8 15 (65) 
15 21 M 55 5 Positive 
28 27 5 22 (82) 
CR 
29 15 4 11 (73) 
16 25 M 85 4 Positive N/A N/A N/A N/A NE 
17 56 F 70 1 Negative 30 18 11 7 (39) SD 
18 23 M 68 1 Negative 
31 23 13 10 (44) 
PR 
32 19 7 12 (63) 
19 51 M 82 1 Negative 
33 37 16 21 (57) 
SD 
34 52 28 24 (46) 
35 39 27 12 (31) 
36 29 22 7 (24) 
20 70 M 65 5 Positive 
37 22 9 13 (59) 
CR 
38 18 6 12 (67) 
 
Table 3.7: Response Assessment Results using Deauville Criteria (PET) and IWC (CT) 
The response for each dataset is listed according to the Deauville score and the IWC criteria. For Deauville 
criteria, a score of 1-3 is regarded as ‘negative’ and 4-5 as ‘positive’ for lymphoma. For IWC Criteria, CR 
= Complete Response, CRu = Complete Response (unconfirmed), PR = Partial Response, SD = Stable 
Disease and NE = Non-Evaluable. Nodal measurements for IWC are of the longest transverse diameter of 
the node in mm. 
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Figure 3.3: Visual Comparison of Change between PET and CT 
The images show (A1) pre-therapy PET/CT and (A2) post-therapy PET/CT for a dataset for which IWC on 
CT indicates complete response as does visual inspection on PET (Dataset 2) and (B1) pre-therapy PET/CT 
and (B2) post-therapy PET/CT for a dataset for which IWC on CT indicates stable disease but visual 
inspection on PET shows response (Dataset 19).  
 
3.3.5) Summary of Findings on Registration Accuracy 
Both the qualitative visual assessment and quantitative anatomical landmark results show that the 
non-rigid registration algorithm provides the greatest improvement in alignment of CT and PET 
images. The landmark analysis results on CT and good registration quality scores suggest that 
PET images are aligned with accuracy comparable to their resolution and therefore have the 
potential to provide useful information in identifying response to therapy. It was considered that 
initial patient positioning could affect the success of registrations. However, the quantitative 
study shows almost no correlation between no-registration and rigid (Pearson correlation 
coefficient (pcc) = 0.009, for TRE 3-D distances over all landmarks on all 20 scans) or non-rigid 
(pcc = 0.0324) registration. Therefore, the initial positioning of the patient has no bearing on 
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success of registration. This study has shown that misalignment of pre- and post- therapy PET 
scans can frequently be ~40mm. Improved PET-PET image alignment achieved using image 
registration could help aid clinicians with visual analysis, either by helping them find 
corresponding tumours more easily or by giving them extra information in terms of the areas of 
response.  
 
There is potential for more work on registration algorithms. For example, the use of CT 
transformations being applied to PET images relies on pre- and post- therapy CT images being 
accurately aligned with pre- and post- therapy PET images. Visual registration results are positive 
for both PET and CT, and studies showing that there are usually only marginal misalignments 
between concurrent PET/CT scans. However, there is still potential for some mismatch, 
particularly in certain cases where there are significant differences in respiration between scans 
which would be especially relevant when studying lung tumours for example. Therefore, further 
work on adding a PET to CT registration stage into the rigid and non-rigid IRTK algorithms 
would be beneficial.  
 
Additional testing of the rigid and non-rigid registrations on different datasets of differing 
diseases should be conducted to ensure the algorithm’s flexibility. Although the methods are 
designed to be robust, this needs to be validated fully. Testing of the algorithms using finer 
resolutions, more iterations and cubic rather than linear interpolation could improve the 
registration accuracy. However, these changes would most likely severely affect efficiency and 
the time taken to register images, although, it could be useful when looking at smaller volumes of 
specific areas of disease. It may also be beneficial to modify the non-rigid algorithm so that hard 
structures, such as the skeleton, are kept as rigid transformations as there should be little 
deformation in these areas (Little et al., 1997). 
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3.4) Affect of Registration of PET/CT scans on SUVs 
3.4.1) Importance of SUV Changes on Registered PET Images 
Registration of PET/CT studies is likely to be of benefit when it comes to identifying response to 
therapy as looking at registered images can allow the viewer to see both pre- and post- therapy 
scans in the same anatomical space, making it easier to compare lesions from one scan to the 
next. There is also the potential to use registered PET images to quantify the change between pre- 
and post- therapy uptake in the same tumour area using techniques such as voxel-by-voxel 
analysis. However, registration transformations can cause changes in SUVs and the shape of PET 
structures on the registered image compared to the unregistered image. Ideally, SUVs and tumour 
size should be consistent between registered and unregistered post-therapy images for a fair 
comparison of analysis between pre- to post- therapy images with just the tumour location 
changing so it is aligned between the two. Therefore, it is important to know the scope of the 
changes in SUV and volume of PET structures between pre- and post- therapy images to know 
how much they could affect user interpretation of a registered image and, more importantly, the 
potential impact on quantitative techniques. For example, an unregistered post-therapy image 
may have a SUVmax of one value but when a registration transformation is applied it may change 
and this could have an affect when being interpreted by a clinician or when using quantitative 
analysis. When using novel registration analysis methods to identifying response to therapy, it is 
important that registered post-therapy images have not had major, unwarranted changes in SUVs 
or TVs because of registration rather than physiological changes due to therapy. 
 
There has been very little research on the effect of registration on PET SUVs, particularly when 
registering pre- and post- therapy PET/CT scans. The difference between rigid and non-rigid 
registration for aligning PET to CT in patients with lung cancer was investigated and there were 
no significant differences found in SUVmax between algorithms but  there was potential for non-
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rigid algorithms to cause changes of up to 3ml in TV depending on the breathing procedure used 
in CT acquisition (Grgic et al., 2011). The study concluded that non-rigidly registered post-
therapy PET scans achieved using the CT component of a PET/CT scan could not be used 
reliably to provide unchanged TV measures between unregistered and registered post-therapy 
images when the CT scan was performed during inspiration. TVs were segmented using a S/B 
algorithm using scanner parameters, background-SUV and a 70% isocontour of SUVmean. The 
image registration used was performed in HERMES software using a rigid linear algorithm, with 
NMI as a similarity measure, and a non-rigid nonlinear warping algorithm, using thin-plate 
splines (Grgic et al., 2009). Another study investigating various registration algorithms on 
PET/CT test-retest scans of 11 patients with colorectal carcinoma found there was no significant 
difference in SUVmax, SUVmean, TV or TLG between registered and unregistered scans (van 
Velden et al., 2012). However, neither of these studies investigated clinical pre- and post- therapy 
PET/CT studies and the possible effect of registration transformations. 
3.4.2) Methodology for Evaluating SUV and Volume Changes on PET Images 
For each of the 20 datasets of patients with lymphoma, the unregistered post-therapy images were 
compared with IRTK rigidly and non-rigidly registered post-therapy images to assess the changes 
in SUVmax, SUVpeak and volume for tumours and other areas of physiological uptake in the image. 
While taking data from other PET structures, typically the heart, kidneys and bladder, is a useful 
indication of changes due to registration, differences in tumours are of more relevance and 
importance as these are areas of interest when assessing response to therapy. Using registered 
post-therapy images is not ideal, as due to successful treatment there are only a small number of 
tumours present in post-therapy images over the 20 datasets. Therefore, to obtain more data 
regarding potential changes in tumour parameters, registration algorithms were run in reverse i.e. 
registering pre-therapy images to post-therapy images, using the same IRTK registration 
techniques to ensure more data on the changes in tumours could be obtained. The data analysis 
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was completed in PETTRA software, described in chapter 2. SUVmax was obtained for each PET 
structure as the maximum value in the TV. TV was delineated using the fixed 2.5 SUV region 
segmentation method in PETTRA. For this study, SUVpeak was defined as the SUVmax and its 26-
connected neighbours. 
3.4.3) Results of SUV and Volume Changes on PET Images 
3.4.3.1) Results of SUV and Volume Changes on Post-Therapy Registered Images 
For each of the 20 datasets, unregistered post-therapy images were compared with IRTK rigidly 
and non-rigidly registered post-therapy images to quantify changes in SUVmax, SUVpeak and TV. 
The results are shown in Table 3.8 where mean values over the 20 datasets and absolute mean 
differences and percentage differences were calculated. There were a total of 47 distinguishable 
areas of uptake. However, only five of these were tumours. IRTK rigidly registered post-therapy 
images showed no significant change in values from the unregistered post-therapy images with 
differences across all parameters and all uptake areas being, on average, <2% with the difference 
always <0.5 SUV. For SUVmax, there was no change in any of the tumour values while for 
SUVpeak only two tumours had differences of 1% and 5% with absolute changes <0.2 SUV. TV 
differences were always <1%. For IRTK non-rigidly registered images, there were only minor 
changes in SUVmax values, particularly in tumours where there was a difference in only one 
tumour of just 0.8%. SUVpeak values had a mean difference of ~5% in tumours, however, absolute 
differences were <0.3 SUV. Differences in TV were more significant with changes in all five 
tumours, two of which showed differences of 7.3ml (35%) and 16.2ml (87%). 
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Unreg RR Abs Diff Abs Diff % Unreg NR Abs Diff Abs Diff % 
Tumour 5 8.14 (4.31) 8.14 (4.31) 0.00 (0.00) 0.00 (0.00) 8.14 (4.31) 8.14 (4.31) 0.01 (0.02) 0.16 (0.35) 
Bladder 14 26.79 (13.63) 26.81 (13.63) 0.02 (0.06) 0.08 (0.31) 26.79 (13.63) 26.72 (13.54) 0.11 (0.34) 0.31 (0.90) 
Kidney 16 35.54 (28.61) 35.54 (28.61) 0.00 (0.00) 0.00 (0.00) 35.54 (28.61) 34.73 (27.70) 0.82 (3.27) 1.27 (5.07) 
Heart 12 11.35 (4.46) 11.37 (4.47) 0.03 (0.09) 0.20 (0.58) 11.35 (4.46) 11.35 (4.49) 0.05 (0.10) 0.45 (0.90) 




SUVpeak (27 voxels) SUVpeak (27 voxels) 
Unreg RR Abs Diff Abs Diff % Unreg NR Abs Diff Abs Diff % 
Tumour 5 4.59 (1.69) 4.54 (1.69) 0.05 (0.09) 1.13 (2.04) 4.59 (1.69) 4.51 (1.84) 0.17 (0.12) 5.18 (5.48) 
Bladder 14 18.29 (8.75) 18.34 (8.72) 0.06 (0.21) 0.40 (1.50) 18.29 (8.75) 18.90 (9.80) 0.97 (1.88) 4.39 (7.31) 
Kidney 16 18.52 (15.80) 18.41 (15.83) 0.19 (0.34) 0.82 (2.30) 18.52 (15.80) 17.54 (15.41) 1.02 (2.89) 6.37 (11.25) 
Heart 12 7.81 (2.88) 7.90 (3.00) 0.12 (0.23) 1.21 (2.04) 7.84 (2.88) 7.42 (2.98) 0.51 (0.50) 7.58 (8.11) 




Volume (Fixed 2.5 SUV Threshold Segmentation) Volume (Fixed 2.5 SUV Threshold Segmentation) 
Unreg RR Abs Diff Abs Diff % Unreg NR Abs Diff Abs Diff % 
Tumour 5 20.84 (24.94) 20.81 (24.82) 0.09 (0.12) 0.29 (0.29) 20.84 (24.94) 23.11 (25.51) 5.29 (6.75) 30.38 (33.89) 
Bladder 14 118.8 (94.44) 118.6 (94.67) 0.41 (1.11) 0.50 (1.56) 118.9 (94.44) 123.8 (101.9) 10.85 (10.15) 10.27 (8.60) 
Kidney 16 59.10 (27.93) 59.14 (27.88) 0.13 (0.19) 0.27 (0.39) 59.10 (27.93) 60.93 (26.94) 5.04 (5.54) 10.47 (11.79) 
Heart 12 207.6 (94.40) 207.4 (94.32) 0.29 (0.18) 0.17 (0.14) 207.6 (94.40) 211.6 (104.4) 24.96 (24.95) 10.56 (7.71) 
Total 47 110.7 (96.08) 110.6 (96.07) 0.25 (0.62) 0.32 (0.88) 110.7 (96.08) 114.1 (101.1) 11.88 (16.06) 12.55 (14.80) 
Table 3.8: Changes in SUVmax, SUVpeak and Volume between Unregistered Post-Therapy Scans and IRTK Registered Post-Therapy Scans  
All parameters are given as mean values for each uptake area over the 20 datasets. SUVmax is the intensity of the maximum voxel in the uptake area, SUVpeak 
represents the mean of the SUVmax and its 26-connected neighbouring voxels, and the volume (in ml) is segmented using fixed 2.5 SUV threshold region 
growing. Unreg = Unregistered post-therapy values, RR = rigidly registered post-therapy values, NR = non-rigidly registered post-therapy values, Abs Diff = 
absolute difference between unregistered and registered values, Abs Diff % = % difference between unregistered and registered values. (S.D. in brackets).
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Further investigation into these tumours shows why there are large changes in TV between 
unregistered and registered post-therapy images. The difference of 7.3ml (35%) in TV in dataset 
3 can be explained by the deformation in the non-rigidly registered image creating a gap in the 
connectivity of the segmentation. This has led to some of the disease not being segmented in the 
non-rigidly registered image. With another segmentation added to the existing segmentation to 
take this into account, the difference in TV is 0.9ml (4%). The change in TV in dataset 5 of 16ml 
(~60%) appears to be due to a combination of factors. Once again, difference in the segmentation 
of disease seems to have been caused due to the deformation in the non-rigidly registered image 
but also the registration seems to have been affected by changes due to patient motion around the 
lung. This seems to have caused unwarranted changes on the non-rigidly registered image and has 
increased TV. In this example, it is the unregistered post-therapy image which has not been able 
to fully segment all the disease in one attempt and if the post-therapy image has the same areas of 
disease added the difference in TV is 13.4ml (50%). This is still a sizeable change and likely to be 
a result of the motion around the lungs causing significant changes in the tumour size and shape 
on the transformed image. Both of these cases are shown visually in Figure 3.4. 
 
3.4.3.2) Results of SUV and Volume Changes on Pre-Therapy Registered Images 
The pre-therapy images in the dataset had double the number of uptake areas compared to the 
post-therapy scans as there were 58 more tumours before therapy. Table 3.9 shows the mean 
values for each type of uptake area over the 20 datasets. Once again, rigid registration had very 
little effect on the SUVmax from unregistered pre- therapy images, with no change in all but two of 
the uptake areas. Two tumours were found to have changes of 0.9 SUV (17%) and 1.8 SUV 
(11%) between unregistered and rigidly registered scans. SUVpeak differences showed consistent 
small differences in tumours of <0.5 SUV, with one exception of 1.8 SUV. The largest 
percentage differences were 18.5%, 12% and 11%. 
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Figure 3.4: Volume Changes between Registered and Unregistered Post-Therapy Images 
The images show sagittal slices from (A1) Dataset 3 unregistered post-therapy PET image, (A2) Dataset 3 
non-rigidly registered post-therapy PET image, (B1) Dataset 5 unregistered post-therapy PET image, and 
(B2) Dataset 5 non-rigidly registered post-therapy PET image. For Dataset 3, the non-rigidly registered 
post-therapy image needed further segmentation to include all the disease seen in the unregistered post-
therapy image. For Dataset 5, there appears to be significant deformation on the non-rigidly registered 
image meaning the tumour has increased in volume and included more disease than in the segmentation on 




TV for rigid registration showed very little difference between images with an absolute mean 
difference of 0.23ml (<1%) between volumes. The largest absolute difference in tumours was just 
4ml (0.7%) and 95% of tumours had a volume change of <1ml, the equivalent of <12 voxels. 
Over half the tumour uptake areas showed no difference in volume. 
 
Pre-therapy images with non-rigid registration transformations applied showed significant 
differences compared to unregistered images for all parameters, particularly SUVpeak and volume. 
There were more substantial changes in SUVmax than when using rigid transformations with a 
mean difference of 2.2% over all uptake areas and 2.5% in tumours. The largest differences in 
SUVmax in tumours were 3.1 SUV (14%) and 1.8 SUV (11%), with other differences <1.5 SUV. 
The differences of 3.1 and 1.8 SUV were in dataset 2 and dataset 20 respectively and assessment 
of these tumours revealed that they were positioned in the lungs and images showed more 
significant change in their visual appearance compared to other tumours, most likely due to 
deformations in non-rigid registration transformations (Figure 3.5). The tumour highlighted in 
dataset 20 corresponded to the same tumour which had the largest absolute SUVmax change when 
using the rigid registration transformation. Despite these SUVmax changes in some tumours, 73% 
showed no change in SUVmax between the non-rigidly registered pre-therapy PET image and the 
unregistered equivalent but those that did change were of a significant margin. 
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Unreg RR Diff % Diff Unreg NR Diff % Diff 
Tumour 62 10.95 (5.67) 10.91 (5.65) 0.04 (0.25) 0.43 (2.43) 10.95 (5.67) 10.74 (5.61) 0.22 (0.53) 2.47 (5.91) 
Bladder 19 36.84 23.01) 36.84 (23.01) 0.00 (0.00) 0.00 (0.00) 36.84 (23.01) 35.82 (21.47) 1.02 (2.32) 1.61 (3.33) 
Kidney 18 21.35 (31.10) 21.35 (31.10) 0.00 (0.00) 0.00 (0.00) 21.35 (31.10) 21.21 (31.09) 0.14 (0.42) 1.05 (3.85) 
Heart 6 10.40 (4.37) 10.40 (4.37) 0.00 (0.00) 0.00 (0.00) 10.40 (4.37) 10.08 (4.52) 0.32 (0.45) 4.69 (7.91) 




SUVpeak (27 voxels) SUVpeak (27 voxels) 
Unreg RR Diff % Diff Unreg NR Diff % Diff 
Tumour 62 6.14 (3.26) 6.08 (3.18) 0.08 (0.25) 1.37 (3.41) 6.14 (3.26) 5.56 (2.94) 0.62 (0.81) 10.56 (10.29) 
Bladder 19 33.68 (33.52) 33.43 (33.46) 0.39 (0.88) 1.28 (2.68) 33.68 (33.52) 30.70 (33.11) 3.49 (8.27) 9.23 (18.06) 
Kidney 18 12.67 (20.11) 12.59 (20.13) 0.07 (0.18) 1.21 (2.64) 12.67 (20.11) 12.54 (20.01) 0.76 (1.89) 4.54 (8.56) 
Heart 6 7.31 (3.27) 7.28 (3.20) 0.10 (0.12) 1.57 (1.87) 7.31 (3.27) 6.02 (2.27) 1.29 (1.35) 17.98 (12.07) 




Volume (Fixed 2.5 SUV Threshold Segmentation) Volume (Fixed 2.5 SUV Threshold Segmentation) 
Unreg RR Diff % Diff Unreg NR Diff % Diff 
Tumour 62 78.94 (189.0) 78.8 (189.7) 0.23 (0.66) 0.73 (1.95) 78.94 (190.0) 63.01 (146.6) 18.26 (46.83) 20.77 (19.05) 
Bladder 19 151.2 (139.9) 151.1 (139.9) 0.15 (0.18) 0.11 (0.21) 151.2 (139.9) 190.7 (186.9) 43.76 (63.89) 21.69 (24.70) 
Kidney 18 41.22 (27.12) 41.28 (21.12) 0.12 (0.16) 0.29 (0.33) 41.22 (27.12) 40.85 (26.86) 1.56 (1.90) 4.94 (6.82) 
Heart 6 216.8 (159.7) 216.5 (159.5) 0.32 (0.36) 0.21 (0.32) 216.8 (159.7) 223.1 (152.7) 18.02 (15.89) 8.61 (6.59) 
Total 105 93.42 (167.1) 93.29 (167.1) 0.21 (0.52) 0.52 (1.53) 93.42 (167.3) 91.47 (153.7) 19.20 (46.58) 17.53 (19.23) 
Table 3.9: Changes in SUVmax, SUVpeak and Volume between Unregistered Pre-Therapy Scans and IRTK Registered Pre-Therapy Scans  
All parameters are given as the mean for each uptake area over the 20 datasets. SUVmax is the intensity of the maximum voxel in the uptake area, SUVpeak 
represents the mean of the SUVmax and its 26-connected neighbouring voxels, and the volume (in ml) is segmented using fixed 2.5 SUV threshold region growing 
algorithm. Unreg = Unregistered pre-therapy values, RR = rigidly registered pre-therapy values, NR = non-rigidly registered pre-therapy values, Abs Diff = 
absolute difference between unregistered and registered values, Abs Diff % = % difference between unregistered and registered values. (S.D. in brackets).
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The mean difference in SUVpeak between unregistered and non-rigidly registered post-therapy 
scans was ~10% across all uptake areas and 10.6% for tumours. For tumours, there was a mean 
difference of 0.6 SUV and while changes were more significant compared to rigid registration 
transformations, they were more consistent. Only two differences in SUVpeak were >2.5 SUV. 
SUVpeak is more likely to change with registration, particularly non-rigid, as the transformations 
can mean that the area around the SUVmax changes shape and therefore covers different voxels. 
The two largest differences in SUVpeak were in dataset 20, although in different tumours to the 
largest SUVmax changes. These changes suggest that registration of dataset 20 resulted in a 
transformation which significantly altered the registered PET image. This could be due to greater 
reductions in tumour size between pre- and post- therapy CTs and/or the positioning of tumours 
in and around the lung where breathing is likely to cause more changes between pre- and post- 
therapy images. This can result in more deformation in non-rigid transformations in an attempt to 
align images causing values to be affected more.     
 
Volumes of the uptake areas showed substantial differences between unregistered and non-rigidly 
registered pre-therapy images, particularly in tumours where differences of >100ml  were found 
in 10% of tumours. There was a mean difference of 18ml (21%) between TVs. In contrast to 
differences in post-therapy images, where areas of disease had been under- or over- segmented 
(Figure 3.4), differences in pre- therapy images appear to be because of a clear change in TV 
(Figure 3.6). This is most likely because of greater deformations of shape and manipulation of 
values on the transformed PET image caused by the non-rigid registration algorithm. There were 
six TVs which changed by >100ml and all of these were due to the volume shrinking causing 




Figure 3.5: Changes in SUVmax between Unregistered and Registered Pre-Therapy Images 
The images show coronal slices from (A1) Dataset 2 unregistered pre-therapy PET image, (A2) Dataset 2 
non- rigidly registered pre-therapy PET image, (B1) Dataset 20 unregistered pre-therapy PET image, and 
(B2) Dataset 20 non-rigidly registered pre-therapy PET image. Both show the different positions, 
highlighted by green crosshairs, and values of SUVmax between images. As can be seen, particularly in 
Dataset 20, different coronal slices contain the SUVmax. 
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Figure 3.6 highlights two of these differences in TV on dataset 6 (reduction of 475ml to 278ml) 
and dataset 15 (reduction from 607ml to 496ml). The non-rigid registration on dataset 15 also 
seems to have caused a registration artefact visible in the lower half of the spleen. Given these 
examples and the overall results (Table 3.9) it is clear that non-rigid registration causes 
significant changes in TV and a modest reduction in SUVmax and SUVpeak. There was a mean TV 
of 79ml on unregistered pre-therapy images compared to a mean of 63ml on non-rigidly 
registered pre-therapy images. All changes in SUVmax showed a reduction from the unregistered 
pre-therapy images to those with non-rigid registration applied and while there were some 
increases in SUVpeak and TV, the significant majority of changes were negative.  
 
Registration transformations on both pre-therapy and post-therapy images show a mean decrease 
in SUVmax and SUVpeak values, potentially due to interpolation effects on a transformed image. 
While transformed post-therapy images show a mean increase in TV (20.8ml to 23.1ml), 
transformed pre-therapy images show a mean decrease in TV (79ml to 63ml). This is to be 
expected as there is greater tumour mass on pre-therapy CT images compared to post-therapy CT 
images, where treatment has reduced tumour size. Non-rigid registration will deform post-therapy 
CT TVs to try and match larger volumes on pre-therapy scans. In the reverse, registration of pre-
therapy CT scans will deform tumour size and shape to match smaller lesions on post-therapy 
scans. Therefore, when these transformations are applied to pre-therapy PET images it is 
unsurprising that there is a reduction in the size of segmented TVs from unregistered PET images. 
Rigidly registered images, which only allow the translation and rotation of tumours, do not suffer 
from the same issues with changes in TV as they do not manipulate the size or shape of the 
tumour, so only minimal changes between transformed and unregistered images are found.  
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Figure 3.6: Volume Changes between Unregistered and Registered Pre-Therapy Images 
The images show coronal slices of (A1) Dataset 6 unregistered pre-therapy PET image, (A2) Dataset 6 non-
rigidly registered pre-therapy PET image, (B1) Dataset 15 unregistered pre-therapy PET image, and (B2) 
Dataset 15 non-rigidly registered pre-therapy PET image. For both datasets, there is a significant decrease 
in the segmented TV due to the non-rigid registration transformation reflecting the volume changes in the 
corresponding CT images. In dataset 15, the registration has also caused an artefact, visible in the lower 
spleen. All volumes were segmented using a fixed 2.5 SUV threshold region growing algorithm. 
 
There was no noticeable relation between changes in SUV and volume of PET tumours in the 
pre-therapy images and the size of pre-therapy CT lesions or change in size of CT lesions from 
pre- to post- therapy. For each dataset, mean pre-therapy CT tumour size and relative change in 
RECIST tumour measurements were correlated with the mean percentage differences in SUVmax, 
SUVpeak and TV for both rigid and non-rigid registration. Relative change was given as the 
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product of absolute change and percentage change between the pre- and post- therapy CT 
measurements. Pearson correlation coefficients (pcc) were calculated and showed just one 
significant correlation of the 24 tested (Table 3.9). This was done per dataset rather than for each 
individual tumour measurement as there was considerable difficulty in establishing which CT 
measurements related to which PET tumours. Anatomical and metabolic areas of disease can be 
distinct as metabolic activity and change in intensity do not necessarily relate to the change in 
anatomical size of a significant area of tumour mass. Equally, an area of tumour mass may 
warrant a different number of measurements on each imaging modality – a PET segmentation 
may include two or three lesions on CT or vice versa. Correlation was performed on 17 of the 20 
datasets. Two were omitted because there were no viable PET tumour measurements that could 
be made and another was omitted due to no viable CT measurements. 
 
In relation to the number of datasets, correlation values would have to be at least 0.483 to be 
significant (p < 0.05). There is a weak but insignificant correlation between relative changes of 
CT lesions and differences in SUVmax and SUVpeak when using non-rigid registration (pcc = 0.365, 
p < 0.15, and pcc = 0.325, p < 0.21, respectively). This suggests that greater change in CT tumour 
size increases the likelihood of there being changes in SUV between unregistered and non-rigidly 
registered scans. There is a correlation between the pre-therapy CT size and the difference in TV 
between unregistered and rigidly registered images (pcc = 0.512, p < 0.036). However, this is not 
unexpected as a larger pre-therapy CT size is likely to result in greater absolute differences in 
segmentation as there is more disease to segment and therefore greater chances of differences. 
Non-rigid registration is likely to cause more unpredictable changes, compared to rigid 
registration and therefore does not have similar correlation. 
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Pearson Correlation Coefficients 
Change in 
CT Size CT Relative Change 
RR NR RR NR 
SUVmax -0.163 -0.04 0.040 0.365 
SUVmax (%) -0.120 -0.06 0.119 0.238 
SUVpeak -0.270 -0.01 -0.113 0.325 
SUVpeak (%) -0.259 0.03 0.008 0.284 
Tumour Volume 0.512 0.10 -0.100 -0.104 
Tumour Volume (%) -0.344 0.22 -0.163 0.056 
Table 3.9: Pearson Correlation Coefficients between CT Size and SUV/Volume 
Pccs for the difference in SUVmax, SUVpeak and TV on unregistered and registered pre-therapy images, 
using both IRTK rigid (RR) and IRTK non-rigid (NR) algorithms, correlated with the pre-therapy CT 
tumour size as measured by RECIST criteria (Table 3.7) and relative change between the pre- therapy and 
post- therapy CT tumour size. Correlations were calculated for absolute and percentage differences of 
SUVmax, SUVpeak and TV. 
 
The exact reason for changes in transformed registered images has not been investigated in the 
literature. In performing any sort of registration there are likely to be interpolation effects from 
transformation parameters covering changes on a registered image. For a rigid algorithm, where 
the registration only changes the translation and rotation of an image, this is unlikely to have 
much of an impact, apart from at the edge of images, especially in comparison to non-rigid 
registration. A non-rigid algorithm will produce a more complicated transformation and is more 
likely to affect the intensity values in an image and the shape of high intensity areas, depending 
on the properties of the chosen transformation. Therefore, the TVs segmented in these PET 
images are likely to change. Changes in segmented PET TV occur not just because of changes in 
intensity but also due to changes in the size and shape of tumours. The results obtained when 
looking at the differences between unregistered and registered images do correlate with these 
theories. 
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3.4.4) Summary of Results for SUV and Volume Changes 
The application of IRTK rigid and non-rigid registration transformations to PET scans can cause 
differences from unregistered images. Rigid registration causes minimal changes to SUVmax while 
SUVpeak and TV show very small differences with a mean change of <2%. Non-rigid registration 
transformations can cause large changes in tumours from unregistered images with SUVmax 
differing by a mean of 2%, SUVpeak by 11% and TVs by 21%. These results suggest that rigid 
registration transformations can be applied with little concern over changes between unregistered 
and registered images, however, non-rigid registration transformations must be used with care as 
they can cause large changes in SUV and TV which may cause issues when analysing registered 
pre- and post- therapy images.  
3.4.5) Theory and Importance of Results for SUV and Volume Changes 
One of the reasons for registering pre- and post- therapy scans is to obtain subtraction images 
which can be used to identify response to therapy. Parametric images have been used in other 
studies and extracted parameters have been shown to predict response (Necib et al., 2008; Necib 
et al., 2011). In an ideal scenario, with perfect image registration and unaffected transformed 
images, this methodology is, theoretically, an excellent way of investigating changes in tumours 
and predicting response. However, in reality, there are many issues which cause this technique to 
be problematic. 
 
The methodology used for registering pre- and post- therapy PET/CT studies uses the CT 
component of the PET/CT scan to register the images. The reason for this is that the CT has a 
higher resolution and there is less change in morphology between scans than on PET (Weider et 
al., 2005). However, CT registration relies on minimal change in anatomy between pre- and post- 
therapy scans. Otherwise, changes in tumour size can affect the registration accuracy and 
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resulting transformation. Data has shown that the reduction in CT tumour size from pre- to post- 
therapy scans is of a significant degree and is therefore likely to affect the registration (Table 3.7). 
Additionally, registration on an image is unlikely to be perfect on a voxel-by-voxel basis, no 
matter how impressive the algorithm used. Even when applying the CT transformations on a PET 
image, which has a lower resolution, matching two PET scans to a voxel level accuracy is 
difficult to achieve and clearly vital for parametric imaging to be successful.  
 
Using transformed, registered images also poses another issue as the application of the 
transformation on an image can result in changes in SUV and of the shape and size of tumours 
(Table 3.8; Table 3.9). A subtracted image should be of the pre-therapy SUVs subtracted by the 
post-therapy SUVs, however, if the post-therapy SUVs have changed due to the registration 
process then this has an effect on the subtraction image, as this is not a true representation of the 
difference between the two images. These three issues mean that a parametric image is unlikely to 
detect just the changes in tumours between pre- and post- therapy scans but also the error in the 
registration algorithm, the affect of changes in tumour size on CT and the affect of the 
transformation on the post-therapy PET scan.  
 
Figure 3.7 attempts to depict the difference between the idealistic scenario, in which parametric 
imaging is almost certainly of great use, and the realistic scenario, in which the aforementioned 
issues make parametric imaging problematic. Figure 3.7 (A1, A2) depict a theoretical pre-therapy 
PET/CT image with a homogeneous tumour. In an ideal scenario, the tumour in the post-therapy 
PET image responds to treatment and shows a metabolic change, i.e. a reduction in size and  
intensity, while the size of the tumour on CT remains the same (Figure 3.7 (B1, B2)). The stable 
size of the tumour on the CT image aids the registration of pre- and post- therapy PET/CT 
images, so registration is perfect, and the transformed post-therapy PET image suffers no changes 
in tumour SUV or volume from the unregistered PET image (Figure 3.7 (C1, C2)). However, in a 
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realistic scenario, the size of the tumour on the CT post-therapy image is likely to reduce in size, 
as well as change position (Figure 3.7 (D1, D2)). This is likely to cause more issues in the 
registration, which is not going to be perfect, and SUV and tumour size are likely to change 
between the unregistered and transformed post- therapy image too (Figure 3.7 (E1, E2)). 
 
The difference between the ideal and realistic scenarios does not mean that there is no hope for 
parametric imaging. However, these flaws do need to be considered and addressed as best 
possible to make it a success. To see if this technique is a plausible method of identifying 
response to therapy, it makes sense to use data with minimal change in the size of CT lesions 
between pre- and post- therapy scans. Equally, the registration method used needs, if possible, to 
be one which is both accurate and preserving of SUVs when the transformation is applied to a 
post- therapy image.  
 
Unfortunately, the data used herein has large changes in the size of tumours on CT from pre- to 
post- therapy images (there is a mean reduction of 16mm (58%) in the longest diameter). It may 
be that this is typical across the majority of datasets. However, it could be that some studies, with 
different scanning times and types of disease, have much smaller changes. While the registration 
algorithms used in this work were shown to be accurate by both qualitative and quantitative 
analysis, there is the possibility that other methods could enhance the robustness and accuracy of 
registration further. The affect on SUV may be dependent on the data and registration methods 
used and the affect of them on the change in SUVs between images should be considered. 
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Figure 3.7: Theoretical Issues with using Registered Post-Therapy Images in PET Analysis 
Illustration of the potential issues in registering pre- and post- therapy PET/CT scans for parametric 
imaging in an attempt to identify response to therapy. 
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To increase the chances of parametric imaging working, a dataset which has minimal changes in 
tumour size between scans on CT and a registration method which is both accurate and reduces 
the change in SUV on transformed images is needed. In terms of registration accuracy and the 
change in SUV on transformed images, there becomes a possible trade-off in what is more 
important. Results show that the non-rigid algorithm is more accurate than the rigid algorithm 
making it more suitable for parametric imaging. However, the non-rigid algorithm also shows 
larger changes in SUV on transformed post- therapy images so which of these registration 
methods is more suitable for parametric imaging is dependent on which of these factors is more 
important and how significant the effect is on the analysis. There is also more to understand in 
terms of how the registration transformation parameters manipulate the image. It is possible that 
other affects could also cause issues in the process of using parametric images, for example, the 
presence of artefacts on the transformed image (Figure 3.6) should theoretically ruin any attempt 
at predicting response using parametric images. 
 
3.5) Discussion on Registration of PET/CT Scans 
Herein, a registration methodology was used that registers pre- and post- therapy PET/CT scans, 
using the CT component of the scan. The methodology used both customised rigid and non-rigid 
IRTK algorithms to align CT images, with the resulting transformations applied to PET images. 
The rigid and non-rigid registrations were found to have a registration accuracy of ~10mm and 
~6.5mm respectively on a quantitative landmark analysis on CT and had good visual scores in a 
qualitative analysis on both PET and CT images. These results suggest both types of registration 
are useful in aligning PET/CT studies whether it is for visual assessment or quantitative purposes. 
 
However, there are issues with using both types of registration for aligning pre- and post- therapy 
PET/CT images. The rigid registration does not produce the accuracy of alignment in comparison 
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to non-rigid registration meaning voxel-by-voxel analysis is flawed. Without tumour areas 
overlapping accurately, this type of analysis will become redundant as results will predominantly 
show differences in mis-registration rather than changes in the tumour. There is the possibility 
that rigid registration applied to smaller volumes containing tumours will produce more accurate 
registration which could be suitable for voxel-by-voxel analysis techniques but this would need 
thorough investigation.  
 
Non-rigid registration suffers from the opposite problem to rigid registration. It is likely to 
register images very well but the danger is that it does so by changing the source image in the 
registration too much in order to align changes in tumour size on the CT, particularly if large 
changes on the CT are seen between pre- and post- therapy scans. There are significant changes 
in tumour size between pre- and post- therapy CT scans in the dataset used for registration 
validation (Table 3.7). This could result in a non-rigid algorithm deforming a post-therapy image 
to match a pre-therapy image with changes being unrealistic and deforming the image too much 
to be considered realistic registration. This is then transferred onto the PET image. It would be 
useful to discover if non-rigid registration would have a similar affect on PET images if tumours 
on CT images show little change between scans, which could be the case in other types of 
datasets with different diseases. A major factor in the registration process with this methodology 
is the assumption that the change between CT lesions from pre- to post- therapy images will be 
smaller than the changes on PET images. While this is the case, RECIST measurements show that 
CT changes were of a larger factor than expected and this may have unwanted effects on 
transformed images, in particular, when using the non-rigid transformations where deformations 
will have been applied to match changes in tumour size. This is supported by results analysing the 
affect of registration transformations which produced changes of 21% on TV and 11% on 
SUVpeak between unregistered and non-rigidly registered scans.  
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Using registrations to analyse post-therapy images becomes a trade-off between using a rigid 
registration, which is unlikely to produce large changes from unregistered image values but will 
have more imperfect alignment in comparison to non-rigid registration, and non-rigid registration, 
which will produce more accurate image alignment but is likely to manipulate image values in a 
way which could be damaging to any analysis. Both methods are worth further investigation and 
show accuracy which suggests they may be useful in analysing response to therapy in pre- and 
post- therapy PET/CT scans. However, the inherent flaws of both must be considered during 
analysis. Other registration methods which could provide more accurate registration without 
deforming original image values would be of particular interest. 
3.6) Conclusion to Registration of PET/CT Scans 
Registration of PET/CT scans is a relatively new area of research and data presented herein has 
shown there is potential for accurately registering scans. In a cohort of 20 lymphoma patients 
misalignment errors between pre- and post- therapy images were found to be 40mm on average, 
which is greater than the size of most lesions of interest in patients. Image registration was shown 
to substantially reduce this misalignment with both rigid and non-rigid IRTK registrations found 
to be accurate methods for registering pre- and post- therapy PET/CT images. Both rigid and non-
rigid IRTK registrations obtained good visual analysis results on both PET and CT scans and 
demonstrated an average misalignment error of ~10mm on rigid and ~6.5mm on non-rigid images 
using an anatomical landmark study on CT data.  
 
The affect of the registration transformations on the PET images was also investigated. Rigid 
registration caused minimal changes in SUVmax values while differences in SUVpeak and TV were 
minimal with mean a percentage difference of <2%. Non-rigid registration transformations 
caused more significant changes, with SUVmax differing by a mean of 2% and SUVpeak and TV 
varying by differences of 11% and 21% respectively between unregistered and non-rigidly 
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registered images for tumours. While non-rigid registration was found to be more accurate, the 
substantial changes it showed in the transformed image’s SUV and TV suggest that using 
transformed images to identify response is problematic. On the other hand, while rigid 
registration produced transformed PET images with little or no change, an estimated registration 
accuracy of ~1cm may be too large for voxel-by-voxel analysis to be applicable. 
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4) Response to Therapy in Patients with Mesothelioma 
4.1) Introduction to Response to Therapy in Patients with Mesothelioma 
4.1.1) Identifying Response to Therapy in Mesothelioma Patients 
The aim of this study was to use PETTRA and the response parameters it can produce to analyse 
a group of patients with mesothelioma. All patients in the study underwent pre- and post- therapy 
PET/CT scans. Images were analysed using PETTRA software with the aid of an experienced 
clinician to deduce which areas of uptake were disease, and which were physiological. Image 
analysis response parameters were compared with measures of survival to deduce their 
effectiveness. Comparisons were made between different response parameters and segmentation 
methods to deduce their variability and reproducibility. 
4.1.2) Mesothelioma 
Malignant pleural mesothelioma (MPM) is a rare cancer of the pleura that arises from cells which 
then develop into either epithelial or sarcomatoid neoplasms (Rusch, 1995). The involvement of 
epithelial, sarcomatoid or mixed cells determines the subtype of disease with epithelial subtypes 
tending to survive longer (Bénard et al., 1999). Tumours spread locally, typically extending into 
thoracic structures such as chest wall, pericardium and myocardium (Bénard et al., 1998). 
Patients commonly die because of cardiac or pulmonary involvement after persistent growth of 
disease, at which point blood-borne metastases can occur and are often detected at autopsy 
(Roberts, 1970; Sugarbaker et al., 1996). Patients are usually diagnosed after experiencing 
symptoms such as dyspnoea (shortness of breath), chest pain, cough or weight loss (Wang et al., 
2004). MPM is often diagnosed late as the disease develops within body cavities and patients can 
often have extensive tumour involvement by the time they are diagnosed (Robinson and Lake, 
2005). 
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Mesothelioma has been strongly linked to asbestos exposure, up to 30-40 years previously, and as 
a result mesothelioma incidence is expected to rise as the worst affected cohorts were born in the 
1940s (Peto et al., 1999). A recent study estimates mesothelioma causing up to 250,000 deaths in 
Western Europe from 1995-2019, peaking in incidence between 2015 and 2019 (Pelucchi et al., 
2004). In Great Britain, mesothelioma deaths are predicted to peak between 2011 and 2015, 
causing between 1950 and 2450 deaths (Hodgson et al., 2005). Many cases in South East England 
occur along the Thames and its estuary, where shipbuilding and other industries used asbestos 
within the last century (Mak et al., 2008). Asbestos is thought to cause mutations in some of the 
estimated two billion mesothelial cells in the mesothelium (Robinson and Lake, 2005), while the 
simian virus (SV40) is also believed to be a factor, particularly in the rarer cases where there is no 
asbestos exposure, as mesothelial cells have high levels of p53 protein expression and are 
unusually susceptible to SV40 mediated transformation (Gazdar and Carbone et al., 2005). 
However, asbestos remains the major cause and the role of SV40 remains unclear (Robinson et 
al., 2005). MPM is most common in older men, ~80% of patients are male and the age of patients 
at diagnosis is typically ~60 (Herndon et al., 1998; Andreopoulou et al., 2004; Bottomley et al., 
2006). The disease is usually fatal with a median survival of <12 months even with chemotherapy 
(Andreopoulou et al., 2004; Bottomley et al., 2006; Schaefer et al., 2012), although, on 
occasions, median overall survival can be doubled with effective treatment (Gerbaudo et al., 
2011).  
4.1.3) Treatment of Mesothelioma 
Treatments vary for patients with MPM, ranging from radiotherapy for palliation only or 
combined modality treatment involving chemotherapy, aggressive surgical resection and 
radiotherapy. Surgery can be both palliative, for example, partial pleurectomy with pleurodesis to 
control effusions, or curative, involving an extrapleural pneumonectomy or radical pleurectomy 
and decortication to try and remove all gross tumour in the patient (Sugarbaker et al., 2004). Only 
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a few patients are suitable for curative surgery and adjuvant therapy is usually considered 
afterwards to eliminate any residual disease (Robinson et al., 2005). Early reports suggested 
unacceptable levels of toxicity involved with the use of radiotherapy in MPM, however, 
radiotherapy is often used locally, following curative surgery and for palliation of symptoms 
(Baldini, 2009). The use of advanced radiotherapy methods, including intensity-modulated 
radiotherapy (IMRT), may reduce toxicity by more accurately irradiating the desired areas in 
patients, thus making it a more attractive treatment option (Baldini, 2009). 
 
Several chemotherapy regimes have proved valuable for palliation in MPM patients, reducing 
tumour burden, pain and breathlessness. Pemetrexed plus cisplatin, with a response rate of 41% 
and an increase in survival of three months in comparison to chemotherapy with just cisplatin 
(Vogelzang et al., 2003), and gemcitabine plus cisplatin, with a response rate of 48% (Nowak et 
al., 2002), have proven to be the most effective. While surgery, radiotherapy and chemotherapy 
have yielded disappointing survival times on their own, studies have shown that selected patients 
who have surgery and then undergo chemotherapy and/or radiotherapy have an improved median 
survival time of ~18-19 months (Sugarbaker et al., 1999; Lee et al., 2002). Pemetrexed plus 
cisplatin chemotherapy is commonly used as standard first line treatment in many institutions 
with no standard second line treatment yet established (Hazarika et al., 2005). 
 
Many chemotherapy regimes have been used as second line treatment including vinorelbine, 
pemetrexed plus carboplatin, raltitrexed plus oxaliplatin, oxaliplatin plus carboplatin, gemcitabine 
plus vinorelbine, ZD0437 (a platinum analogue) and a combination of irinotecan, cisplatin and 
mitomycin-C with disappointing response rates of <20% (Ceresoli et al., 2010). MPM has been 
shown to express vascular endothelial growth factor (VEGF) which could be a potential drug 
target (Ohta et al., 1999). Using targeted therapy in pre-treated MPM patients has become more 
popular, with studies investigating the impact of agents such as thalidomide, sorafenib, sunitinib, 
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belinostat, erlotinib plus bevacizumab, and ranpirnase plus doxorubicin (Ceresoli et al., 2010). 
Sorafenib is an inhibitor of Raf-kinase, VEGF receptor-2, and platelet-derived growth factor 
receptor-b, another target of MPM, making it a candidate for second line treatment (Wilhelm et 
al., 2004). A phase II trial using sorafenib to treat 51 mesothelioma patients reported a poor 
response rate but good clinical benefit and increased survival times (Janne et al., 2006).  
4.1.4) Role of 18F-FDG PET/CT in Management of Mesothelioma  
The pattern of growth of MPM makes it a challenging disease to quantify using traditional, 
anatomical CT imaging. Standard RECIST criterion has been found to be inadequate for 
measuring MPM tumours (van Klaveren et al., 2004). Updated RECIST criteria have been 
created for MPM patients (Byrne and Nowak, 2004), and used to predict survival in MPM 
patients treated with chemotherapy (Schaefer et al., 2012). However, it is the PET component of 
PET/CT which is of the most interest in recent mesothelioma studies as its functional imaging 
capabilities provide metabolic information anatomical imaging modalities cannot obtain. PET/CT 
is used in patients with MPM for pre-operative staging, post-treatment surveillance and response 
to treatment assessment (Basu et al,. 2011). In patients with MPM, high SUVs have been shown 
to correlate with poor survival (Flores, 2005; Ceresoli et al., 2006). SUV is also higher in 
malignant lesions than in benign pleural lesions related to asbestos exposure (Bénard et al., 1998; 
Lee et al., 2009; Sharif et al., 2011). However, variation of SUVs in patients with MPM can be 
large (Bénard et al., 1999), and represent only a single pixel rather than the true extent of the 
disease. PET tumour volume (TV) and total lesion glycolysis (TLG), which take into account the 
entirety of the tumour and the degree of uptake within that entirety, could be more relevant 
measures.  
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4.1.5) Identifying Response to Therapy in Mesothelioma Patients 
TV and TLG are theoretically ideal measurements for assessing response in MPM. MPM can be 
an expansive and heterogeneous disease (Figure 4.1), unlike other cancers with smaller, more 
homogenous tumours. Therefore, analysing the full extent of the disease could be more beneficial 
than measuring its maximum intensity. SUVmax or SUVpeak measurements do not show the change 
in spread of disease and will not accurately reflect changes in tumour distribution between pre- 
and post- therapy scans, whereas TV and TLG will account for this. TLG has been found to relate 
to clinical results and survival better than SUVmax in a number of studies (Steinhart et al., 2005; 
Francis et al., 2007; Lee et al., 2010; Nowak et al., 2010; Veit-Haibach et al., 2010; Schaefer et 
al., 2012). TV has been segmented using different algorithms including 2.5 SUV thresholding to 
account for all voxels within a cubic VOI placed over the disease (Veit-Haibach et al., 2010; 
Schaefer et al., 2012), the recommended segmentation in the PERCIST criteria (Lee et al., 2010), 
and the GRAB segmentation algorithm (Francis et al., 2007; Nowak et al., 2010). 
 
Figure 4.1: PET Scan of a Patient with Mesothelioma 
PET scan shows 
18
F-FDG uptake in mesothelium in the left lung of the patient. The heterogeneity and 
volume of uptake suggests measures such as TV and TLG could be suitable to quantify the disease. 
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4.1.6) Aim of Response Analysis  
The aim of this chapter was to explore a variety of methods in a pilot study to assess the response 
to therapy in a cohort of mesothelioma patients treated in a clinical trial in a uniform way with 
VEGF inhibitor, sorafenib. The primary aim was to investigate whether visual assessment, 
SUVmax or volumetric measures, such as TV and TLG, could predict response. The secondary aim 
was to investigate different methods of segmentation for obtaining TVs and further methods of 
quantitative analysis with a view to assess response. Quantitative measures such as TV, TLG and 
IVH parameters have all shown potential for assessing response (Francis et al., 2007; El Naqa et 
al., 2009a, EL Naqa et al., 2009b, Lee et al., 2010).  
 
4.2) Patients and Scanning 
4.2.1) Patient Eligibility and Treatment 
53 eligible patients were recruited for the study, 14 of whom had pre- and post- therapy PET/CT 
scans as part of a subset of patients recruited to a PET pilot substudy, an exploratory study to 
assess PET/CT as a measure of response. All patients had measurable disease, as defined by 
modified RECIST criteria (Byrne and Nowak, 2004), a European Cooperative Oncology Group 
(ECOG) performance status score of 0-2 (Oken et al., 1982), a life expectancy of >12 weeks and 
adequate organ function. All patients were deemed unsuitable for surgery and had received first 
line treatment of pemetrexed plus cisplatin chemotherapy, before undergoing second line 
sorafenib chemotherapy.  Prior surgery, before relapse, and palliative radiotherapy were 
permitted. The study was approved by the UK National Research Ethics Service. All patients 
signed consent forms before the start of treatment which involved continuous dosing with 800mg 
sorafenib daily in two doses. Dosing was reduced to 400mg daily or every two days if toxicity 
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was deemed to be an issue. Treatment was continued until disease progression could be 
confirmed, the patient withdrew from the study or toxicity was deemed to be unacceptable.  
4.2.2) PET/CT Scanning 
All patients in the study underwent stand alone CT scans at baseline and at 8-weekly intervals as 
part of the study. Pre- and post- therapy PET/CT scans were acquired at baseline and after 
therapy for 14 patients between October 2008 and December 2009 for the PET pilot substudy. All 
scans were acquired at the PET Imaging Centre in St Thomas’ Hospital on either a GE Discovery 
ST or GE Discovery VCT PET scanner (Waukesha, WI). The post- therapy PET/CT scans was 
performed ~8 weeks after the start of treatment to investigating the success of sorafenib 
chemotherapy (Papa et al., 2013). For the PET and CT scan components of the PET/CT study, 
patients were scanned during free breathing and CT scans were low dose non-contrast enhanced 
scans. 
 
For all 14 PET/CT datasets, CT image dimensions were 512 x 512 x 223 or 267 (with voxel sizes 
of 0.98mm x 0.98mm x 3.27mm) while PET image dimensions were 128 x 128 x 223, 267 or 311 
(with voxel sizes of 5.47mm x 5.47mm x 3.27mm for all but one image with voxel sizes of 
4.69mm x 4.69mm x 3.27mm). All PET images analysed were attenuation corrected using a 
smoothed CT dataset. Administered FDG dose ranged from 315 to 380MBq (median, 342MBq). 
The dose for the post- therapy scan was within 10% of the dose of the pre- therapy scan for all but 
one dataset, where the dose was 15% (48MBq) less. The median time between administration of 
FDG and the start of the scan was 93min (range, 79-122min), with 9/14 pre- therapy scans within 
10min of the post- therapy scans. The other five datasets had differences between 12-23min 
(median: 20min). 
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4.2.3) Patient Characteristics 
Patients had a median age of 63 (range, 55-77) and 86% were male (12 male, 2 female). Patients 
weighed between 47-99kg (median, 78kg) and there was a mean decrease in weight of 5kg 
between pre- and post- therapy scans (range, 0-10kg), most likely due to the effects of the disease 
and the chemotherapy. Patient height ranged from 163-188cm (median, 175cm) with a median 
change in height between scans of 1cm (range, 0-5cm) within the error of measurement. Of the 14 
patients, 13 had stopped treatment at the time of data collection with treatment lasting between 
42-300 days (median, 155 days).  
4.2.4) Study End Point 
When trying to assess a method of predicting response to therapy, an end point or measure was 
needed to see how successful it is at achieving this goal. A number of different end points can be 
used as measures of response (Table 4.1), including overall survival (OS) and progression free 
survival (PFS). OS measures the time till death after treatment has begun, making it a good 
measure for trials where there is a low response in patients, as would be expected in patients with 
MPM. PFS is similar to OS except that it measures the time till progression of disease is 
confirmed, indicating that treatment has failed. In literature, both these methods have been used 
to measure response in patients with mesothelioma (Benard et al., 1999; Hazarika et al., 2005; 
Bottomley et al., 2006; Lee et al., 2009; Nowak et al., 2010; Veit-Haibach et al., 2010). 
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End Point Definition 
Overall Survival (OS) The time from the entry onto the clinical trial until death as a result of any cause 
Progression Free 
Survival (PFS) 




The time from the entry onto the study to any treatment failure including disease 
progression or discontinuation of treatment for any reason 
Time to Progression 
(TTP) 
The time from the entry onto the study to documented progression or result of 
death due the disease under study 
Disease-Free Survival 
The time from the occurrence of a disease-free state or a complete response to 
disease recurrence or death as a result of the disease under study or toxicity to 
treatment 
Table 4.1: Definitions of End Points for Response Studies 
Comparison of different end points used in studies for identifying response in patients.  
(Modified from Cheson et al., 2007)  
 
4.3) Data Analysis – Response Measures 
4.3.1) Visual Analysis 
Visual analysis of pre- and post- therapy PET/CT studies were completed by two consultants, a 
nuclear physician and a radiologist with 20 and 7 years of experience of PET, respectively. 
Response was assessed using both PET and CT, viewed on HERMES Hybrid Viewer 
workstations (Nuclear Diagnostics AB, Stockholm, Sweden). Visual assessments of response 
were scored based on newly developed criteria, defined a priori for the trial, categorising patient 
response as either: response, PMD or SMD (Table 4.2). SUVmax values were also listed by 
consultants as a guide. Scans were viewed scaled to a SUVmax of 10, normalised for injected 
activity and body weight. PET/CT scans were read independently by the two observers and any 
differences were resolved by consensus. Anatomical visual analysis on CT scans was also 
performed using modified RECIST for MPM by an experienced radiologist without reference to 
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the PET/CT scans or reports (Byrne and Nowak, 2004). Patient response was categorised as CR, 
PR, SD or PD (Table 4.3). A key change in the modified RECIST criteria for MPM is the way 
tumours are quantified, as measuring the ‘longest unidimensional diameter’ of disease can be 
difficult as the tumour mass will often encapsulate the curve of the chest wall. The modified 
criteria recommend tumour mass is measured in two positions at three separate points at least 
1cm apart on transverse slices of the CT, related to anatomical points to increase reproducibility. 
The sum of these measurements define a pleural unidimensional measure and all the measures 
combine to make the total tumour measurement. 
 
Response Cat Description 
Response 
A Overall reduction in intensity of uptake compared to staging scan 
B Regression of lesions (with or without overall reduction) 
PMD 
A Increase in intensity of uptake compared to staging scan 
B New lesions within affected hemithorax (with or without increased intensity) 
C New lesions outside affected hemithorax (with or without increased intensity) 
SMD  Response does not fall into response or PMD categories 
Table 4.2: Criteria for PET Visual Assessment of Patients with Mesothelioma 
Response to therapy can be defined as response, progressive metabolic disease (PMD) or stable metabolic 
disease (SMD) with separate categories (Cat) defining response and PMD. 
 
Response Description 
CR Disappearance of all target lesions with no evidence of tumours elsewhere 
PR >30% reduction in total tumour measurement 
SD <30% reduction and <20% increase in the total tumour measurement 
PD 
>20% increase in the total tumour measurement or the appearance of one or 
more new lesions 
Table 4.3: Modified RECIST for Visual Assessment of Patients with Mesothelioma 
Response to therapy can be defined as complete response (CR), partial response (PR), stable disease (SD) 
or progressive disease (PD). Confirmed response required a repeat observation on two occasions, four 
weeks apart. (Modified from Byrne and Nowak, 2004). 
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4.3.2) SUV, SUL and SUVBSA 
SUV was the used quantification unit for response measures. However, SUL/SUVLBM and 
SUVBSA were also investigated to determine if there was a significant difference between the 
three values. A correction for plasma glucose was not used in any of the methods of 
quantification due to studies showing that applying a correction for glucose does not affect the 
reliability of SUV measures or improve the accuracy of SUV as a measure of glucose metabolism 
(Diederichs et al., 1998; Hallett et al., 2001). Response parameters will primarily use SUV but 
segmentation and response parameters were also investigated using SUL and SUVBSA to assess 
whether there were significant differences depending on which measure of total distribution 
volume for quantification was used. 
4.3.3) SUVmax 
SUVmax was taken as the maximum SUV within the entire TV on the HERMES Hybrid Viewer 
software by the two readers and on PETTRA software within the segmented TV, the two being 
identical for all values.  
4.3.4) Tumour Volume Segmentation 
Semi-automated segmentation of TV was conducted with the aid of a consultant physician who 
decided which areas of abnormal uptake in the PET image represented tumour, as opposed to 
physiological uptake. For simplicity, a region growing method with a fixed 2.5 SUV threshold 
using 6-voxel connectivity was originally used to segment the disease in each of the 28 whole 
body PET images. While there are issues using a fixed SUV to segment disease, it has been 
successful in other studies investigating TLG in patients with mesothelioma (Veit-Haibach et al., 
2010; Schaefer et al., 2012). It has the advantage that it is simple, objective, well-defined, 
computationally efficient and less likely to produce unpredictable results, in comparison to other 
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methods. While it may result in some segmentations spilling into areas of physiological uptake 
more often than other methods, this can be easily rectified by restricting the segmentation or 
removing areas of physiological uptake from areas of segmented tumour, judged by the 
consultant physician. If need be, disease was restricted to a given cubic volume in the image to 
include just tumour rather than physiological or background uptake. Equally, there were 
occasions where cubic volumes were removed from the segmented disease area to remove 
physiological or background uptake. After this segmentation method was used initially, all the 
segmentation methods implemented in PETTRA (described in 2.3, p91) were used to try and 
segment areas of tumour. 
4.3.5) Tumour Volume and Total Lesion Glycolysis 
TV in a PET scan was taken as the total of all segmented areas of disease. TV was calculated as 
the volume of each voxel multiplied by the number of segmentation voxels, given in ml. TLG 
was calculated as the product of TV and SUV, given in ml*SUV. 
4.3.6) Intensity Volume Histogram Parameters 
All six of the IVH parameters (I10, I90, I10-90, V10, V90, V10-90), as defined in PETTRA in 2.4.6 
(p121), were investigated as potential measures of response. 
 
4.4) Results for Segmentation of Disease in Mesothelioma Patients 
4.4.1) Fixed 2.5 SUV Segmentation of Disease in Mesothelioma Patients 
Disease was present in all 28 PET images of the 14 datasets. The fixed 2.5 SUV threshold region 
growing algorithm successfully segmented disease in all 28 images. In 21 of the 28 images, no 
restrictions on segmentation in PETTRA were needed to stop the segmentation of disease 
‘spilling’ into areas of physiological uptake or the background in the image. In the remaining 
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seven images, nine areas of physiological uptake interfered with segmentation of disease (Table 
4.4). Five of these were the heart and were removed from the segmented disease using the 
methodology described in 2.3.9 (Figure 2.25, p110), the one exception being the pre-therapy 
image in dataset 10 where disease was restricted from entering the heart using a similar 
methodology. All segmentations, including those where physiological uptake was removed, were 
viewed by a consultant who deemed the segmentation to capture diseased areas only and not 
areas of physiological uptake. Over the 28 images, there were a total of 290 segmented areas of 
disease with a mean of 10 for each image (range, 2-25). The mean TV was 2593ml (range, 7-
1786ml).  
 
While the number of areas of physiological uptake included in segmented disease was not huge, 
in an ideal scenario segmentation would not need the removal of unwanted uptake. Segmentation 
of disease in PET scans is often a more problematic task in real clinical images than in phantoms, 
simulated images or images where histological samples can be taken, which are often used to test 
segmentation algorithms. Images with high background uptake and more heterogeneous lesions 
are also often more difficult to segment. The pre-therapy scan for patient 6 in this dataset is a 
good example of the problems that can arise in segmenting PET lesions (Figure 4.2), particularly 
when using a fixed 2.5 SUV threshold which does not take into account background uptake. In 
this example, the liver and bowel have been included in the segmentation of disease and have had 
to be removed. Many of the higher fixed threshold segmentation methods and those that used 
background uptake to determine a threshold, segmented disease in the pre-therapy scan in dataset 











2 Pre Heart Removed from segmented area 1 
4 Pre Heart Removed from segmented area 1 
6 
Pre 
Liver Removed from segmented area 5 
Spleen Removed from segmented area 1 
Bladder/Bowel Removed from segmented area 1 
Post Liver Removed from segmented area 1 
10 
Pre Heart Disease restricted from heart 1 
Post Heart Removed from segmented area 1 
13 Post Heart Removed from segmented area 1 
Table 4.4: Physiological Uptake Segmented using a Fixed 2.5 SUV Threshold 
Over the dataset, nine areas of physiological uptake were segmented with disease using a fixed 2.5 SUV 
region growing segmentation algorithm. Physiological uptake was either removed from the segmented area 
of disease or restricted to a particular volume so it did not ‘spill’ into areas of physiological uptake. VOIs 
Needed refers to the number of cubic VOIs that were needed to remove the physiological uptake. 
 
 
 Figure 4.2: Removed Areas of Physiological Uptake for 2.5 SUV Segmentation  
Coronal view of a pre-therapy PET image for dataset 6 in which both disease and physiological uptake is 
present (A). A fixed 2.5 SUV threshold segments both disease and background uptake in the liver and 
bowel (B). This is removed using restricted segmentation, before other disease is segmented (C). 
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4.4.2) Segmentation of Mesothelioma Patients using Different Voxel Connectivity  
All segmentations used the region growing algorithm to segment disease searching for 6-
connected voxels, however, searching for 18-connected or 26-connected voxels may have a 
significant impact on segmented TV. To test this, a fixed 2.5 SUV threshold segmentation was 
performed searching for 18-connected and 26-connected voxels and the results compared to 6-
connected voxels. All the methods had to have the same areas of physiological uptake removed, 
with the removal of the liver in the post-therapy image of dataset 6 needing the co-ordinates 
extended to remove further physiological uptake when using 18-connected and 26-connected 
voxels. Using higher numbers of connected voxels resulted in needing fewer VOIs to segment the 
disease and increased TV and TLG (Table 4.5). The mean change in TV and TLG between pre- 
and post- therapy segmentations was less when using higher numbers of connected voxels. Over 
the 28 images, the mean difference between using 6-connected voxels and 26-connected voxels to 
obtain TV and TLG was 19ml (2.5%) and 54ml*SUV (2.2%) respectively. The mean difference 
in the change between TV and TLG between pre- and post- therapy images was 13ml (3.2%) and 
36ml*SUV (2.4%). All three types of voxel connectivity correlated extremely well for both TV 
and TLG measurements (pcc >= 0.998, p = 0) and the change between pre- and post- therapy TV 
and TLG (pcc >= 0.990, p = 0). However, it should be noted that the percentage change, while 
still showing a strong correlation, was not as high (pcc >= 0.618, p < 0.02). Change was 
calculated as the post-therapy value minus the pre-therapy value and the percentage change as: 
 









Mean Mean Absolute Change 
TV TLG TV TLG 
6-connected 290 586 2593 154 840 
18-connected 249 598 2626 153 831 
26-connected 233 605 2647 151 827 
Table 4.5: Difference between 6-, 18- and 26-Connected Voxel Segmentation Algorithms  
Table shows the total number of VOIs needed to segment disease, mean TV (ml) and mean TLG (ml*SUV) 
for all 28 images and the mean absolute change in TV and TLG between pre- and post- therapy scans. 
Segmentations were done using a fixed 2.5 SUV threshold region growing algorithm for 6-connected, 18-
connected and 26-connected voxels. 
 
These results suggest that the affect of voxel connectivity used in the segmentation algorithm is 
not hugely significant although changes are more significant when comparing the percentage 
change between pre- and post- therapy images. In this scenario, the mean difference between 
using 6-connected and 26-connected voxels is 30%. However, after further investigation into 
these results it was discovered that this was heavily influenced by one dataset having a huge 
positive percentage change when using 6-voxel connectivity and a more modest increase when 
using 26-voxel connectivity (without this dataset included, differences were <10%). On this 
dataset, disease in the liver was initially segmented using 6-voxel connectivity on just one side of 
the liver whereas with 26-voxel connectivity the algorithm identifies connected voxels above the 
threshold throughout the liver (Figure 4.3). It could be argued that not all the disease was 
segmented using the 6-voxel connectivity algorithm or that the 26-voxel connectivity algorithm 
has included unwanted physiological uptake, when dealing with abnormal uptake in the liver. 
This is hard to define or to know for sure and is one of the main issues when segmenting disease 
using any segmentation method. In this dataset, disease on the edge of the liver is rare and not a 
typical area for disease to be segmented. Without this specific example, it can otherwise be stated 
that the voxel connectivity used in region growing segmentation for fixed algorithms does not 




Figure 4.3: Differences in Segmentation using 6-Voxel and 26-Voxel Connectivity  
Segmented disease in the liver on the pre-therapy image in dataset 8 over five connected coronal slices 
using both (A) 6-voxel and (B) 26-voxel connectivity for a fixed 2.5 SUV threshold region growing 
algorithm. While the 6-connected voxel segmentation does not spread throughout the liver, the 26-
connected voxel segmentation does. This could be prevented by restricting the segmentation but for this 
region of disease it is difficult to determine which areas of uptake are disease and which are physiological 
uptake so no restrictions were performed during the segmentation process. 
4.4.3) Segmentation of Mesothelioma Patients using Different Fixed Thresholds 
The fixed 2.5 SUV threshold was chosen because of its use in literature (Veit-Haibach et al., 
2010; Schaefer et al., 2012). However, different thresholds and variations in total distribution 
volume used for quantification of SUV, including SUL and SUVBSA, are worthy of investigation 
with regard to segmentation as they may prove to be better thresholds for detecting disease. 
Values of 2.2, 2.4, 2.6, 2.8 and 3 SUV were used for fixed threshold segmentation, chosen at 
logical increments/decrements from each other. A SUV of 2 was also considered but 
segmentation included physiological uptake too easily on numerous occasions. For SUL, the 
same thresholds were used as only a small reduction in values is common from SUV, while for 
SUVBSA, values are much lower when compared to SUV so thresholds of 0.5, 0.6 and 0.7 were 
used following experimentation to find suitable thresholds. 
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Table 4.6 shows the results of these segmentations, starting with the default fixed SUV 2.5 
threshold. The higher the SUV threshold the more VOIs are used to segment all the disease in the 
image using region growing segmentation, as segmentation is more likely to stop between disease 
areas because there are less voxels connected by the higher threshold. The number of restricted 
VOIs used to aid segmentation is reversely proportional to the threshold value with higher 
thresholds meaning less restricted areas are needed. Using SUL, opposed to SUV or SUVBSA, 
reduced the number of restricted areas needed. This is partially due to the fact that the intensity 
values for SUL are lower than SUV and so the same group of thresholds are effectively higher for 
SUL. However, to only need three restricted areas at a fixed 2.2 SUL threshold suggests that for 
ease of use it could be beneficial. 
 
TV and TLG are smaller when higher thresholds are used as fewer voxels are included in 
segmentations as there are fewer voxels above the threshold. Mean TLG varies significantly when 
using SUV, SUL and SUVBSA as the intensity values are greatly affected by the distribution 
volume used for quantification. However, mean TV can give an idea at what threshold similar 
volumes for SUV, SUL and SUVBSA are obtained with TV relatively similar when using 
thresholds of 0.7 SUVBSA, 2.2 SUL and 2.6-2.8 SUV. The absolute change (i.e. decrease or 
increase, both taken as a positive value) in TV and TLG is larger at lower thresholds as there is 
more disease included in segmentations so there is more likely to be greater changes in the 
quantity of disease between pre- and post- therapy scans. The mean absolute percentage change 
between TV and TLG is larger at higher thresholds, as they segment smaller regions of disease 
which are likely to produce a greater percentage change than thresholds which produce larger 















Abs Change Abs % Change 
TV TLG TV TLG 
2.5 SUV 290 13 586 2593 154 840 82 89 
2.2 SUV 229 16 760 3008 182 872 65 70 
2.4 SUV 286 16 636 2716 165 847 72 78 
2.6 SUV 354 9 545 2487 142 818 64 71 
2.8 SUV 435 5 481 2313 136 825 77 86 
3 SUV 464 5 428 2159 133 832 85 96 
2.2 SUL 278 3 504 1930 141 650 104 116 
2.4 SUL 337 3 437 1776 133 662 150 169 
2.5 SUL 437 3 408 1705 130 664 148 167 
2.6 SUL 388 3 383 1640 129 666 174 197 
2.8 SUL 410 3 338 1518 128 668 236 264 
3 SUL 436 3 301 1411 126 660 452 492 
0.5 SUVBSA 186 24 996 912 260 260 95 93 
0.6 SUVBSA 332 11 677 736 177 230 121 126 
0.7 SUVBSA 477 5 517 632 144 212 103 114 
Table 4.6: Difference between Fixed SUV, SUL and SUVBSA Threshold Segmentation  
Table shows the total number of VOIs needed to segment disease, number of times restricted areas were 
used to stop segmentation, the mean TV (ml) and TLG (ml*SUV) for all 28 images and mean absolute 
change and absolute percentage change between pre- and post- therapy scans for all 14 datasets.  All 
segmentation algorithms used threshold region growing algorithms using 6-connected voxels. 
 
The visual difference between these segmentation methods is difficult to show, as 3-D VOIs are 
difficult to illustrate, however, a comparison of different SUV thresholds on the main regions of 
disease for three pre-therapy images is displayed in Figure 4.4. The effects of different thresholds 
can be seen in dataset 1 and dataset 12. In dataset 1, an area of disease uptake near the top of the 
lung is not included at a threshold of SUV 2.5 but is included using an SUV 2.4 while in dataset 
12 a similar scenario occurs between SUV 2.5 and 2.6. The missing areas of disease can be 
segmented using an additional VOI, however, in an ideal scenario segmentation should include 




Figure 4.4: Segmentation using Different Fixed SUV Thresholds  
Segmentation of the primary disease region on pre-therapy scans for datasets 1, 7 and 12 using a fixed 
region growing algorithm for 2.2, 2.4, 2.5, 2.6, 2.8 and 3 SUV. TV is shown in the bottom left corner of 
each image. Images are of the coronal slice in which the SUVmax of the disease is present. 
 
Dataset 7 shows the opposite scenario, all SUV thresholds segment the same main area of 
disease, which is less heterogeneous and more connected making this an easier task, with lower 
thresholds segmenting more voxels on the edge of the tumour as would be expected. Figure 4.5 
shows the same datasets for SUL and SUVBSA at various thresholds. Different thresholds using 
SUL seem to make less of a difference to segmentation in the three datasets, as they appear 
similar with TV changing moderately, as would be expected. For the three SUVBSA thresholds 







Figure 4.5: Segmentation using Different Fixed SUL and SUVBSA Thresholds 
Segmentation of the primary disease region on pre-therapy scans for datasets 1,  7 and 12 using a fixed 
region growing algorithm for 2.2, 2.5, 2.8 SUL and 0.5, 0.6, 0.7 SUVBSA. TV is shown in the bottom left 
corner of each image. Images are of the coronal slice in which the SUVmax of the disease is present.  Images 
using SUL are shown with the default colour range of 0-5 SUL, where as images using SUVBSA are shown 






The correlation of SUVmax, TV and TLG parameters between segmentation using 2.5 SUV and 
those with different thresholds and normalisation methods is strong (pcc >= 0.850, p < 0.001 in 
all but one case, Table 4.7). Even when investigating the change between pre- and post- therapy 
scans, correlations are still significant showing that even though there is an impact when using 
different fixed thresholds, it is unlikely to have an effect on the prediction of response. The one 
instance where correlation was weak was between the change in TV using 2.5 SUV and 0.5 
SUVBSA thresholds (pcc = 0.283, p < 0.33). This can be explained by the significant amount of 
extra disease, possibly some of which could be physiological uptake, which may have been 
included due to the low threshold (once again, the segmentation of the disease in the liver is likely 
to be part of the reason for this in a similar way to the difference between 6-connected voxel 
segmentation and 26-connected voxel segmentation, Figure 4.3). This may have had enough of an 
influence to cause significant differences in the change between TV in comparison to using a 2.5 
SUV threshold, explaining its lower correlation coefficient. The TLG correlation with a fixed 2.5 
SUV segmentation is also lower than others for this method. However, it is still high in 
comparison to TV correlations, because even with increased TV, the SUV intensity within the TV 
is likely to remain more stable as the highest intensity regions will always be segmented no 













Over all 28 images Change % Change  
Max TV TLG Max TV TLG Max TV TLG 
2.5 SUV 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
2.2 SUV 1.000 0.992 0.997 1.000 0.850 0.984 1.000 0.897 0.924 
2.4 SUV 1.000 0.999 1.000 1.000 0.983 0.998 1.000 0.995 0.995 
2.6 SUV 1.000 0.999 1.000 1.000 0.980 0.997 1.000 0.902 0.917 
2.8 SUV 1.000 0.996 0.998 1.000 0.963 0.996 1.000 0.963 0.973 
3 SUV 1.000 0.990 0.996 1.000 0.943 0.993 1.000 0.902 0.918 
2.2 SUL 0.993 0.993 0.995 0.994 0.961 0.991 0.996 0.977 0.981 
2.4 SUL 0.993 0.989 0.992 0.994 0.953 0.992 0.996 0.963 0.966 
2.5 SUL 0.993 0.985 0.990 0.994 0.946 0.991 0.996 0.964 0.968 
2.6 SUL 0.993 0.981 0.988 0.994 0.938 0.991 0.996 0.924 0.933 
2.8 SUL 0.993 0.971 0.984 0.994 0.924 0.989 0.996 0.875 0.887 
3 SUL 0.993 0.960 0.978 0.994 0.914 0.988 0.996 0.856 0.875 
0.5 SUVBSA 0.981 0.967 0.979 0.981 0.283 0.881 0.995 0.582 0.678 
0.6 SUVBSA 0.981 0.988 0.985 0.981 0.859 0.967 0.995 0.958 0.960 
0.7 SUVBSA 0.981 0.983 0.982 0.981 0.941 0.977 0.995 0.980 0.986 
Table 4.7: Correlation between Fixed SUV, SUL and SUVBSA Threshold Segmentations  
Pearson correlation coefficients (pccs) are shown for the correlation of various fixed thresholds of SUV, 
SUL and SUVBSA with a 2.5 SUV threshold for SUVmax, TV and TLG. Pccs were calculated for SUVmax, 
TV and TLG over the 28 pre- and post- therapy images and for the change and percentage change between 
the 14 pre- and post- therapy scans. For p < 0.01, pcc > 0.479 over the 28 images and for p < 0.01, pcc > 
0.662 for changes and % change. 
 
4.4.4) Segmentation of Mesothelioma Patients using Percentage of SUVmax 
While segmentation using a percentage of SUVmax has been used successfully for segmenting 
disease in many recent cancer studies (Chen et al., 2012; Chung et al., 2012; Dibble et al., 2012; 
Im et al., 2012; Lim et al., 2012), it is not the best technique to use when segmenting 
mesothelioma patients. Figure 4.6 shows a comparison of segmentations using a given percentage 
of SUVmax over three datasets. Using 40-70% of SUVmax gives thresholds which are too high for 
segmenting large regions of disease accurately, resulting in severe under segmentation of the 
main region of disease in the PET image. For example, using 40-70% of SUVmax segmentation 
gives TVs of <23ml for the main region of disease in dataset 1 compared to 1590ml using a fixed 
 198 
2.5 SUV threshold segmentation. To get a TV comparable with 1590ml, deemed suitable 
segmentation of the region of disease by a consultant physician, a threshold of 13%-14% of 
SUVmax is needed (TV: 1749ml using 13% and 1496ml using 14%).  
 
 
Figure 4.6: Segmentation using Percentage of SUVmax  
Segmentation of the primary disease region on pre-therapy scans for datasets 1, 7 and 12 using fixed region 
growing algorithm for 30%, 40%, 50%, 60% and 70% of SUVmax. TV is shown in the bottom left corner of 
each image. Images are of the coronal slice in which the SUVmax of the disease is present. 
 
While this might work for large regions of disease, using this sort of threshold on smaller regions 
results in very low thresholds which then severely over-segment disease and include huge areas 
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of background and physiological uptake. For example, for dataset 1, using the same 14% SUVmax 
threshold on a smaller lesion in the patient, not connected to the rest of the disease, produces a 
threshold of 0.8 SUV and a large TV of 16,341ml which segments almost the entire patient 
including physiological uptake in the brain, liver, bowel and bladder (Figure 4.7). In comparison, 
segmentation using a 2.5 SUV threshold produces a TV of just 2ml. While segmentation using a 
fixed 2.5 SUV threshold is not perfect, it has been shown to produce suitable results as assessed 
by a consultant physician and, in comparison, using a percentage of SUVmax is unreliable and 
prone to vastly over- or under- segment disease (Figure 4.6, Figure 4.7). Therefore, segmentation 
using percentage of the SUVmax was not investigated further. 
 
 
Figure 4.7: Issues with Segmentation using a Percentage of SUVmax  
Segmentation of the primary disease region on pre-therapy scan for dataset 1 needs a suitable threshold of 
around 14% of SUVmax. When this is applied to a smaller disease lesion (A), segmented with at least some 
degree of visual success using a fixed 2.5 SUV threshold (B), it clearly spills into areas of physiological 
uptake including brain, liver and bowel with a threshold of just 0.8 SUV (C).  
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This does not mean that using a percentage of SUVmax has no place in PET tumour segmentation. 
For many cancers where lesions are typically homogeneous and of similar small sizes, it has been 
shown to work competently enough (Chen et al., 2012; Chung et al., 2012; Dibble et al., 2012; 
Im et al., 2012; Lim et al., 2012). However, for mesothelioma, where there is more heterogeneous 
uptake and both small and large regions of disease, it has been found to be inadequate at reliably 
segmenting TV.   
4.4.5) Segmentation of Mesothelioma Patients using SUVmean 
Segmentation using SUVmean can be done in the form of a threshold based method which relates 
SUVmean to a threshold using two fixed constants (Black et al., 2004), and an adaptive region 
growing algorithm using a fixed percentage of SUVmean (Green et al., 2008). Both are 
implemented in PETTRA as described in 2.3.5 (p99). In both studies, the segmentation methods 
were tested on phantom studies so experimentation was done on the mesothelioma dataset to test 
their viability before pursuing with these methods. Modifications were made to the constants and 
percentages used where necessary. Figure 4.8 shows the performance of the adaptive SUVmean 
based segmentation method for three pre-therapy images on the main region of disease using 
thresholds of 50%, 60%, 65%, 70% and 85% of SUVmean using the adaptive algorithm.  
 
The problems with using the adaptive mean algorithm using a percentage of SUVmean are 
highlighted when viewing Figure 4.8. The 85% threshold used on phantom studies is too high on 
clinical data of mesothelioma patients, under-segmenting TV while a threshold of 50% appears 
too low, as can be seen on dataset 1 where the segmentation has ‘escaped’ from the tumour 
(region of local maxima), ending up with a very low threshold which then floods into other 
regions of the PET scan so the maximum voxel is in a different PET structure, in this case the 
bladder (region of global maxima). This issue is illustrated further in Figure 4.9. Despite this, the 
adaptive SUVmean algorithm was used on the dataset using 60%, 65% and 70% thresholds and a 
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70% threshold was found to work successfully enough to segment TV in 26/28 images with the 
percentage level increased to 80% on one dataset (dataset 14) and 90% on another (dataset 8) to 
ensure valid segmentation could take place. The changes in threshold percentages were used if 
the seed voxel fell outside the final VOI when using a 70% threshold, for any segmentation where 
the seed voxel falls outside the final VOI is rejected. The potential issues with this method are 
dealt with in its later incarnation, GRAB, which uses background uptake (Boucek et al., 2008). 
 
Figure 4.8: Segmentation using Adaptive SUVmean  
Segmentation of the primary disease region on pre-therapy scans for datasets 1, 7 and 12 using adaptive 
SUVmean segmentation using thresholds of 50%, 60%, 65%, 70% and 85% of SUVmean. TV is shown in the 
bottom left corner of each image. Images are of the coronal slice in which the SUVmax of the disease is 
present. For dataset 1 at a 50% threshold the segmentation has flooded into the bladder and segmented the 
bladder instead of the main region of disease. 
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Figure 4.9: Issue of Local Maxima in Segmentation using Adaptive SUVmean  
If the percentage used in the adaptive SUVmean segmentation is too low the threshold will get to a point 
where it is low enough to ‘flood’ into other regions of the image and the SUVmean will take into account 
other uptake areas and end up segmenting another PET structure. 
 
Similar testing was conducted on the SUVmean method using a threshold calculation involving two 
fixed constants (Black et al., 2004). The given constants of 0.307 and 0.588 visually appeared to 
be too low and included physiological uptake while those with higher constant values seemed to 
provide better segmentation (Figure 4.10). Different calculations using alternative constant values 
were decided by logical increments in values to provide higher threshold values. All four 
modified calculations used in Figure 4.10 were used in segmenting the dataset although the 
calculation using the lowest constant values (0.4 * SUVmean + 0.6) was found to give thresholds 
which were too low on some datasets where it was impossible to restrict disease from the 
background or remove background regions. For this reason, this variation of the calculation was 




Figure 4.10: Segmentation using SUVmean Threshold Calculation Method 
Segmentation of the primary disease region on pre-therapy scans for datasets 1, 7 and 12 using SUVmean 
calculation method using various values for the constants (Black et al., 2004). Calculations used were 0.307 
* SUVmean + 0.588, 0.4 * SUVmean + 0.6, 0.4 * SUVmean + 1, 0.5 * SUVmean + 0.6 and 0.5 * SUVmean + 1. TV 
is shown in the bottom left corner of each image. Images are of the coronal slice in which the SUVmax of 
the disease is present. 
 
For all threshold calculations using SUVmean, it is assumed that the SUVmean is known and, 
therefore, determining the value used for SUVmean is problematic. In PETTRA, implementation is 
achieved by using a starting SUVmean obtained from a fixed 2.5 SUV threshold segmentation and 
then recalculating the threshold until the TV does not change significantly, as described in 2.3.5 
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(p99). It was important to ensure that initial segmentation did not heavily influence the method. 
Therefore, other fixed thresholds from 2.2 SUV to 4 SUV were used on the main regions of 
disease on pre-therapy images in the dataset to see if there would be any significant changes in 
the final fixed threshold using the SUVmean calculation method (Black et al., 2004). Differences 
were found to be <1% on all occasions so the starting value of SUV was considered irrelevant 
and kept at 2.5 SUV. 
 
The SUVmean calculation algorithm stops when the change in TV is <1% or after 10 iterations of 
re-calculating the threshold value based on the new SUVmean (as described in 2.3.5, p99). In 
testing the SUVmean calculation method, it was found that the algorithm often gets ‘stuck’ between 
two different PET structures. For example, when using the calculation of 0.5 * SUVmean + 1 for a 
small tumour region on dataset 1, the algorithm reaches a point where the threshold is 4 SUV, 
giving a 140 voxel TV with a SUVmean of 5.1. Using the calculation, the new threshold becomes 
3.55 SUV, giving an 8840 voxel TV with a SUVmean of 6. The recalculation of the threshold sets 
it back to 3 and this loop continues. One of the thresholds needs to be used for the segmentation 
and the algorithm has been modified to take the smaller volume/higher threshold to stop separate 
segmentations overlapping each other. In line with this change, the number of iterations of the 
algorithm performed was increased to 20 rather 10 to ensure that if convergence was possible it 
would take place. It was found that convergence to a volume change of <1% sometimes did not 
occur until a higher number of iterations had been performed. No other changes were made to the 
algorithm and the three suggested calculation variations (0.4 * SUVmean + 1, 0.5 * SUVmean + 0.6 
and 0.5 * SUVmean + 1) were used to segment all 14 datasets of mesothelioma patients 
successfully. These same changes used in this segmentation method were also applied to similar 
methods which used this methodology of obtained the SUVmean, mainly those by Nestle et al. 
(Nestle et al., 2005; Nestle et al., 2007). 
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4.4.6) Background Uptake for Segmentation 
A major factor in segmentations using background uptake is the methodology used to obtain the 
background value (and S.D., if needed). While automated or semi-automated methods are 
possible and will eliminate or limit variation due to observer variability, there is no standard 
method used in clinical practice. Therefore, a manual methodology was used because of its easy 
of use and the opportunity to assess the levels of variation in background uptake. One observer 
placed eight different sized VOIs (listed in Table 4.8) over three background regions (middle of 
the liver, top of liver and middle of the mediastinum) for all 28 PET images. VOIs ranged from 
~2ml to >200ml. Seven were fixed VOIs while another VOI was taken as a user defined volume 
over the whole of the liver. 
 
The liver and mediastinum were chosen as the regions of background uptake due to 
recommendations of the PERCIST criteria (Wahl et al., 2009). The one observer had some 
experience of viewing PET images and had no issues identifying the liver in all 28 images but 
found it more difficult to identify the mediastinum, particular a region which could be defined as 
the ‘middle’. All 22 VOIs (seven fixed VOIs over the three background regions and the user 
defined liver region) were used over the 14 datasets, however, if the observer believed that the 
VOI was too large for the region or would include areas of disease then it was not included in the 
analysis. While the presence of disease in and around the lung made this a particularly problem in 
the mediastinum, in the liver there were only three datasets where disease was a problem. In two 
of these, disease was only present on the outer areas so background regions could be obtained 
with care, although on dataset 8, where disease was present in the liver, it was more likely some 









X Y Z Volume X Y Z Volume 
2.6 ml VOI 16.41 16.41 9.81 2,642 3 3 3 27 
12 ml VOI 27.35 27.35 16.35 12,230 5 5 5 125 
22 ml VOI 27.35 27.35 29.43 22,014 5 5 9 225 
34 ml VOI 38.29 38.29 22.89 33,560 7 7 7 343 
53 ml VOI 38.29 38.29 35.97 52,736 7 7 11 539 
119 ml VOI 49.23 49.23 49.05 118,877 9 9 15 1215 
201 ml VOI 60.17 60.17 55.59 201,260 11 11 17 2057 
User Defined (Mean) 111.04 101.33 103.17 801,731 20 19 32 8198 
 





X Y Z Volume X Y Z Volume 
2 ml VOI 14.07 14.07 9.81 1,942 3 3 3 27 
13 ml VOI 23.45 23.45 22.89 12,587 5 5 7 175 
25 ml VOI 32.83 32.83 22.89 24,671 7 7 7 343 
32 ml VOI 32.83 32.83 29.43 31,720 7 7 9 441 
52 ml VOI 42.21 42.21 29.43 52,435 9 9 9 729 
113 ml VOI 51.59 51.59 42.51 113,142 11 11 13 1573 
210 ml VOI 70.35 70.35 42.51 210,387 15 15 13 2925 
User Defined (Mean) 100.84 96.15 73.58 474,935 22 21 23 8189 
Table 4.8: Different Sizes of VOI used for Obtaining Background Uptake 
Table shows the eight different VOIs used over the 28 images for obtaining background. All seven fixed 
VOIs were applied to all three areas of background uptake (top of the liver, middle of the liver and the 
mediastinum) while the final user defined VOI was applied to the liver only. VOIs are given in voxels and 
mms for each plane and for the 3-D volume. 
 
While disease should not be present in areas of background uptake, it was felt that a background 
region in the liver had to be used for dataset 8, as the background mean in the mediastinum was 
found to be too low to segment the disease in the liver accurately using many different 
segmentation methods. Therefore, background uptake was taken from the liver although the 
volume used was careful not to include the most intense regions of disease uptake. Otherwise, 
there were no issues with disease being included in background regions throughout the dataset.  
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Intra-observer variability was investigated by the one observer identifying each size VOI over the 
three regions twice and the differences between the obtained values (SUVmax, SUVmean, S.D. and 
SUVmean + 2 S.D, the calculation used to determine the segmentation threshold in PERCIST) were 
calculated. Table 4.9 shows the mean absolute and percentage differences for each VOI size and 




Mean Difference (% in Brackets) 
Used SUVmax SUVmean S.D. Mean + 2 S.D. 
Mediastinum  0.232 (2.35) 0.115 (1.88) 0.042 (3.55) 0.156 (1.83) 
2.5 ml VOI 13 0.330 (3.65) 0.194 (3.28) 0.081 (6.63) 0.310 (3.67) 
13 ml VOI 12 0.298 (2.86) 0.122 (1.90) 0.037 (3.22) 0.176 (2.01) 
22 ml VOI 11 0.127 (1.30) 0.076 (1.28) 0.035 (3.01) 0.102 (1.24) 
34 ml VOI 11 0.238 (2.27) 0.091 (1.45) 0.030 (2.54) 0.101 (1.17) 
53 ml VOI 8 0.154 (1.45) 0.078 (1.26) 0.027 (2.25) 0.076 (0.85) 
119 ml VOI 4 0.153 (1.45) 0.080 (1.29) 0.018 (1.43) 0.060 (0.72) 
Top of the Liver  0.183 (1.55) 0.058 (0.78) 0.028 (2.32) 0.081 (0.83) 
2.5 ml VOI 14 0.307 (3.07) 0.130 (1.71) 0.069 (6.21) 0.215 (2.25) 
13 ml VOI 14 0.180 (1.45) 0.059 (0.79) 0.024 (1.92) 0.085 (0.84) 
22 ml VOI 14 0.183 (1.60) 0.061 (0.84) 0.025 (2.04) 0.070 (0.71) 
34 ml VOI 14 0.138 (1.18) 0.028 (0.40) 0.019 (1.50) 0.038 (0.40) 
53 ml VOI 14 0.252 (1.82) 0.046 (0.64) 0.023 (1.75) 0.059 (0.63) 
119 ml VOI 13 0.092 (0.68) 0.035 (0.49) 0.012 (0.90) 0.033 (0.35) 
201 ml VOI 7 0.063 (0.47) 0.031 (0.40) 0.022 (1.39) 0.038 (0.35) 
Middle of the Liver  0.120 (1.00) 0.047 (0.63) 0.018 (1.41) 0.055 (0.55) 
2.5 ml VOI 14 0.148 (1.43) 0.092 (1.24) 0.028 (2.44) 0.123 (1.24) 
13 ml VOI 14 0.177 (1.55) 0.044 (0.60) 0.021 (1.74) 0.066 (0.68) 
22 ml VOI 14 0.131 (1.06) 0.039 (0.53) 0.020 (1.60) 0.065 (0.65) 
34 ml VOI 14 0.130 (1.09) 0.034 (0.47) 0.018 (1.39) 0.047 (0.48) 
53 ml VOI 14 0.084 (0.73) 0.040 (0.57) 0.015 (1.21) 0.038 (0.39) 
119 ml VOI 14 0.130 (0.95) 0.045 (0.61) 0.012 (0.89) 0.043 (0.42) 
201 ml VOI 13 0.082 (0.56) 0.031 (0.44) 0.011 (0.82) 0.026 (0.27) 
User Defined 11 0.064 (0.45) 0.046 (0.58) 0.018 (1.07) 0.019 (0.17) 
ALL  0.168 (1.50) 0.066 (0.97) 0.027 (2.22) 0.087 (0.94) 
Table 4.9: Intra-Observer Variability for Obtaining Background Uptake 
Table shows the difference between the SUVmax, SUVmean, S.D. and SUVmean + 2 S.D (recommended 
threshold calculation for segmentation in PERCIST) for each VOI size over each region of background. 
Used = the number of datasets of the 14 the VOI was validly taken for. User Defined was a volume taken 
over the largest region of the liver possible, focused on the middle. % Difference is in brackets. 
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Overall, differences were minimal with the mean difference in SUVmean just 0.066 (<1%) and the 
difference in SUVmean + 2 S.D, just 0.087 (<1%). Using larger VOIs showed less variation as the 
likelihood of the placement of the VOIs overlapping was greater, reducing variability. The region 
with the least variation was the middle of the liver, followed by the top of the liver. Given these 
results, it seems appropriate to use the largest VOI possible in the middle of the liver to define 
background uptake in terms of reducing observer variability. 
 
The mean values over the 14 datasets for each size VOI and region of uptake were calculated and 
are presented in Table 4.10. The background mean over all VOIs and regions of uptake was 1.80, 
however, mean values in the liver were higher (1.85 in the middle and 1.92 at the top) compared 
to those in the mediastinum (1.53). The same trend was true for S.D. with values higher in the 
liver than the mediastinum. While there is no ‘known’ value of background to compare these to, it 
is more appropriate to use the higher intensity region of background uptake to ensure that the 
thresholds used for segmentation are high enough to include areas of disease only, therefore, once 
again choosing a background region in the liver (either in the middle or at the top) seems to be the 
most sensible option.  
 
Table 4.11 shows that both SUVmean and S.D. were relatively consistent over the different sized 
VOIs and, as a consequence, the formula for PERCIST threshold calculation (Mean + 2 S.D.). 
From the results, it can be concluded that obtaining a background region has low intra-observer 
variability and does not appear to alter too much depending on the size of the VOI. However, the 
region in which the background is taken is significant. Given these findings, it was decided that 
the background mean and S.D. for the segmentation methods would be based on the largest sized 





Mean Values over 14 Datasets 
Used SUVmax SUVmean Mean + 2 S.D. 
Mediastinum  2.48 (0.42) 1.53 (0.24) 2.13 (0.33) 
2.5 ml VOI 13 2.27 (0.37) 1.58 (0.27) 2.19 (0.33) 
13 ml VOI 12 2.39 (0.39) 1.54 (0.23) 2.09 (0.31) 
22 ml VOI 11 2.45 (0.48) 1.50 (0.26) 2.07 (0.37) 
34 ml VOI 11 2.57 (0.40) 1.51 (0.22) 2.13 (0.35) 
53 ml VOI 8 2.69 (0.49) 1.52 (0.22) 2.14 (0.35) 
119 ml VOI 4 2.86 (0.39) 1.50 (0.16) 2.15 (0.25) 
Top of the Liver  3.07 (0.59) 1.92 (0.35) 2.55 (0.47) 
2.5 ml VOI 14 2.59 (0.53) 1.93 (0.38) 2.52 (0.52) 
13 ml VOI 14 2.86 (0.59) 1.91 (0.37) 2.52 (0.50) 
22 ml VOI 14 2.98 (0.59) 1.91 (0.36) 2.52 (0.48) 
34 ml VOI 14 3.14 (0.61) 1.90 (0.37) 2.54 (0.48) 
53 ml VOI 14 3.23 (0.58) 1.89 (0.35) 2.54 (0.45) 
119 ml VOI 13 3.35 (0.62) 1.92 (0.32) 2.59 (0.43) 
201 ml VOI 7 3.63 (0.64) 2.00 (0.25) 2.74 (0.38) 
Middle of the Liver  3.05 (0.62) 1.85 (0.32) 2.49 (0.45) 
2.5 ml VOI 14 2.50 (0.42) 1.86 (0.30) 2.42 (0.40) 
13 ml VOI 14 2.85 (0.61) 1.84 (0.32) 2.45 (0.44) 
22 ml VOI 14 2.91 (0.67) 1.85 (0.33) 2.46 (0.46) 
34 ml VOI 14 3.02 (0.60) 1.86 (0.32) 2.48 (0.44) 
53 ml VOI 14 3.06 (0.63) 1.85 (0.33) 2.48 (0.45) 
119 ml VOI 14 3.20 (0.61) 1.87 (0.33) 2.51 (0.45) 
201 ml VOI 13 3.41 (0.73) 1.87 (0.35) 2.56 (0.48) 
User Defined 11 3.64 (0.69) 1.83 (0.29) 2.60 (0.47) 
ALL  2.93 (0.56) 1.80 (0.31) 2.43 (0.43) 
Table 4.10: Mean Values for Background Uptake for Different VOIs 
Table shows the mean values for SUVmax, SUVmean, S.D. and SUVmean + 2 S.D (recommended threshold 
calculation for segmentation in PERCIST) for each VOI size over each region of background. Used = the 
number of datasets of the 14 the VOI was validly taken for. User Defined was a volume taken over the 
largest region of the liver possible, focused on the middle. S.D. is in brackets. For each dataset the values 
for the VOIs were taken as the mean of the two attempts made at taking a region by the observer. 
 
4.4.7) Segmentation of Mesothelioma Patients using PERCIST Recommendations 
Segmentation using background uptake is recommended in PERCIST (Wahl et al., 2009), and is 
implemented in PETTRA as described in 2.3.6 (p102). It calculates the threshold based on the 
background mean + 2 S.D., an earlier study used a similar calculation using 3 S.D. (Zasadny et 
al., 1998). Both of these will be tested on the dataset. There were no problems with segmentation 
 210 
using either of these methods. The background values used for all segmentation methods and the 
thresholds used for PERCIST segmentation are shown in Table 4.11. The mean value for the 
background uptake was 1.86 with a 0.34 S.D. resulting in PERCIST thresholds of 2.54 and 2.87 
when using 2 S.D. and 3 S.D, respectively. There were no noticeable differences between pre- 
and post- therapy background uptake. Examples of segmentations using the PERCIST thresholds 
are shown in Figure 4.11. The background mean and S.D. values in Table 4.11 were applied for 










+2 S.D. +3 S.D. +2 S.D. +3 S.D. 
1 201ml 2.08 0.36 2.80 3.16 1.76 0.35 2.46 2.81 
2 201ml 1.77 0.30 2.37 2.67 1.69 0.29 2.27 2.56 
3 201ml 1.68 0.35 2.38 2.73 1.89 0.34 2.57 2.91 
4 201ml 1.56 0.24 2.04 2.28 1.36 0.19 1.74 1.93 
5 201ml 2.12 0.41 2.94 3.35 2.21 0.40 3.01 3.41 
6 201ml 2.34 0.40 3.14 3.54 2.19 0.42 3.03 3.45 
7 201ml 1.26 0.27 1.80 2.07 1.42 0.25 1.92 2.17 
8 119ml 2.09 0.40 2.89 3.29 2.21 0.41 3.03 3.44 
9 201ml 1.86 0.31 2.48 2.79 1.53 0.25 2.03 2.28 
10 201ml 2.13 0.46 3.05 3.51 2.14 0.46 3.06 3.52 
11 201ml 1.95 0.29 2.53 2.82 1.60 0.31 2.22 2.53 
12 201ml 1.86 0.37 2.60 2.97 1.78 0.34 2.46 2.80 
13 201ml 1.44 0.27 1.98 2.25 1.50 0.25 2.00 2.25 
14 201ml 2.31 0.42 3.15 3.57 2.36 0.42 3.20 3.62 
MEAN 1.89 0.35 2.58 2.93 1.83 0.33 2.50 2.83 
Table 4.11: Values for Background Uptake for all 14 Datasets 
The table shows the background region mean, S.D. and resulting PERCIST calculated segmentation 
thresholds for pre- and post- therapy images for each of the 14 datasets and the mean over all datasets. 
PERCIST thresholds are calculating using the background mean + 2 S.D. and 3 S.D. respectively.  
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4.4.8) Segmentation of Mesothelioma Patients using SUVmax and Background 
Segmentation using 50% and 70% of the combination of SUVmax and background was used but 
produced high thresholds which only appeared to segment partial areas of disease (Figure 4.11). 
Lower percentages were used to try and solve this problem but caused major over-segmentation 
so this method was not used further in the segmentation of disease on the dataset. 
 
Figure 4.11: PERCIST and Boellaard Segmentation Methods 
Segmentation of the primary disease region on pre-therapy scans for datasets 1, 7 and 12 using PERCIST 
segmentation threshold recommendations (Background Mean + 2 S.D./3 S.D) (Wahl et al., 2009), and 50% 
and 70% of SUVmax + Background Mean (Boellaard et al., 2004). TV is shown in the bottom left corner of 
each image. Images are of the coronal slice in which the SUVmax of the disease is present. 
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Another study using SUVmax and background, using a threshold based on a background corrected 
SUVmax calculation (Davis et al., 2006), was also applied to the mesothelioma data using different 
relative thresholds/percentages. Figure 4.12 shows examples of this method using different 
relative thresholds. A relative threshold of 30-50% appears too high to segment all disease, 
however, a lower relative threshold of 10% was used to segment the dataset with success. 
 
 
Figure 4.12: Background Corrected SUVmax Segmentation Method 
Segmentation of the primary disease region on pre-therapy scans for datasets 1, 7 and 12 using background 
mean + % of SUVmax – background (Davis et al., 2006). 10%, 20%, 30% 40% and 50% were used as the 
relative threshold i.e. % in the equation (see 2.3.7 for more details, p103). TV is shown in the bottom left 
corner of each image. Images are of the coronal slice in which the SUVmax of the disease is present. 
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4.4.9) Segmentation of Mesothelioma Patients using SUVmean and Background 
Finally, the three segmentation methods using SUVmean and background were tested on the 
mesothelioma patients, both threshold based calculations (Nestle et al., 2005; Nestle et al., 2007), 
and the adaptive GRAB threshold method (Boucek et al., 2008). Examples of segmentations 
using these methods are shown in Figure 4.13. 
 
Figure 4.13: Segmentation Methods using Background and SUVmean 
Segmentation of the primary disease region on pre-therapy scans for datasets 1, 7 and 12 using threshold 
calculations of 0.15 * SUVmean + Background (Nestle et al., 2005), (0.7 * SUVmean) + (0.15 * Background) 
(Nestle et al., 2007), and the GRAB method using a threshold factor based on Background Mean + 3 S.D. 
(Boucek et al., 2008). TV is shown in the bottom left corner of each image. Images are of the coronal slice 
in which the SUVmax of the disease is present. 
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While two of the methods appeared to provide suitable segmentation, one threshold based 
calculation produced thresholds which appeared too high for the dataset (Nestle et al., 2007). 
Therefore, this method was not performed over the dataset of mesothelioma patients.  
4.4.10) Comparison of Segmentation Methods on Mesothelioma Patients 
With segmentation methods producing unrealistic thresholds removed, the nine remaining 
methods of segmentation were used on the dataset. They included: (i) the adaptive SUVmean 
region growing method (Green et al., 2008), (ii) a SUVmean threshold calculation method using 
three different combinations of fixed constants (Black et al., 2004), (iii) the recommended 
PERCIST threshold based on background uptake using both 2 S.D. and 3 S.D. (Wahl et al., 
2009), (iv) a SUVmean method using background uptake and a relative threshold (Davis et al., 
2006), a calculation method using a percentage of SUVmean and background uptake (Nestle et al., 
2007) and the adaptive GRAB method using both SUVmean and background uptake (Boucek et al., 
2008).  
 
While different fixed thresholds produced TV and TLG measurements which showed a low 
variability and high correlation, segmentation methods using calculations with varying 
parameters to decide upon a suitable threshold for each image individually, or in some cases for 
each tumour individually, can be expected to produce more variable results with lower 
correlations. A comparison of the number of segmented regions used throughout the 28 images, 
the number of times segmentation had to be restricted from background uptake and the mean 
values and changes between TV and TLG are displayed in Table 4.12. The results show that there 
are a low number of restricted areas across the segmentation methods, suggesting that the 
thresholds used are suitable as the segmentations do not require physiological uptake removing 
from disease, and the mean TV and TLG values are not drastically different to the fixed 2.5 SUV 
measure approved by a consultant physician. However, there are clear differences between the 
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segmentation methods which may have a positive or negative impact on TV and TLG measures 
in terms of accurately identifying response. The similarities with the physician approved 2.5 SUV 
threshold method would seem to suggest the inclusion of the nine segmentation methods is 









Abs Change Abs % Change 
TV TLG TV TLG 
2.5 SUV 290 13 586 2593 154 840 82 89 
Adaptive SUVmean 152 3 187 1195 122 811 48 48 
0.4 * SUVmean + 1 270 8 507 2344 127 680 41 49 
0.5 * SUVmean + 0.6 261 13 533 2351 164 628 73 65 
0.5 * SUVmean + 1 358 3 311 1737 104 646 44 50 
PERCIST 2 S.D. 312 7 636 2677 182 811 82 92 
PERCIST 3 S.D. 369 5 523 2392 156 775 105 115 
Davis et al. (2006) 254 6 459 2191 181 951 63 63 
Nestle et al. (2005) 253 6 636 2684 175 801 45 53 
GRAB 379 3 327 1799 121 778 125 143 
Table 4.12: Difference between Non-Fixed Threshold Segmentation Algorithms  
Table shows the total number of VOIs needed to segment disease, number of times restricted areas were 
used to stop segmentation, the mean TV (ml) and TLG (ml*SUV) for all 28 images and mean absolute 
change and absolute percentage change between pre- and post- therapy scans for all 14 datasets.  All 
segmentation algorithms used region growing algorithms using 6-connected voxels. A fixed 2.5 SUV 
algorithm is included as a reference point. 
 
As predicted, the correlation of the nine segmentation methods compared to a fixed 2.5 SUV 
threshold method was not as high as other fixed threshold methods and there was often very little 
correlation in the change and percentage change between pre- and post- therapy scans (pcc 
ranging from 0.109 to 0.943 for TV and 0.219 to 0.974 for TLG, Table 4.13). The percentage 
change between pre- and post- therapy scans can be used as a response measure and the lack of 
correlation between segmentation methods suggest that the method chosen could have a 
significant influence on its predictability. Of the segmentation methods, it is interesting to note 
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that the PERCIST recommended threshold calculations correlate highly with SUV (pcc = 0.943, p 
= 0.0001 and pcc = 0.867, p = 0.0001 for percentage change in TV). This is not surprising given 
the mean thresholds were ~2.5 SUV over the dataset and that the method does use a fixed 




Over all 28 Images Change % Change 
TV TLG TV TLG TV TLG 
Fixed 2.5 SUV 1.000 1.000 1.000 1.000 1.000 1.000 
Adaptive SUVmean 0.877 0.927 0.846 0.954 0.282 0.451 
0.4 * SUVmean + 1 0.969 0.993 0.675 0.978 0.686 0.768 
0.5 * SUVmean + 0.6 0.864 0.974 0.070 0.895 0.160 0.219 
0.5 * SUVmean + 1 0.974 0.990 0.897 0.983 0.109 0.259 
PERCIST 2 S.D. 0.946 0.984 0.677 0.962 0.943 0.974 
PERCIST 3 S.D. 0.942 0.981 0.823 0.977 0.867 0.903 
Davis et al. (2006) 0.920 0.965 0.879 0.955 0.188 0.369 
Nestle et al. (2005) 0.950 0.985 0.416 0.920 0.475 0.654 
GRAB 0.927 0.970 0.892 0.982 0.781 0.836 
Table 4.13: Correlation between Non-Fixed Threshold Segmentation Methods  
Pearson correlation coefficients (pccs) are shown for the correlation of various non-fixed threshold 
segmentation methods with a 2.5 SUV fixed threshold for TV and TLG (correlation with SUVmax was 
1.000 in all cases). Pccs were calculated for TV and TLG over the 28 pre- and post- therapy images and for 
the change and percentage change between the 14 pre- and post- therapy scans. For p < 0.01, pcc > 0.479 
over the 28 images and for p < 0.01, pcc > 0.662 for changes and percentage change. 
 
To highlight the potential difference the segmentation method can make, Tables 4.14 and 4.15 
show the correlation between each of the nine segmentation methods for the percentage change 
between pre- and post- therapy for TV and TLG between, respectively. The correlation varies 
from strong correlations to no correlation amongst the nine segmentation methods for both TV 
and TLG so while using some segmentation methods may not result in significant changes in 
terms for the TV or TLG measures, other methods may influence this considerably. The effect on 
response is analysed in the 4.5.5 and 4.5.6. However, it can be conclude that the segmentation 
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method has an influence on TV and therefore, when assessing the success of TV and TLG at 































(A) Adapt SUVmean 1.000 0.169 0.391 0.584 0.200 0.239 0.685 0.136 0.144 
(B) 0.4 * Mean + 1 0.169 1.000 0.374 0.491 0.696 0.668 0.395 .698 0.691 
(C) 0.5 * Mean + 0.6 0.391 0.374 1.000 0.355 -0.057 -0.092 0.273 -0.179 -0.064 
(D) 0.5 * Mean + 1 0.584 0.491 0.355 1.000 0.216 0.323 0.719 0.636 0.375 
(E) PERCIST 2 S.D. 0.200 0.696 -0.057 0.216 1.000 0.965 0.227 0.703 0.912 
(F) PERCIST 3 S.D. 0.239 0.668 -0.092 0.323 0.965 1.000 0.282 0.788 0.964 
(G) Davis (2006) 0.685 0.395 0.273 0.719 0.227 0.282 1.000 0.446 0.280 
(H) Nestle (2005) 0.136 0.698 -0.179 0.636 0.703 0.788 0.446 1.000 0.817 
(I) GRAB 0.144 0.691 -0.064 0.375 0.912 0.964 0.280 0.817 1.000 
Table 4.14: Correlation of Percentage Change in Tumour Volume between Segmentations  
Pearson correlation coefficients (pccs) are shown for the correlation of percentage change in TV between 
all non-fixed threshold segmentation methods in all 14 pre- and post- therapy scans. For p < 0.01, pcc > 






























(A) Adapt SUVmean 1.000 0.489 0.349 0.648 0.396 0.410 0.775 0.432 0.303 
(B) 0.4 * Mean + 1 0.489 1.000 0.446 0.669 0.782 0.786 0.661 0.838 0.802 
(C) 0.5 * Mean + 0.6 0.349 0.446 1.000 0.365 0.072 0.015 0.368 0.013 0.035 
(D) 0.5 * Mean + 1 0.648 0.669 0.365 1.000 0.322 0.437 0.857 0.742 0.461 
(E) PERCIST 2 S.D. 0.396 0.782 0.072 0.322 1.000 0.968 0.397 0.776 0.922 
(F) PERCIST 3 S.D. 0.410 0.786 0.015 0.437 0.968 1.000 0.468 0.873 0.976 
(G) Davis (2006) 0.775 0.661 0.368 0.857 0.397 0.468 1.000 0.671 0.454 
(H) Nestle (2005) 0.432 0.838 0.013 0.742 0.776 0.873 0.671 1.000 0.893 
(I) GRAB 0.303 0.802 0.035 0.461 0.922 0.976 0.454 0.893 1.000 
Table 4.15: Correlation of Percentage Change in Total Lesion Glycolysis between Segmentations 
Pearson correlation coefficients (pccs) are shown for the correlation of percentage change in TLG between 
all non-fixed threshold segmentation methods in all 14 pre- and post- therapy scans. For p < 0.01, pcc > 
0.479 over the 28 images and for p < 0.01, pcc > 0.662 for changes and percentage change. 
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4.5) Predicting Survival using Response Measures 
4.5.1) Measures of Survival 
For the 14 patients with MPM, PFS and OS were chosen as parameters with which to measure 
response, with longer PFS and OS times indicating patients with good response to therapy. Any 
response parameter which can accurately predict good or bad PFS and/or OS would be of 
particular interest. OS and PFS of the 14 patients are listed in Table 4.16. All patients were found 
to have disease progression and died before data was collected with the exception of patient 14 
who did not die or have disease progression confirmed 800 days after the start of treatment. 800 
days was the 2nd longest OS time and longest PFS time so while there is no definite endpoint for 
this patient it was not thought that it would significantly alter results as the patient had already 
had a long survival time, in comparison to others, at the last time of follow-up. 
4.5.2) Statistical Methods for Assessing Response 
Three different methods of statistical analysis were used to assess the success both qualitative and 
quantitative parameters. Firstly, Pearson correlation coefficients (pcc) were used to see how well 
the response measures correlated with OS and PFS, with well correlated measures potentially 
being accurate response measures because they are heavily related to the survival time of patient. 
However, just because a parameter correlates well with survival, it does not necessairily mean 
that it will be useful in a clinical setting without a way of diving patients into groups of 
responders and non-responders. Secondly, receiver operator characteristics (ROC) curves were 
used in an attempt to detect the sensitivity and specificity of a measure at predicting the status of 
a patient. ROC curves attempt to define the accuracy of a response measure by defining the 
ability of a response method for having true positives or negatives. Using ROC analysis allows 
the most appropriate threshold to be obtained for dividing patients into groups of responders and 
non-responders with the best discrimination between groups. The area under the curve (AUC) 
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helps define whether any threshold of a particular measure can discriminate groups of patients 
better than random guessing. 
 
If ROC analysis showed a parameter could divide patients into responders and non-responders 
successfully, Kaplan-Meier survival curves were plotted to analyse the significance of the two 
groups OS and PFS. However, with a sample size of only 14 patients, even very strong 
correlations or ROC curves with high AUC have low predictive power and statistical 
significance. For example, for the pcc to be statistically significant (p < 0.05) for 14 patients, 
correlation would have to be >0.533. Conclusions made must take into account the small sample 
size of the dataset. However, results should at least show what measures have the potential to be 
effective even if more studies with more patients are needed to determine this further. The 
potential clinical benefit of a response measure which could accurately distinguish between 
responders and non-responders is that non-responding patients could be taken off a therapy 
regime which is not resulting in a response and given an alternative treatment. 
 
For ROC analysis, the OS and PFS data must be in a binary format so the predicted response 
parameter can predict whether a patient has, for example, survived or not. Therefore, a threshold 
is used for OS and PFS to determine whether a patient has survived for a long or short period of 
time. Thresholds for studies looking at the survival of patients in medical scenarios can be 
variable, however, in MPM patients OS or PFS is relatively low so an OS or PFS of over six 
months or a year is seen as a positive outcome. With 14 patients, it is also important to make sure 
that patients are relatively uniformly separated into two groups. Therefore, for ROC analysis a 
threshold of six months for OS and PFS was used to differentiate responders and non-responders 
with nine patients alive and five patients deceased for OS at six months and eight patients alive 
and six patients deceased or found to have disease progression for PFS. As the measures are 
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similar, it is not expected that results will differ significantly. Statistical analysis was done using 
statistical software package SPSS Statistics Version 20 (IBM, Armonk, NY, USA). 
4.5.3) Predicting Survival in Patients with Mesothelioma using Visual Analysis 
The visual analysis responses using both custom-made PET criteria (Table 4.2, p185) and 
modified RECIST (Table 4.3, p185) are listed for all 14 patients in Table 4.16 along with OS and 
PFS. By viewing this table, it can be seen that visual analysis does not predict either OS or PFS. 
There are only three patients classified as responders using visual analysis on PET and all three 
have short survival times as opposed to longer survival times that one would expect for 
responding patients. Visual analysis on CT only has one patient as partially responding and while 
they have a reasonably long survival time, other patients with longer survival are classified as 
having stable disease. There is some correlation between CT visual analysis and OS and PFS (pcc 
= 0.405, p = 0.15 and pcc = 0.209, p = 0.48, respectively with each category of response given as 
a numerical index i.e. 1 = PR, 2 = SD, 3 = PD), however, it is not statistically significant. 
Similarly, PET visual analysis did not have any statistically significant correlation. ROC analysis 
and Kaplan-Meier survival curves were used to investigate both visual analysis methods but these 
results only confirmed that the two measures did not predict response. 
 
Figure 4.14 shows the Kaplan-Meier survival curves for OS and PFS for all 14 patients. The 
curves show that there are low levels of survival using both measures. The one patient who did 
not die or progress in the study is marked with a + on the curve, whereas all other patients were 
deceased at the time of follow-up. A good response measure should produce two curves for two 
groups of patients, one in which cumulative survival decreases rapidly for non-responders and 





Survival Parameters Visual Response Assessment 
OS (days) PFS (days) CT Response (RECIST) PET Response 
1 164 96 Stable Disease Response 
2 155 48 Progressive Disease Response 
3 577 229 Partial Response Progressive Metabolic Disease 
4 515 247 Stable Disease Stable Metabolic Disease 
5 1070 196 Stable Disease Progressive Metabolic Disease 
6 250 217 Stable Disease Progressive Metabolic Disease 
7 158 97 Stable Disease Response 
8 477 244 Stable Disease Progressive Metabolic Disease 
9 132 68 Progressive Disease Progressive Metabolic Disease 
10 750 286 Stable Disease Stable Metabolic Disease 
11 418 221 Stable Disease Progressive Metabolic Disease 
12 545 114 Stable Disease Stable Metabolic Disease 
13 152 13 Stable Disease Progressive Metabolic Disease 
14 800 800 Stable Disease Progressive Metabolic Disease 
Mean 440 205 N/A N/A 
Table 4.16: Survival and Visual Response for Mesothelioma Patients 
Table shows OS and PFS, in days, for all 14 mesothelioma patients in the dataset. Patient 14 was the only 
patient still alive when the data was collected, 800 days after the start of patient 14’s therapy start date, and 
the disease had not been found to progress. PET and CT response were judged based on custom-made 
criteria (Table 4.2, p185) and modified RECIST (Table 4.3, p185, (Byrne and Nowak, 2004)), respectively. 
 
 
Figure 4.14: Kaplan-Meier Survival Curves for all Mesothelioma Patients 
Survival curves for (A) PFS and (B) OS for all 14 mesothelioma patients. OS and PFS are in days. 
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4.5.4) Predicting Survival in Patients with Mesothelioma using SUVmax and SUVpeak 
In investigating response based on SUVmax and SUVpeak measurements, a number of factors must 
be taken into consideration. All parameters are taken before and after therapy so response can be 
based on measurements before therapy, after therapy or the change between the two values as 
either an absolute or percentage change. It is generally considered that the change from pre-
therapy to post-therapy, usually as a percentage, is, theoretically, the best predictor of response 
considering it shows the impact treatment has had on disease. However, this is not necessarily the 
case. The change from pre- to post- therapy is noted as a change (or percentage change) with 
negative values indicating a reduction from pre- to post- therapy, therefore, suggesting a good 
response, while positive values indicate an increase from pre- to post- therapy suggesting a poor 
response. If TV has percentage change of -5% from pre- to post- therapy scans then it has reduced 
in size and should indicate a response in the patient compared to a change of +5%. 
 
Maximum uptake values were obtained with different methods of calculating the total volume 
(SUV, SUL and SUVBSA) and peak values were obtained using both PETTRA and HERMES 
software. As expected there is excellent correlation between SUVmax, SULmax and SUVBSA, both 
in terms of pre- and post- therapy values and the change and percentage change between them. 
The lowest correlation is still high, between the change in pre- and post- therapy values, between 
SUVmax and SUVBSA (pcc = 0.968, p < 0.0001). SUVpeak values taken by HERMES and PETTRA 
are also very highly correlated with the lowest correlation being the percentage change between 
pre- and post- therapy parameters (pcc = 0.970, p < 0.0001). The correlation of all the parameters 
with each other for pre- and post- therapy values and the change and percentage change between 
them is shown in Table 4.15. The table shows very high correlation between values, suggesting 
that the difference in predicting response between them will be negligible. However, there does 
seem a weaker correlation between the SUVmax and SUVpeak parameters. 
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SUVmax 1.000 0.993 0.978 0.955 0.954 
SULmax 0.993 1.000 0.979 0.940 0.942 
SUVBSAmax 0.978 0.979 1.000 0.955 0.958 
PETTRA SUVpeak 0.955 0.940 0.955 1.000 0.996 
HERMES SUVpeak 0.954 0.942 0.958 0.996 1.000 
      
(B) Change 
between Pre- and 








SUVmax 1.000 0.994 0.968 0.742 0.761 
SULmax 0.994 1.000 0.984 0.698 0.728 
SUVBSAmax 0.968 0.984 1.000 0.638 0.669 
PETTRA SUVpeak 0.742 0.698 0.638 1.000 0.975 
HERMES SUVpeak 0.761 0.728 0.669 0.975 1.000 
 
(C) % Change 
between Pre- and 








SUVmax 1.000 0.996 0.990 0.849 0.873 
SULmax 0.996 1.000 0.995 0.842 0.876 
SUVBSAmax 0.990 0.995 1.000 0.832 0.858 
PETTRA SUVpeak 0.849 0.842 0.832 1.000 0.970 
HERMES SUVpeak 0.873 0.876 0.858 0.970 1.000 
Table 4.17: Correlation between Max and Peak Response Measures  
Pearson correlation coefficients (pccs) are shown for each SUVmax and SUVpeak measure. Pccs were 
calculated for both pre- and post-therapy values for each of the response parameters (Table A) and the 
change (Table B) and percentage change (Table C) between them over the 14 pre- and post- therapy scans. 
For p < 0.01, pcc > 0.662 and p < 0.05, pcc > 0.533. The only difference between the SUVmax, SULmax and 
SUVBSAmax was in the units used and not in the formulation of the maximum value in TV. 
 
Both pre- and post- therapy values for all five parameters correlated well with OS and PFS with 
pcc ranging from -0.467 to -0.702 (p = 0.1 to 0.005) while the change and percentage change 
between them had much weaker correlation with OS with pcc ranging from 0.191 to 0.480 (p = 
0.5 to 0.08) and no correlation with PFS with pcc ranging from 0.091 to 0.199 (Table 4.18). As 
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would be expected, a high pre- or post- therapy SUVmax correlates with a low OS or PFS. SUL 
and SUVBSA show mildly better correlations with OS and PFS than for SUVmax but the three are 
very similar. Pre- and post- therapy SUVpeak values, both from PETTRA and HERMES, have the 
strongest correlation with OS and PFS, the difference between the two is minimal. The change 
between pre- and post- therapy values for all five parameters produces a correlation where a 
negative change from pre- to post- therapy correlates with a low OS or PFS when a negative 
change is supposed to be an indicator of response. This is a surprising result as one would expect 





Pre Post Change % Chg Pre Post Change % Chg 
SUVmax -0.467 -0.507 0.278 0.422 -0.579 -0.650 0.199 0.139 
SULmax -0.507 -0.528 0.237 0.404 -0.575 -0.652 0.147 0.104 
SUVBSAmax -0.526 -0.548 0.191 0.397 -0.591 -0.653 0.122 0.091 
PETTRA SUVpeak -0.620 -0.527 0.468 0.414 -0.606 -0.702 0.100 -0.091 
HERMES SUVpeak -0.606 -0.540 0.466 0.480 -0.587 -0.699 0.108 -0.091 
Table 4.18: Correlation between Max and Peak Response Parameters and Survival 
Pearson correlation coefficients (pccs) are shown for the correlation of each SUVmax and SUVpeak response 
measure with OS and PFS for pre-therapy values, post-therapy values, and change and percentage change 
(chg) from pre- to post- therapy values. For p < 0.01, pcc > 0.662 and p < 0.05, pcc > 0.533. 
 
This is confirmed further when using ROC curves to investigate the parameters predicting PFS 
and OS at 6 months. Pre- and post- therapy SUVmax produce excellent ROC curves which predict 
response accurately, however, the change and percentage change do the inverse of this (Figure 
4.15). It is difficult to determine an exact reason for the inverse correlation of change and 
percentage change, however, studying the data, it appears that higher SUVmax values are more 
likely to have a negative change between pre- and post- therapy scans than lower SUVmax values. 
For example, for dataset 1 there is a change of -1.6 SUV, however, the original pre-therapy SUV 
of 18.5 is high so it is unsurprising the patient had poor OS of 164 days. In comparison, a low 
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SUVmax in dataset 5 changes from 6 SUV to 9.2 SUV, however, with a much lower SUVmax for 
both values it is hardly surprising that the patient went on the have an OS of 1070 days. While the 




Figure 4.15: ROC Curve for SUVmax Parameters for PFS at 6 months 
ROC curves are plotted for pre-therapy SUVmax , post-therapy SUVmax, change in SUVmax and percentage 
change in SUVmax. The curves show that pre- and post- therapy SUVmax provide strong ROC curves while 
change and percentage change in SUVmax have unwanted results. ROC curves for all five maximum and 
peak response measures are very similar. Pre-therapy SUVmax has an AUC of 0.844 (Standard Error (SE) = 
0.113, 95% Confidence Intervals (CI) of 0.622 – 1). Post-therapy SUVmax has an AUC of 0.800 (SE = 
0.131, 95% CI = 0.544 – 1). 
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There is very little difference between using SUVmax, SULmax, SUVBSA, PETTRA SUVpeak or 
HERMES SUVpeak for predicting response. As shown in Table 4.18, their correlations are similar 
as are their ROC curves, highlighted in Table 4.19, which shows the AUC for each of parameters 




6 Month OS 6 Month PFS 
Pre Post Change % Chg Pre Post Change % Chg 
SUVmax 0.844 0.800 0.222 0.222 0.958 0.917 0.104 0.125 
SULmax 0.867 0.822 0.222 0.222 0.979 0.937 0.104 0.125 
SUVBSAmax 0.867 0.800 0.267 0.222 0.979 0.917 0.146 0.125 
PETTRA SUVpeak 0.844 0.778 0.178 0.200 0.958 0.896 0.104 0.146 
HERMES SUVpeak 0.844 0.778 0.178 0.222 0.958 0.896 0.104 0.188 
Table 4.19: AUC for Max and Peak Response Parameters Predicting Survival 
Area under the curve (AUC) is shown for the ROC curves for all five response parameters for predicting 
six month OS and PFS for pre- and post- therapy values and change and percentage change between them. 
 
The results show there is no significant difference between the max and peak parameters when it 
comes to predicting OS and PFS. Also, pre- or post- therapy values alone are more valuable than 
investigating the change and percentage change between them in terms of predicting response for 
this dataset. A pre-therapy SUVmax of 13 is the best threshold for ROC analysis, however, as SUV 
is heavily dependent on the scanner and scanning protocol using this value for other studies, 
particularly given the small number of patients in this study, is not advisable. The Kaplan-Meier 
survival curves for two groups of patients split by a pre-therapy SUVmax of 13 are shown in 
Figure 4.16. While this is statistically significant (p < 0.001), it should be considered that with 
only 14 patients, there is more of a possibility that this has happened by chance than because the 




Figure 4.16: Kaplan-Meier Survival Curve for Pre-Therapy SUVmax and PFS 
Survival curves are plotted for two groups of patients, those with pre- therapy SUVmax > 13 SUV (Mean 
PFS = 74, SE = 19, 95% CI = 37-110) and those < 13 SUV (mean PFS = 279, SE = 64, 95% CI = 153-405) 
Comparing the survival distributions using the log-rank method shows a significance of p < 0.001.  
4.5.5) Predicting Survival in Patients with Mesothelioma using Tumour Volume 
and Total Lesion Glycolysis using Fixed Threshold Segmentation 
The segmentation method is an important factor in assessing response using TV and TLG. A 
variety of fixed and non-fixed threshold methods have been used to obtain TV and TLG in this 
study. The correlation between fixed threshold methods was found to be high while the 
correlation between non-fixed threshold methods is more variable. Therefore, different fixed 
threshold methods are expected to have similar results in terms of predicting OS and PFS while 
non-fixed methods are expected to have more of a difference. Segmentation using 6-connected 
and 26-connected voxels was found to correlate so well that the differences in terms of 
identifying response has not been investigated as it is thought to be inconsequential.  The 
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correlation of TV and TLG with OS and PFS for pre- and post- therapy values and the change and 
percentage change between them are shown in Table 4.20, for TV, and Table 4.21, for TLG. 
 
Segmentation 
Methods for TV 
OS PFS 
Pre Post Change % Chg Pre Post Change % Chg 
SUV 2.2 -0.641 -0.622 0.103 0.264 -0.430 -0.458 -0.095 0.019 
SUV 2.5 -0.642 -0.638 0.064 0.195 -0.419 -0.447 -0.059 -0.038 
SUV 3 -0.635 -0.633 0.154 0.319 -0.405 -0.429 0.049 -0.148 
SUL 2.2 -0.643 -0.649 0.012 0.304 -0.411 -0.441 -0.076 -0.064 
SUL 2.5 -0.634 -0.644 0.111 0.327 -0.402 -0.428 0.026 -0.019 
SUL 3 -0.617 -0.625 0.173 0.455 -0.386 -0.402 0.093 0.002 
SUVBSA 0.5 -0.720 -0.690 -0.058 0.449 -0.480 -0.525 -0.288 0.083 
SUVBSA 0.6 -0.668 -0.678 -0.228 0.189 -0.439 -0.476 -0.289 0.020 
SUVBSA 0.7 -0.651 -0.673 -0.096 0.297 -0.423 -0.459 -0.135 -0.064 
Table 4.20: Correlation between TV with Fixed Segmentation Thresholds and Survival 
Pearson correlation coefficients (pccs) are shown for the correlation of TV, for each fixed threshold 
segmentation method, with OS and PFS for pre-therapy values, post-therapy values, and the change and 




Methods for TLG 
OS PFS 
Pre Post Change % Chg Pre Post Change % Chg 
SUV 2.2 -0.639 -0.626 0.203 0.296 -0.419 -0.439 0.067 0.009 
SUV 2.5 -0.637 -0.627 0.178 0.238 -0.411 -0.424 0.075 -0.034 
SUV 3 -0.631 -0.613 0.202 0.362 -0.402 -0.404 0.107 -0.125 
SUL 2.2 -0.631 -0.634 0.130 0.336 -0.402 -0.419 0.052 -0.054 
SUL 2.5 -0.624 -0.623 0.162 0.346 -0.396 -0.405 0.087 -0.015 
SUL 3 -0.613 -0.600 0.191 0.464 -0.387 -0.380 0.118 0.005 
SUVBSA 0.5 -0.689 -0.683 0.079 0.489 -0.455 -0.492 -0.079 0.079 
SUVBSA 0.6 -0.651 -0.666 0.031 0.210 -0425 -0.455 -0.030 0.016 
SUVBSA 0.7 -0.638 -0.654 0.062 0.319 -0.414 -0.438 0.013 -0.056 
Table 4.21: Correlation between TLG with Fixed Segmentation Thresholds and Survival 
Pearson correlation coefficients (pccs) are shown for the correlation of TLG, for each fixed threshold 
segmentation method, with OS and PFS for pre-therapy values, post-therapy values, and the change and 
percentage change (chg) from pre- to post- therapy values. For p < 0.01, pcc > 0.628 and p < 0.05, pcc > 
0.497. 
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The results in both Table 4.20 and 4.21 indicate that TV and TLG are very similar when 
investigating response, as are the different segmentation methods for obtaining them. Correlations 
are very similar for each segmentation method and between the TV and TLG parameters 
themselves. Once again, results show that the pre- and post- therapy values both correlate with 
OS significantly. However, the change and percentage change between them suffer the same 
issues with SUVmax and SUVpeak values and often show very little correlation or no correlation at 
all. This is also true for PFS and while pre- and post- therapy TV and TLG show a significant 
correlation with OS, there is insignificant correlation with PFS. When assessing ROC curves a 
similar pattern is seen, both pre- and post- therapy TV appear to predict both six month OS and 
PFS with an AUC between 0.750 – 0.911, while the change between TV does not appear to 
predict OS and PFS in any meaningful way (Table 4.22).  
 
Segmentation 
Method for TV 
OS PFS 
Pre Post Change % Chg Pre Post Change % Chg 
SUV 2.2 0.867 0.844 0.422 0.444 0.875 0.750 0.313 0.375 
SUV 2.5 0.867 0.889 0.511 0.489 0.875 0.812 0.396 0.438 
SUV 3 0.889 0.889 0.444 0.467 0.875 0.833 0.354 0.396 
SUL 2.2 0.889 0.889 0.578 0.489 0.875 0.833 0.500 0.438 
SUL 2.5 0.867 0.867 0.533 0.444 0.875 0.833 0.417 0.375 
SUL 3 0.867 0.867 0.444 0.400 0.875 0.833 0.354 0.354 
SUVBSA 0.5 0.933 0.911 0.600 0.356 0.896 0.833 0.521 0.271 
SUVBSA 0.6 0.911 0.911 0.600 0.400 0.875 0.833 0.500 0.333 
SUVBSA 0.7 0.911 0.889 0.622 0.422 0.875 0.854 0.500 0.354 
Table 4.22: AUC for TV for Fixed Segmentation Methods for Predicting Survival 
Area under the curve (AUC) is shown for the ROC curves for TV using nine different fixed segmentation 
thresholds for predicting six month OS and PFS for pre- and post- therapy values and the change and 
percentage change between them. 
 
The results for TLG provide very similar results to TV with pre- and post- therapy TLG 
predicting both six month OS and PFS with an AUC ranging from 0.812 – 0.911 (Table 4.23). 
Once again, the change and percentage change between pre- and post- therapy have no real 
 230 
predictive power and as with SUVmax, occasionally a negative change in TV and TLG actually 
correlates with a poor prognosis. This is presumably for the same reason as with SUVmax where 
by greater changes in TV and TLG are seen in higher TVs and TLGs. Of all the fixed threshold 
segmentation methods, SUVBSA 0.5 has the best AUC on ROC analysis and correlations. This is 
worth considering, however, all the fixed segmentation methods produce similar results and 
further assessment on larger datasets would be needed to see which produces TVs most beneficial 
for predicting survival. 
 
Segmentation 
Method for TLG 
OS PFS 
Pre Post Change % Chg Pre Post Change % Chg 
SUV 2.2 0.867 0.889 0.311 0.400 0.875 0.812 0.229 0.333 
SUV 2.5 0.867 0.867 0.400 0.444 0.875 0.833 0.313 0.396 
SUV 3 0.867 0.867 0.444 0.378 0.875 0.833 0.354 0.333 
SUL 2.2 0.867 0.867 0.422 0.444 0.875 0.833 0.333 0.375 
SUL 2.5 0.867 0.867 0.444 0.356 0.875 0.833 0.354 0.313 
SUL 3 0.867 0.867 0.444 0.400 0.875 0.833 0.354 0.354 
SUVBSA 0.5 0.911 0.889 0.467 0.289 0.875 0.833 0.375 0.208 
SUVBSA 0.6 0.911 0.889 0.578 0.400 0.875 0.854 0.458 0.333 
SUVBSA 0.7 0.889 0.867 0.467 0.400 0.875 0.833 0.375 0.313 
Table 4.23: AUC for TLG for Fixed Segmentation Methods for Predicting Survival 
Area under the curve (AUC) is shown for the ROC curves for TLG using nine different fixed segmentation 
thresholds for predicting six month OS and PFS for pre- and post- therapy values and the change and 
percentage change between them. 
 
To show the similarities between the segmentation methods, pre-therapy TLG ROC curves for six 
month OS are shown for segmentations using thresholds of SUV 2.2, SUV 3, SUL 2.2, SUL 3, 
SUVBSA 0.5 and SUVBSA 0.7 (Figure 4.17). The ROC curves for six month PFS are even more 
similar, in fact, they are identical. A Kaplan-Meier survival curve for PFS grouping the two 
patients into groups based on a cut-off of ~1300ml TV based on a SUV 2.5 threshold shows the 
potential pre-therapy TV has in predicting response (Figure 4.18). While there is clearly some 
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divide between these patients, only three have a pre-therapy value below the cut-off and it is not 




Figure 4.17: ROC Curve for Pre-Therapy TLG for PFS at 6 months 
ROC curves are plotted for pre-therapy TLG for six fixed segmentation thresholds (SUV 2.2, SUV 3, SUL 
2.2, SUL 3, SUVBSA 0.5 and SUVBSA 0.7) for PFS at 6 months. TV using SUV 2.2, SUV 3, SUL 2.2 and 
SUL 3 all had an AUC of 0.867 (SE = 0.102, 95% CI = 0.666 – 1). Using SUVBSA 0.5, AUC = 0.911 (SE = 






Figure 4.18: Kaplan-Meier Survival Curve for Pre-Therapy TV and OS 
Survival curves are plotted for two groups of patients, those with pre- therapy TV > 1300ml (Mean PFS = 
159, SE = 2.6, 95% CI = 154-164) and those < 1300ml TV (mean PFS = 541, SE = 97, 95% CI = 351-732) 
using a fixed 2.5 SUV threshold segmentation. Comparing the survival distributions using the log-rank 
method shows a significance of p < 0.021. 
4.5.6) Predicting Survival in Patients with Mesothelioma using Tumour Volume 
and Total Lesion Glycolysis using Non-Fixed Threshold Segmentation 
While fixed threshold methods had similar results in terms of predicting response, non-fixed 
threshold methods have shown less correlation between each other and are therefore more likely 
to show differences in predicting response. Correlations between the nine non-fixed threshold 
methods and OS and PFS for both pre- and post- therapy values and change and percentage 
change between them were calculated for both TV and TLG and are shown in Tables 4.24 and 
4.25 respectively.  
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Segmentation 
Methods for TV 
OS PFS 
Pre Post Change % Chg Pre Post Change % Chg 
Adapt SUVmean -0.599 -0.502 0.300 -0.017 -0.367 -0.276 0.208 -0.222 
0.4 * Mean + 1 -0.624 -0.591 -0.167 0.100 -0.443 -0.443 -0.203 0.078 
0.5 * Mean + 0.6 -0.368 -0.490 -0.450 0.183 -0.429 -0.359 0.012 0.525 
0.5 * Mean + 1 -0.604 -0.641 -0.016 -0.084 -0.415 -0.448 -0.026 -0.164 
PERCIST 2 S.D. -0.649 -0.704 -0.416 0.189 -0.440 -0.489 -0.330 -0.160 
PERCIST 3 S.D. -0.630 -0.700 -0.272 0.270 -0.418 -0.479 -0.229 -0.235 
Davis (2006) -0.620 -0.686 -0.024 -0.073 -0.495 -0.510 0.035 -0.049 
Nestle (2005) -0.654 -0.687 -0.507 0.008 -0.452 -0.481 -0.369 -0.353 
GRAB -0.598 -0.699 0.015 0.424 -0.390 -0.463 -0.006 -0.063 
Table 4.24: Correlation between TV with Non-Fixed Segmentation Thresholds and Survival 
Pearson correlation coefficients (pccs) are shown for the correlation of TV, for each non-fixed threshold 
segmentation method, with OS and PFS for pre-therapy values, post-therapy values, and the change and 




Methods for TLG 
OS PFS 
Pre Post Change % Chg Pre Post Change % Chg 
Adapt SUVmean -0.604 -0.494 0.306 0.040 -0.373 -0.267 0.218 -0.250 
0.4 * Mean + 1 -0.629 -0.620 0.131 0.235 -0.420 -0.434 0.041 0.066 
0.5 * Mean + 0.6 -0.562 -0.588 0.003 0.235 -0.427 -0.409 0.095 0.579 
0.5 * Mean + 1 -0.616 -0.622 0.139 0.090 -0.406 -0.415 0.083 -0.146 
PERCIST 2 S.D. -0.643 -0.687 0.006 0.263 -0.424 -0.464 -0.023 -0.109 
PERCIST 3 S.D. -0.633 -0.683 0.055 0.341 -0.413 -0.455 0.015 -0.176 
Davis (2006) -0.619 -0.642 0.077 0.080 -0.454 -0.447 0.086 -0.076 
Nestle (2005) -0.644 -0.678 -0.051 0.221 -0.429 -0.462 -0.058 -0.246 
GRAB -0.612 -0.670 0.136 0.468 -0.396 -0.435 0.086 -0.042 
Table 4.25: Correlation between TLG with Non-Fixed Segmentation Thresholds and Survival 
Pearson correlation coefficients (pccs) are shown for the correlation of TLG, for each non-fixed threshold 
segmentation method, with OS and PFS for pre-therapy values, post-therapy values, and the change and 
percentage change (chg) from pre- to post- therapy values. For p < 0.01, pcc > 0.662 and p < 0.05, pcc > 
0.533. 
 
Different non-fixed threshold segmentation methods do not have an influence on TV and TLG in 
terms of predicting response. All nine methods generally have significance in predicting OS using 
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pre- and post- therapy values (for example, pcc ranging from -0.494 to -0.687 for pre-therapy 
TLG, p from ~0.07 to 0.007) but only show a weak correlation with PFS. There is no correlation 
with either OS or PFS using change or percentage change. These findings are supported by ROC 
analysis where good ROC curves are produced for six month OS, and to a lesser extent six month 
PFS, for all nine segmentation methods pre- and post- therapy TV and TLG (Table 4.26 and 
Table 4.27, respectively). Changes and percentage changes between pre- and post- therapy TV 
and TLG show poor accuracy in predicting six month OS and PFS. Some segmentation methods 
have slightly better ROC curves than others but the confidence intervals are large so it would be 
unfair to draw conclusions on which segmentation methods are more accurate. Results show that 
on this small cohort of mesothelioma patients the segmentation method makes no difference to 
the success or failure of TV and TLG in terms of predicting OS or PFS. 
 
Segmentation 
Method for TV 
OS PFS 
Pre Post Change % Chg Pre Post Change % Chg 
Adapt SUVmean 0.889 0.711 0.244 0.378 0.875 0.708 0.313 0.438 
0.4 * Mean + 1 0.889 0.867 0.600 0.467 0.813 0.792 0.521 0.396 
0.5 * Mean + 0.6 0.844 0.844 0.578 0.422 0.750 0.729 0.542 0.479 
0.5 * Mean + 1 0.867 0.911 0.689 0.644 0.875 0.854 0.583 0.583 
PERCIST 2 S.D. 0.911 0.911 0.711 0.489 0.875 0.875 0.646 0.437 
PERCIST 3 S.D. 0.889 0.911 0.667 0.511 0.875 0.875 0.604 0.458 
Davis (2006) 0.933 0.867 0.511 0.489 0.938 0.833 0.396 0.417 
Nestle (2005) 0.911 0.911 0.844 0.689 0.875 0.875 0.729 0.604 
GRAB 0.889 0.911 0.578 0.422 0.875 0.875 0.458 0.354 
Table 4.26: AUC for TV for Non-Fixed Segmentation Methods for Predicting Survival 
Area under the curve (AUC) is shown for the ROC curves for TV using nine different non-fixed 
segmentation thresholds for predicting six month OS and PFS for pre- and post- therapy values and the 




Method for TLG 
OS PFS 
Pre Post Change % Chg Pre Post Change % Chg 
Adapt SUVmean 0.889 0.711 0.289 0.311 0.875 0.729 0.292 0.313 
0.4 * Mean + 1 0.911 0.889 0.467 0.444 0.875 0.812 0.396 0.375 
0.5 * Mean + 0.6 0.889 0.844 0.511 0.333 0.833 0.771 0.479 0.354 
0.5 * Mean + 1 0.867 0.867 0.489 0.511 0.875 0.833 0.396 0.458 
PERCIST 2 S.D. 0.889 0.889 0.622 0.467 0.875 0.854 0.500 0.396 
PERCIST 3 S.D. 0.889 0.889 0.467 0.467 0.875 0.854 0.375 0.396 
Davis (2006) 0.889 0.867 0.400 0.444 0.875 0.833 0.313 0.375 
Nestle (2005) 0.889 0.889 0.644 0.511 0.875 0.854 0.521 0.458 
GRAB 0.889 0.867 0.467 0.356 0.875 0.833 0.375 0.292 
Table 4.27: AUC for TLG for Non-Fixed Segmentation Methods for Predicting Survival 
Area under the curve (AUC) is shown for the ROC curves for TLG using nine different non-fixed 
segmentation thresholds for predicting six month OS and PFS for pre- and post- therapy values and the 
change and percentage change between them. 
 
It is worth noting that although segmentation methods produce similar ROC curves, the optimal 
thresholds are different for each method. This is not surprising given that different segmentation 
methods will produce smaller or larger TV based on the methodology used to segment images, 
however, it should be noted that the threshold for TV is dependent of the methods of 
segmentation. For example, when taking the optimal threshold for predicting six month OS using 
pre-therapy TV measures, a fixed 2.5 SUV method has an optimal threshold of ~1300ml 
compared to ~400ml for the adaptive SUVmean method. Similar differences are seen between other 
segmentation methods too and this is an issue with using pre- and post- therapy values, not just 
for TV and TLG but also for SUVmax and any other parameter. In the case of TV and TLG, the 
optimal thresholds are likely to be dependent on the segmentation method, and similar to SUVmax, 
are most likely dependent on other factors such as the PET scanner used and imaging protocol. 
Therefore, even though the thresholds have been successful in identifying response in this cohort 
of patients, it is not viable to apply this to data from another institution. Although changes and 
percentage changes between pre- and post- therapy values have been unsuccessful at predicting 
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response, they can be more easily applied across institutions as they do not rely on definitive 
values. 
4.5.7) Predicting Survival in Patients with Mesothelioma using Intensity Volume 
Histogram Parameters 
All six IVH parameters implemented in PETTRA (discussed in 2.4.6, p121) were used to assess 
response in the cohort of mesothelioma patients using segmented TV from a fixed 2.5 SUV 
threshold. As these statistics are still related to intensity and TV it was thought that response 
would be similar to SUVmax, TV and TLG parameters. The parameter V10 was removed from 
analysis because it was found to be 100% in all but one image in which it was still over 99%. V10 
is a representation of the volume having at least 10% of the SUVmax and in this cohort of patients 
it was clear that the almost all of the TV was over 10% of the SUVmax and therefore there would 
be no way to differentiate datasets into groups of reponders and non-responders. The other five 
IVH parameters were correlated with OS and PFS for pre- and post- therapy values and the 




Pre Post Change % Chg Pre Post Change % Chg 
V90 0.539 0.528 0.214 -0.023 0.717 0.593 0.162 -0.126 
V10-90 -0.544 -0.528 -0.212 -0.212 -0.718 -0.593 -0.164 -0.164 
I10 -0.599 -0.385 0.315 0.360 -0.568 -0.516 0.080 -0.129 
I90 -0.559 -0.522 0.232 0.178 -0.487 -0.539 0.144 -0.005 
I10-90 -0.591 -0.378 0.316 0.366 -0.563 -0.514 0.074 -0.134 
Table 4.28: Correlation between IVH Parameters and Survival 
Pearson correlation coefficients (pccs) are shown for the correlation of five IVH parameters with OS and 
PFS for pre-therapy values, post-therapy values, and the change and percentage change (chg) from pre- to 
post- therapy values. For p < 0.01, pcc > 0.662 and p < 0.05, pcc > 0.533. 
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Correlations between IVH parameters and OS and PFS showed significant correlation with 
survival for most pre- and post- therapy values with no correlation between the change and 
percentage change between them. All parameters showed a negative correlation with OS and PFS 
except for V90 which has a positive correlation. This is not an expected correlation as V90 
expresses the volume containing intensity values within 90% of the SUVmax so it would be 
expected a larger volume of intensity close to the SUVmax would result in a poor response. 
However, analysing the data it would appear that TVs with a high V90 have a lower SUVmax as 
there are similar lower SUVs in the TV. TVs with high SUVmax are unlikely to have other 
similarly high intensities in the TV. 
 
Some of the IVH parameters are complicated to understand and relate to data than measures such 
as SUVmax and TV but they do show additional data which may be useful in response. With just 
14 patients, it is hard to analyse the data to decipher the potential role they could play. In this 
case, SUVmax, SUVpeak, TV and TLG generally have better correlation with OS and PFS, making 
IVH parameters somewhat redundant, although that does not mean they should not be 
investigated in further studies with more patients where their role can be more clearly defined. 
Some IVH parameters produce very accurate ROC curves when using pre-therapy values (Table 
4.29). While almost every pre-therapy TV has shown good correlation and ROC curves when 
compared with OS and PFS and the reasoning for this is clear, this is not the case with IVH with 





Pre Post Change % Chg Pre Post Change % Chg 
V90 0.022 0.100 0.556 0.444 0.000 0.115 0.604 0.542 
V10-90 1.000 0.900 0.444 0.444 0.990 0.885 0.396 0.396 
I10 0.756 0.533 0.289 0.311 0.875 0.646 0.208 0.250 
I90 0.811 0.667 0.278 0.333 0.885 0.688 0.188 0.250 
I10-90 0.756 0.533 0.289 0.311 0.875 0.646 0.229 0.250 
Table 4.29: AUC for IVH Parameters for Predicting Survival 
Area under the curve (AUC) is shown for the ROC curves for five IVH parameters for predicting six month 
OS and PFS for pre- and post- therapy values and the change and percentage change between them. 
 
4.6) Conclusion of Response Analysis in Patients with Mesothelioma 
In this study, 14 patients with mesothelioma underwent pre- and post- therapy PET/CT scans 
before and after therapy and several different methods of PET measurements were used to try and 
identify responders and non-responders. Clinical methods, such as visual analysis, and SUVmax 
and SUVpeak measures were used to try and identify response along with more novel measures 
such as TV and TLG, using a variety of different segmentation methods, and IVH parameters. 
With a small sample size (n=14), the study lacked statistical power, however, it would seem that 
pre- and post- therapy measures of SUVmax, SUVpeak, TV and TLG all provide good indication of 
survival in patients while visual analysis and the change and percentage change between SUVmax, 
SUVpeak, TV and TLG do not predict patient survival. IVH parameters had mixed results and 
while they do not show a good indication of response, they may be worthy of further 
investigation. 
 
A comparison of different methodologies for obtaining SUVmax and SUVpeak parameters showed 
no real difference between them and their ability to predict OS or PFS. A similar comparison of 
segmentation methods also found no impact on TV or TLG values and their ability to predict OS 
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or PFS. This suggests that the segmentation method used for obtaining TV and TLG is 
unimportant, as long as one consistent method is used. However, further testing on a larger 
dataset would be needed before this can be concluded with confidence. Other novel methods of 
response including texture analysis and registered subtraction images are hoped to be used on this 
dataset and they may provide significant results. While many of the response methods tested in 
this analysis are related, these measures look at unrelated factors in PET images and may provide 
a different insight into the data. 
 
It should be noted that this group of patients with mesothelioma had low survival times and a 
very poor prognosis, due to the aggressiveness and severity of the disease, meaning that there was 
no real response to treatment. This does not mean that the parameters could not potentially predict 
which patients were more likely to survive longer and therefore have some form of benefit from 
treatment, even if this was simply prolonging survival. However, it is likely that these factors 
mean that this data cannot be compared accurately to say a lymphoma dataset where a complete 
response is possible and often likely.  
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5) Response to Therapy in Patients with DLBCL 
5.1) Introduction to Response to Therapy in Patients with DLBCL 
5.1.1) Identifying Response to Therapy in DLBCL Patients 
Having investigated response parameters in a group of patients with mesothelioma, similar 
methods were used to analyse response in a larger cohort of DLBCL patients, a disease with a 
higher survival rate due to more effective chemotherapy treatments. Once again, all patients in the 
study underwent pre- and post- therapy PET/CT scans and images were analysed using PETTRA 
software with the aid of an experienced clinician to exclude the inclusion of physiological areas 
of increased uptake in the segmentation of tumours volumes. Image analysis response parameters 
were compared with measures of survival to test their effectiveness. 
5.1.2) Lymphoma 
Lymphomas are a type of blood cancer which affects lymphocytes (white blood cells) causing 
them to behave abnormally. Lymphomas can be classified into two main groups depending on the 
presence or absence of the Reed-Sternberg cell, large cells which have a divided nucleus. 
Hodgkin’s lymphoma (HL), named after its discoverer Thomas Hodgkin (Hodgkin, 1832), is 
characterised by the presence of the Reed-Sternberg cell, which is not found in other lymphomas 
known as non-Hodgkin’s lymphomas (NHL). There are many different forms of NHL and since 
the 1980s they were classified differently using two classification systems: the Working 
Formulation adopted in the US, which classifies NHL based on its degree of aggressiveness, and 
the Kiel classification adopted in Europe and elsewhere, which classifies NHL based on cell 
morphology and B-cell and T-cell lineages (Lu, 2005). However, in 1994, the International 
Lymphoma Study Group developed a single classification system for international 
communication called the Revised European-American Classification of Lymphoid Neoplasms 
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(REAL) specifying clinically distinctive types of lymphoma with different prognostic groups 
(Harris et al., 1994). The WHO has since adopted this classification system with minimal 
modification and of the over 40 types of lymphoma there are six predominant subtypes which 
account for 80% of cases: DLBCL, follicular lymphoma, marginal zone B-cell lymphoma, small 
lymphocytic lymphoma, peripheral T-cell lymphoma and mantle cell lymphoma (Harris et al., 
1997). The most common types of NHL are DLBCL and follicular lymphomas (Chan et al., 
1997). 
5.1.3) Diffuse Large B-Cell Lymphoma (DLBCL) 
Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of NHL which affects B-cells, a 
form of lymphocyte responsible for the production of antibodies (Dupas et al., 2013). In Europe 
and the US, the annual incidence of NHL is estimated to be 15-20 cases/100,000 and ~31% of 
them are DLBCL (Fisher and Fisher, 2004; Chan et al., 1997). Diagnosis of DLBCL is confirmed 
by examining tissue from a biopsy and the disease can be subdivided into four categories: (i) 
DLBCL – not otherwise specified, DLBCL with predominant extranodal location, (iii) large cell 
lymphomas of terminally differentiated B-cells and (iv) borderline cases (Martelli et al., 2013). 
The stage of the disease is distinguished using the Ann Arbor staging system which has four 
stages depending on the extent of spread, at stage I the disease is located in a single region 
whereas in stage IV the disease has spread to the extra-lymphatic organs such as the liver, spleen 
and bone barrow (Carbone et al., 1971). The cause of DLBCL is not known but usually arises 
from normal B-cells mutating although it can also be the result of a transformation from other 
types of less aggressive lymphomas or leukaemia (Martelli et al., 2013). 
5.1.4) Treatment of DLBCL 
DLBCL has become a curable lymphoma since the 1970s following the introduction of the 
chemotherapy regime cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) 
 242 
(McKelvey et al., 1976). This chemotherapy regime has been improved further since, with the 
addition of monoclonal anti-CD20 antibody rituximab (R-CHOP), which has increased the event-
free survival (EFS) and OS compared to the CHOP regime (Coiffier et al., 2002; Feugier et al., 
2005; Coiffier et al., 2010; Pfreundschuh et al., 2011). R-CHOP chemotherapy now means that 
patients with DLBCL can now expect 5-year PFS rates of 55% for patients >60 and 75% for 
patients <60 (Friedberg et al., 2008). Despite improvements in chemotherapy with R-CHOP, 30-
40% of patients are still not cured and salvage treatment appears inadequate in the majority of 
these patients so a strategy to improve patient outcome is to intensify first-line treatment using 
high dose therapy and/or autologous stem cell transplantation (ASCT) which has been efficient in 
curing nearly half of all patients who have resistant or relapsed NHL (Zinzani et al., 2011). High 
dose chemotherapy and ASCT are less effective after R-CHOP so a ‘response-adapted therapy’ 
strategy where non-responding patients change therapy regimes mid-treatment is a potential 
solution (Mikhaeel, 2006; Kasamon et al., 2009; Mikhaeel, 2009). In order to do this a reliable 
method of identifying responding and non-responding patients is needed early in the course of 
treatment. 
 
One method of trying to separate responding and non-responding patients is to risk stratify 
patients before treatment with the International Prognostic Index (IPI). The IPI is a model derived 
from tests on over 4000 patients to determine factors that are associated with prognosis. The IPI 
uses clinical parameters such as disease stage, lactate dehydrogenase level, ECOG performance 
score and extra-nodal disease (International NHL Prognostic Factors Project, 1993). There is also 
a revised version adjusted for age, called the age adjusted IPI (aaIPI), and a version specifically 
for DLBCL patients treated using R-CHOP (R-IPI) (Sehn et al., 2007). Patients divided into risk 
categories according to their IPI have been shown to have significantly different survival times to 
suggesting that it is a useful tool to predict prognosis (Ziepert et al., 2010; Martelli et al., 2013). 
However, although the IPI is valuable for stratification groups of patients in clinical trials, the 
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prediction of outcome is more variable for an individual patient so using the index to tailor 
treatment regimes for the individual patient may be flawed (Sweetenham, 2005).  
5.1.5) Role of 18F-FDG PET/CT in Management of DLBCL 
18
FDG-PET has been shown to accurately detect disease in DLBCL and other types of NHL 
(Elstrom et al., 2003), and, along with R-IPI, pre-therapy SUVmax has been shown to predict 
patients with longer PFS (Chihara et al., 2011; Oh et al., 2012; Miyazaki et al., 2013). To assess 
response to therapy with a view to changing treatment, an interim-PET scan during treatment is 
considered to be a valuable tool (Mikhaeel et al., 2005). Interim-PET scans have been shown to 
predict EFS, PFS and OS strongly in a number of studies, often much better than the IPI 
(Jerusalem et al., 1999; Spaepen et al., 2002; Haioun et al., 2005; Mikhaeel et al., 2005; Dupuis 
et al., 2009; Safar et al., 2012). However, this is not always the case and some studies have 
recently reported that patients with DLBCL have similar PFS for patients with PET-positive 
scans (suggesting active disease) and PET-negative scans (suggesting no disease) scans after two 
to four cycles of chemotherapy with poor positive predictive values of outcome (Moskowitz et 
al., 2010; Cashen et al., 2011; Pregno et al., 2012). These conflicting results may be down to 
different visual criteria being used (Terasawa et al., 2009), a lack of inter-observer reproducibility 
in interpreting PET scans (Horning et al., 2010) or a combination of both.  
 
The visual interpretation of interim/mid-treatment PET scans for identifying response in DLBCL 
patients is a controversial topic and international workshops have constantly revisited and revised 
visual response criteria (Meignan et al., 2009; Meignan et al., 2010; Meignan et al., 2012). When 
using visual analysis, categorising patients into two groups of PET negative patients/responders 
and PET positive patients/non-responders is often done to try and predict outcome (Spaepen et 
al., 2002; Haioun et al., 2005). However, a study at Guy’s and St Thomas’s Hospitals, showed 
that dividing patients into three categories of PET negative, PET positive and minimal residual 
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uptake (MRU) could be more beneficial with five-year PFS’s of 88.8% for PET negative patients, 
59.3% for those with MRU and 16.2% for PET positive patients (Mikhaeel et al., 2005). In an 
attempt to improve on the three category system, a 5-point scoring system has been proposed 
which scores residual uptake compared to the uptake in normal reference regions in the body e.g. 
mediastinal blood pool and liver (Mikhaeel, 2009; Barrington et al., 2010). The 5-point scoring 
system, shown in Table 5.1, has been recommended as the most suitable criteria for assessing 
response in lymphoma patients during the latest International Workshop criteria (Meignan et al., 
2010; Meignan et al., 2012). 
 
Score Category Description 
0 Complete Metabolic Response (CMR) No Uptake 
1 Minimal Residual Uptake 1 Uptake <= Mediastinum 
2 Minimal Residual Uptake 2 Uptake > Mediastinum but <= Liver 
3 Residual Lymphoma Uptake > Liver 
4 Progressive Disease New lesion(s) likely to be lymphoma 
Table 5.1: Five-Point Scoring System for Patients with DLBCL 
Five point scoring system for visual analysis of mid-treatment PET scans for patients with DLBCL 
(Adapted from Mikhaeel, 2009). 
 
Despite these steps forward in terms of defining visual criteria, inter-observer reproducibility is 
still questionable. While the criteria proved to have good inter-observer reproducibility at four 
European centres reporting scans in patients with HL, with Kappa agreements between pairs of 
experts of 0.85 and 0.79 when using the liver and mediastinum as reference backgrounds 
respectively (Barrington et al., 2010), reproducibility between experts is not as strong for DLBCL 
patients (Horning et al., 2010). This has led to researchers investigating more ‘quantitative’ 
approaches of assessing response such as the change in SUVmax between pre- and post- therapy 
scans (∆ SUVmax) (Lin et al., 2007; Meignan et al., 2010, Meignan et al., 2012). Despite the 
issues with visual criteria, the majority of studies have still shown that interim-PET using visual 
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analysis can predict OS or PFS (Jerusalem et al., 1999; Spaepen et al., 2002; Haioun et al., 2005; 
Mikhaeel et al., 2005; Dupuis et al., 2009; Safar et al., 2012), and one study which altered 
treatment based on visual assessment of the interim PET scan and showed favourable results for 
modifying treatment (Kasamon et al., 2009).  
5.1.6) Use of Semi-Quantitative Methods for the Management of DLBCL 
A more quantitative approach to response assessment reduces the subjectivity and observer 
variability compared to visual analysis. A quantitative approach after two cycles of chemotherapy 
has been reported to be better than visual assessment in terms of predicting treatment outcome, 
using a change in SUVmax (∆ SUVmax) of ~66% between pre- and post- therapy values (Torizuka 
et al., 2003; Lin et al., 2007; Meignan et al., 2009; Casanovas et al., 2011; Safar et al., 2012). 
After four cycles of chemotherapy a slightly higher cut-off for the ∆ SUVmax of 70-73% has also 
shown to successfully predict outcome (Itti et al., 2009; Casanovas et al., 2011). Using ∆ SUVmax 
appears to minimise the risk of false positive results obtained using visual analysis with a higher 
positive predictive value of over 50% (Itti et al., 2009; Casanovas, 2012). A caveat to wider 
application of these methods is that careful standardisation of PET methods is required for 
accurate and reproducible measurement of quantitative parameters (Boellaard et al., 2009). 
 
As well as SUVmax measurements, studies have begun to investigate volumetric measures such as 
metabolic tumour volume (MTV) and total lesion glycolysis (TLG) for predicting response in 
DLBCL patients with varying results (Kim et al., 2012; Song et al., 2012). Pre-therapy TLG has 
been shown to predict 2-year PFS and OS better than pre-therapy SUVmax (Kim et al., 2012), 
while patients with high pre-therapy MTV have been shown to have lower PFS and OS (Song et 
al., 2011; Song et al., 2012). Different segmentation methods were used to obtain TV and TLG in 
these studies with thresholds based on a percentage of SUVmax (Kim et al., 2012), and contouring 
of uptake >2.5 SUV (Song et al., 2011; Song et al., 2012), both being implemented. These results 
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show that along with ∆ SUVmax, ∆ TV and ∆ TLG may prove to be useful measures of predicting 
response in patients with DLBCL. 
5.1.7) Aim of Analysis 
The main aim of this analysis was to determine if a quantitative method would better discriminate 
patients into groups of good responders and poor responders than existing methods like IPI and 
visual assessment. The parameters investigated as prognostic factors were the IPI score of the 
patient, visual analysis using the five-point scoring system, SUVmax, TV and TLG. Pre-therapy, 
post-therapy and the change during treatment of SUVmax, TV and TLG were assessed. SUVpeak 
was ommited as the difference between SUVpeak and SUVmax was found to be negligible in terms 
of assessing response on patients with mesothelioma (see 4.5.4). 
 
5.2) Patients and Scanning 
5.2.1) Patient Eligibility and Treatment 
85 patients with a de novo diagnosis of DLBCL and no concurrent low grade lymphoma 
underwent both pre- and post- therapy PET/CT scans before and after two cycles of R-CHOP or 
Rituximab with Cyclophosphamide, Etoposide, Prednisolone, and Vincristine (R-CEOP) 
chemotherapy, an altered regime, similar to R-CHOP, showing excellent outcome in patients with 
a contraindication to anthracyclines (Moccia et al., 2009). All patients had assessable disease on 
the pre-therapy PET scan and had a minimum follow-up of at least 12 months.  
5.2.2) PET/CT Scanning 
Pre- and post- therapy PET/CT scans were acquired at baseline and after two cycles of 
chemotherapy for 85 patients between April 2005 and February 2011. All scans were acquired at 
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the PET Imaging Centre in St Thomas’ Hospital on either a GE Discovery ST or GE Discovery 
VCT PET scanner (Waukesha, WI). For the PET and CT scan components of the PET/CT study, 
patients were scanned during free breathing and CT scans were low dose non-contrast enhanced 
scans. For the 170 whole body PET scans over the 85 datasets, image dimensions were 128 x 128 
x 179, 223, 263, 267 or 311 (with voxel sizes of either 5.47mm x 5.47mm x 3.27mm – on 39 
images – or 4.69mm x 4.69mm x 3.27mm – on 131 images). All PET images analysed were 
attenuation corrected using a smoothed CT dataset. Administered FDG activity ranged from 250 
to 399MBq (mean: 346MBq; S.D. 24.76). The difference in administered activities between pre- 
and post- therapy scans ranged from 0-96MBq (mean: 27.6MBq; S.D. 21.66). The time between 
administration of FDG and the start of the scan ranged from 70-148min (mean: 97min; S.D. 
13.96), with 45/85 post-therapy scans within 10min of the pre-therapy scans and 68/85 post-
therapy scans within 20min of the pre-therapy scans. 
5.2.3) Patient Characteristics 
Patients had a mean age of 57 (range 25-86, S.D. 14.59) and 47% were male (40 male, 45 
female). Patients weighed between 37-121kg (mean: 71kg; S.D. 17.06) and there was a mean 
decrease in weight of 3.6kg between pre- and post- therapy scans (range: 0-14kg), most likely due 
to the effects of the disease and the chemotherapy. Patient height ranged from 149-192cm (mean: 
169cm; S.D. 10.27) with a mean change in height between scans of 1.1cm (range: 0-10cm).  
5.2.4) Study End Point 
Overall survival (OS) and progression free survival (PFS) were the outcome measures used to 
assess response, as for the mesothelioma dataset and other studies investigating patients with 
DLBCL (Jerusalem et al., 1999; Mikhaeel et al., 2005; Safar et al., 2012; Kim et al., 2012).  
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5.3) Data Analysis – Response Measures 
5.3.1) Visual Analysis 
Visual analysis of pre- and post- therapy PET/CT studies was performed by a consultant 
physician with 20 years of experience of PET. Response was assessed using both PET and CT, 
viewed on HERMES Hybrid Viewer workstations (Nuclear Diagnostics AB, Stockholm, 
Sweden). Visual assessments of response were scored based on the Deauville criteria (Table 5.1). 
SUVmax values were also measured by the consultant to confirm the visual assessment of uptake 
as higher than the mediastinum and/or liver when uptake was present in lesions seen on the pre-
therapy scan. Scans were viewed scaled to a SUVmax of 10 normalised for injected activity and 
body weight. 
5.3.2) SUVmax 
SUVmax was taken as the maximum SUV within the entire TV on the HERMES Hybrid Viewer 
software by the consultant physician and on PETTRA software within the segmented TV, the two 
being identical for all values.  
5.3.3) Tumour Volume Segmentation 
Due to its simplicity and successful application on mesothelioma data and its previous use in 
patients with DLBCL (Song et al., 2011; Song et al., 2012), a fixed 2.5 SUV threshold 
segmentation method was chosen to produce TV on all the images. The consultant physician for 
reviewed the TV to ensure that areas with increased physiological uptake were not included. 
While it would have been interesting and beneficial to test different segmentation methods on a 
larger dataset, unfortunately, this was considered too time consuming to be consider in this study. 
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5.3.4) Tumour Volume and Total Lesion Glycolysis 
TV in a PET scan was taken as the total of all segmented areas of disease. TV was calculated as 
the volume of each voxel multiplied by the number of segmentation voxels, given in ml. TLG 
was calculated as the product of TV and SUV, given in ml*SUV. 
5.4) Segmentation of Patients with DLBCL 
A fixed 2.5 SUV threshold region growing segmentation method was used to delineate disease in 
all the images of patients with DLBCL. A consultant physician confirmed that all areas contained 
within the TV were due to lymphomatous involvement in her opinion rather than physiological 
uptake or another process that can cause increased FDG uptake such as infection or inflammation. 
Head and neck and brain images were also used as part of the disease segmentation if extra views 
were obtained in patients in addition to a half-body scan. Disease was segmented on 122 whole 
body images, 20 head and neck images and 2 brain images on pre- and post- therapy scans over 
the 85 patient dataset. Disease was always present on one of the pre-therapy images (whether 
whole body, head and neck or brain), however, 32 patients had no disease with uptake >2.5 SUV 
on post-therapy images and therefore no TV (and therefore TLG) was computed for these patients 
with a CMR. All the post-therapy images with no TV or TLG were also considered to have no 
disease of any form by the consultant physician when performing visual analysis. 
 
Over the 85 patient dataset, 115 images needed no restrictions to stop the fixed 2.5 SUV threshold 
segmentation ‘spilling’ over into physiological areas that did not represent lymphomatous 
disease. In the rest of the dataset a total of 95 VOIs were used to restrict the segemented MTV 
from extending into areas where there was no disease or to remove physiological uptake from 
being incorrectly included in the MTV such as urinary uptake or on one occasion to avoid 
‘double-counting’ an area of tumour which was present on both the body and head and neck 
images. The local views usually contain areas that overlap with the body images to avoid missing 
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any areas of disease when staging and assessing response.  The areas of physiological uptake 
referred to included the brain, tonsils, pharynx, tongue, lung, heart, spleen, liver, kidney, bowel, 
bladder and bone marrow (Table 5.2). Over the 85 patients, there were a total of 939 segmented 
areas of disease, 840 on pre-therapy scans and 99 on post-therapy scans. Pre-therapy images had 
a mean of 9.77 areas of disease (range: 1-59, S.D.: 11.03) while post-therapy images had a mean 
of just 1.15 areas (range: 0-9, S.D.: 11.03). The mean TV was 887.54ml (median: 391.38ml, 
range: 1.50-4616ml, S.D.: 1073) in pre-therapy images and 34.88ml (median: 0.65ml, range: 0-
1609ml, S.D.: 188) in post-therapy images. 
 
Physiological Uptake Area Restricted Removed Total VOIs Needed 
Brain 8 1 9 12 
Tonsils 3 0 3 3 
Pharynx 5 0 5 5 
Tongue 4 0 4 4 
Lung 1 0 1 4 
Heart 2 2 4 4 
Spleen 0 1 1 1 
Liver 4 1 5 5 
Kidney 8 11 19 23 
Bowel 5 1 6 8 
Bladder 14 5 19 19 
Bone Marrow 5 0 5 5 
ALL 59 22 81 93 
Table 5.2: Physiological Uptake Areas Segmented using a Fixed 2.5 SUV Threshold 
Over the dataset, 81 areas of physiological uptake were segmented with disease using a fixed 2.5 SUV 
region growing segmentation algorithm. Physiological uptake was either removed from the segmented area 
of disease or restricted to a particular volume so it did not ‘spill’ into areas of physiological uptake. VOIs 
Needed refers to the number of cubic VOIs that were needed to remove the physiological uptake. 
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The segmentations in the DLBCL dataset were more complex than in the previous mesothelioma 
dataset, partially due to the substantial increase in patients, but also because DLBCL is a disease 
which can affect many different areas of anatomy with a widespread distribution often throughout 
the body in comparison to mesothelioma, which is more often restricted to the thorax and 
sometimes a hemi-thorax. As Table 5.2 shows, areas of physiological uptake often incorrectly 
segmented as lymphoma are situated in widely separated parts of the body, with the most 
common being the brain, kidneys and bladder. This is to be expected as they are often very 
intense areas of physiological uptake in areas where lymphatic tumours are likely to present. An 
example of the segmented areas of disease in DLBCL patients is shown in Figure 5.1 where six 
pre-therapy scans are shown with segmentations.   
 
5.5) Predicting Survival in Patients with DLBCL 
5.5.1) Introduction to Predicting Survival in Patients with DLBCL 
Response measures for visual analysis, SUVmax, TV and TLG were used to predict PFS and OS 
over the 85 patients. Ann Arbor staging and the IPI were also included in the as comparators. 
Pearson correlation coefficients (pcc), ROC curves and Kaplan-Meier survival curves were used 
for the statistical analysis to determine if there was an association between response measures and 
PFS/OS (described in more detail in 4.5.2). Statistical analysis was done using statistical software 




Figure 5.1: Segmentations of 6 Pre-Therapy Images of Patients with DLBCL 
Six pre-therapy images of patients with DLBCL, all of which were within the first 20 patients in the 
dataset, show the difference in TV and regions of disease in different patients. While the first three scans 
have relatively large TVs with disease spread throughout the body, datasets 6, 11 and 15 have smaller TVs 
with disease in more specific regions. Disease is focused in the infraclavicular, axillary and pectoral lymph 
nodes and iliac, inguinal and femoral lymph nodes in dataset 6 (inguinal and femoral nodes not shown on 
this slice), the cervical, supraclavicular occipital and pre-auricular lymph nodes in dataset 11 (occipital and 
pre-auricular lymph nodes not shown on this slice) and localised to the mediastinum in dataset 15. Different 
colours indicate different VOIs of the segmentation of disease. 
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5.5.2) PFS and OS in Patients with DLBCL 
Patients with DLBCL had much longer survival times in comparison to the mesothelioma patients 
with a mean PFS of 1126 days and a mean OS of 1272 days (Table 5.3). There are longer survival 
times for many reasons, mainly because mesothelioma is a particularly aggressive disease in 
comparison to DLBCL, presents later and R-CHOP and R-CEOP often cure DLBCL patients 
resulting in long survival times. This means a larger study population is required to test 
associations with survival in DLBCL than mesothelioma because there will be fewer events 
(disease progression, relapse or death). In the mesothelioma dataset just one patient out of 
fourteen was still alive, in the patients in this dataset just 23/85 patients had died. However, there 
was a good duration of follow up for the majority of patients in the study so for most patients, the 
fact they were still alive would indicate a good response to treatment. Figure 5.2 shows the 
survival curves for both PFS and OS, with the longer survival times compared to mesothelioma 
















Table 5.3: PFS and OS for DLBCL Patients 
Of the 85 patients, 23 were deceased, 8 were alive but had confirmed disease progression and 54 were still 





Figure 5.2: Kaplan-Meier Survival Curves for all DLBCL Patients 
Survival curves for (A) PFS and (B) OS for all 85 DLBCL patients. OS and PFS are in days. 
 
5.5.3) Predicting Survival in DLBCL Patients using Staging, IPI and Visual Analysis 
Visual analysis was done using the Deauville criteria five point scoring system (Table 5.1) and 
the breakdown of patients for each score is shown in Table 5.4 along with the Ann Arbor staging 
and IPI which can both be used as prognosis factors for predicting response. Most patients were 
diagnosed with advanced stage DLBCL with an Ann Arbor staging of IV, while the IPI was 
distributed more evenly.  
 
The correlation between Ann Arbor stage, IPI and Deauville criteria with OS and PFS shows 
good correlation for all three methods with higher correlations for Ann Arbor staging and 
Deauville criteria with correlations of -0.467 and -0.300 for PFS (p < 0.006), and -0.289 for IPI (p 
< 0.008). Negative correlations mean that the higher the Ann Arbor, IPI and Deauville score, the 
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lower the PFS and OS which is to be expected as the higher the score for all three criteria the 
worse the prognosis. .   
 
Ann Arbor Stage 


























Table 5.4: Ann Arbor Staging, IPI and Visual Deauville Criteria for Patients with DLBCL 
The number of patients (# patients) in each category according to Ann Arbor staging, IPI and Deauville 
scoring systems is displayed.  
 
Pearson Correlation Coefficients 
 Ann Arbor IPI Deauville 
PFS -0.467 -0.289 -0.300 
OS -0.433 -0.271 -0.297 
Table 5.5: Correlation between Ann Arbor Staging, IPI and Deauville Score and Survival 
Pearson correlation coefficients (pccs) are shown for the correlation of Ann Arbor staging, IPI and 
Deauville score with OS and PFS. p between 0.012 and 0.0001 for all correlations. 
 
Mean PFS for each Ann Arbor stage, IPI score and Deauville score shows that all the methods 
struggle to separate patients into groups with significantly different PFS and therefore struggle to 
predict patient survival. Ann Arbor staging produces clear differences in survival between 
patients in stages I/II (mean PFS of 1747 for stage I and 1769 for stage II) compared to those in 
stages III/IV (mean PFS of 1473 for stage III and 1329 for stage IV). The IPI shows a general 
trend of higher scores correlating with shorter PFS. However, although a score of 0 results in a 
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much longer average PFS (mean = 1854), the mean PFS is similar for IPI scores 1-4  and patients 
with a score of 3 actually have a lower mean PFS estimate than those with a score of 4 or 5. 
Similar PFS estimates are seen with Deauville scores where patients with a score of 3 have longer 
mean PFS estimates than patients with a score of 1 or 2.  
 
Mean PFS Times for Ann Arbor Staging, IPI and Deauville Scores 
Score 
Ann Arbor Stage IPI Deauville Score 
Estimate SE 95% CI Estimate SE 95% CI Estimate SE 95% CI 
0 N/A 1854 102 1654-2053 N/A 
1 1747 206 1343-2152 1598 151 1302-1894 1608 116 1382-1835 
2 1769 120 1534-2003 1475 179 1124-1826 1462 167 1135-1790 
3 1473 211 1059-1887 1275 174 934-1617 1643 148 1354-1933 
4 1329 82 1169-1489 1455 115 1230-1681 1346 134 1083-1609 
5 N/A 1400 77 1249-1552 1379 296 798-1960 
Table 5.6: Mean PFS for Ann Arbor Staging, IPI and Deauville Score 
Mean PFS estimates with standard error (SE) and 95% confidence intervals (95% CI), using Kaplan-Meier 




ROC analysis further confirms these findings with curves for all three scoring systems running 
close to the reference line of taking random guesses to be considered useful at predicting 5-year 
PFS. Similar curves were observed for predicting 5-year OS too. 5-year PFS and OS was chosen 
as a binary threshold for ROC analysis because a similar time frame has been used in many other 
studies investigating survival in DLBCL patients (Mikhaeel et al., 2005; Dupuis et al., 2009). All 
the statistical results suggest that Ann Arbor stage, IPI score and Deauville score are not suitable 




Figure 5.3: ROC Curve for Ann Arbor Staging, IPI and Deauville Score for 5-year PFS 
ROC curves are plotted for Ann Arbor staging, IPI and Deauville scores for 5-year PFS. All curves show 
limited ability to predict PFS. Ann Arbor staging has an area under the curve (AUC) of 0.706 (Standard 
Error (SE) = 0.60, 95% Confidence Intervals (CI) of 0.587 – 0.824), IPI an AUC of 0.628 (SE = 0.65, 95% 
CI = 0.501 – 0.755) and Deauville score an AUC of 0.627 (SE = 0.61, 95% CI = 0.508 – 0.747). 
 
5.5.4) Predicting Survival in DLBCL Patients using SUVmax, TV and TLG 
Semi-quantitative response measures were taken pre- and post- therapy so can be used to predict 
response using either of these values or using the change or % change between them. TV and 
TLG both were calculated using the fixed 2.5 SUV segmentation method discussed in 5.4. 
Correlations between each response measure and survival are shown in Table 5.7. The best 
correlation with response was for the post-therapy SUVmax (pcc = -0.407, ρ < 0.001 for PFS) and 
the % change in SUVmax (pcc = -0.389, ρ < 0.001 for PFS). Apart from pre-therapy SUVmax, all 
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measures showed some degree of small or moderate correlation with both PFS and OS although 
no correlations could be described as strong. Interestingly, the change in TV and TLG were 
correlated positively rather than negatively with PFS and OS as would have been expected, as 
were the mesothelioma results, perhaps for similar reasons (more likelihood of greater change in 





Pre Post Change % Chg Pre Post Change % Chg 
SUVmax 0.016 -0.407 -0.149 -0.389 -0.093 -0.405 -0.046 -0.357 
TV -0.228 -0.231 0.199 -0.216 -0.201 -0.280 0.161 -0.246 
TLG -0.276 -0.228 0.244 -0.244 -0.267 -0.278 0.224 -0.280 
Table 5.7: Correlation between SUVmax, TV and TLG with Survival 
Pearson correlation coefficients (pccs) are shown for the correlation of SUVmax, TV and TLG with OS and 
PFS for pre-therapy values, post-therapy values, and the change and percentage change (chg) from pre- to 
post- therapy values. For p < 0.05, pcc > 0.217 and p < 0.01, pcc > 0.284. 
 
ROC analysis of all the parameters showed little success at predicting 5-year PFS and OS with 
AUC between 0.408 and 0.646 (Table 5.8). The ROC curves for pre-therapy SUVmax, TV and 
TLG and the % change between the pre- and post- therapt parameters for 5-year PFS are shown 
to illustrate this (Figure 5.4). However, ROC analysis is designed to divide patients into two 
groups of responders and non-responders using just one threshold. This may not always be the 
best way of dividing patients or separating patients who respond from those who don’t. Many 
studies have however reported that a change in SUVmax of -66% has been a good threshold of 
separating responders and non-responders after two cycles of chemotherapy (Torizuka et al., 
2003; Lin et al., 2007; Meignan et al., 2009; Casanovas et al., 2011; Safar et al., 2012). If applied 
to this dataset, this does produce survival curves with patients separated with different estimates 
of survival of >800 days but only 11 out of the 85 patients have a change of SUVmax less than -






Figure 5.4: ROC Curve for SUVmax, TV and TLG for Predicting 5-year PFS 
ROC curves are plotted for pre-therapy SUVmax, TV and TLG and the percentage change between them for 
predicting 5-years PFS. All curves show limited ability to predict PFS. Pre-therapy SUVmax has an area 
under the curve (AUC) of 0.521 (Standard Error (SE) = 0.64, 95% Confidence Intervals (CI) of 0.395 – 
0.646), pre-therapy TV an AUC of 0.628 (SE = 0.63, 95% CI = 0.504 – 0.752), pre-therapy TLG an AUC 
of 0.630 (SE = 0.62, 95% CI = 0.508 – 0.751). Percentage change between pre-therapy and post-therapy 
SUVmax has an AUC of 0.515 (SE = 0.63, 95% CI = 0.391 – 0.639), change for TV an AUC of 0.378 (SE = 







5 Year PFS 5 Year OS 
Pre Post Change % Chg Pre Post Change % Chg 
SUVmax 0.521 0.628 0.515 0.641 0.552 0.600 0.475 0.598 
TV 0.628 0.646 0.378 0.628 0.596 0.612 0.410 0.599 
TLG 0.630 0.645 0.376 0.627 0.599 0.611 0.408 0.594 
Table 5.8: AUC for SUVmax, TV and TLG for Predicting 5 Year Survival 
Area under the curve (AUC) is shown for the ROC curves for SUVmax, TV and TLG for predicting five 
year PFS and OS for pre- and post- therapy values and the change and percentage change between them. 
Standard Error is between 0.60 and 0.65 for all values.   
 
 
Figure 5.5: Kaplan-Meier Survival Curve for 66% Change in SUVmax and PFS 
Survival curves are plotted for two groups of patients, those with change in SUVmax from -100% to -66% 
(mean PFS = 967, SE = 285, 95% CI = 409-1525 and median PFS = 462, SE = 565, 95% CI = 0-1570) and 
those with change in SUVmax from 100% to -65.9% (mean PFS = 1800, SE = 113, 95% CI = 1578-2022 
and median PFS = 2328, SE = 180, 95% CI = 1975-2681). Comparing the survival distributions using the 
log-rank method shows a significance of p < 0.006. 
 261 
The results suggest that there is some correlation between SUVmax, TV and TLG with PFS, 
suggesting they may have some use in predicting outcome but using ROC analysis and Kaplan-
Meier curves to examine associations between these parameters and response showed no real 
benefit in using these methods to predict response. Different approaches to separating patients 
into prognostic groups may result in more promising results which are more suitable for use in 
patients with DLBCL. Dividing patients into three groups (tertiles) rather than two appears like it 
may produce statistically significant results. Statistical analysis on this dataset is still ongoing, as 
is the investigation of other exploratory measures for response including texture analysis and 
subtraction images from registered pre- and post- therapy scans.  
 
5.6) Conclusion to Response to Therapy in Patients with DLBCL 
In this chapter, the ability of several measures of response, including visual analysis, SUVmax and 
the volumetric measures TV and TLG have been tested using pre- and post- therapy PET scans of 
85 patients with DLBCL undergoing R-CHOP or R-CEOP chemotherapy. The main aim of the 
analysis was to see if any of these measures would prove to be beneficial for predicting response 
to therapy with the potential to be used to alter treatment in non-responding patients to improve 
their chances of survival. Visual analysis was done by a consulting physician who also aided the 
segmentation of disease, using a fixed 2.5 SUV threshold region growing algorithm, to obtain TV 
and TLG. SUVmax was taken as the maximum voxel within the TV. All these measures, along 
with Ann Arbor staging and IPI were used to assess OS and PFS in all 85 patients with DLBCL.  
 
Statistical analysis showed some correlation between most measures and OS and PFS, however, 
ROC analysis suggested none of the methods were useful at predicting five-year PFS or OS. 
However, it may be that splitting patients into three, rather than two groups, is a more sensible 
approach and this is being looked into. Most patients do respond to R-CHOP or R-CEOP therapy 
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in NHL patients but there are patients who respond more poorly or with no prolonged response. 
Using three categories of responders can often divide datasets into groups in which patients have 
a very high response rate, a very poor response rate and a divided group between the two where it 
is difficult to distinguish which patients will respond and which won’t. This is potentially useful 
as it can differentiate those patients who are likely to respond and should remain on the same 
treatment regime and those who are unlikely to respond should have their treatment regime 
changed. However, it would still leave a good amount of patients where their potential response 
was unknown, and therefore successfully splitting the patients into responders and non-
responders, if possible, is more ideal. The initial analysis on this group of patients however failed 
to demonstrate that any of the clinical, visual or quantitative parameters could accurately separate 
patients into groups of responders and non-responders.   
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6) Conclusions 
The aim of this project was to investigate the use of pre- and post- therapy 
18
F-FDG PET scans 
for identifying response in cancer patients using both qualitative and quantitative methods. A 
review of the current literature has shown that 
18
F-FDG PET can be successful at identifying 
response in a variety of cancers. Standardisation of imaging protocols and methods is an ever 
important factor in assessing response as it can reduce variation of SUVs and other quantitative 
parameters which can be used to predict response. PETTRA software was developed to allow 
users to view and analyse PET images and compute quantitative response measures, including 
SUVmax, SUVpeak, TV, TLG and IVH parameters. The development of this software was done 
with imaging protocols and methods in mind and customised for assessing quantitative measures 
for investigating response. It was also customised to take into account the work done on 
registering pre- and post- therapy PET/CT studies. 
 
The methodology for registering pre- and post- therapy PET/CT scans, using the CT component 
for registration, was developed and evaluated using both qualitative and quantitative analysis. The 
main aims of developing this methodology were, firstly, with the view to aid consultant physicans 
in visual analysis and secondly, and more importantly, to potentially allow quantitative measures 
to be extracted from registered scans or subtraction images. Both rigid and non-rigid IRTK 
algorithms were customised for registering longitudinal pre- and post- therapy PET/CT scans. 
Registration accuracy was assessed using visual and landmark analysis on a cohort of 20 
lymphoma patients. Visual analysis found IRTK non-rigid and rigid methods produced the most 
accurate registration methods for both PET and CT images, respectively. For the landmark 
analysis, misalignment errors between pre- and post- therapy images were found to be 40mm on 
average. Image registration was shown to substantially reduce this with average misalignments of 
~10mm and ~6.5mm for IRTK rigid and non-rigid algorithms respectively. The affect these 
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registrations had on SUVs and TV in PET images was also investigated. While rigid registration 
transformation caused insignificant changes in SUVmax and minimal changes in SUVpeak and TV 
(<2%), non-rigid transformations caused changes in SUVmax (~2%) and significant changes in 
SUVpeak and TV (mean changes of 11% and 21% respectively).  
 
The registration methodology could potentially be used to aid consultant physicans given its 
accuracy. It could also be used, as planned, to produce subtraction images of pre- and post- 
therapy PET scans which can then be quantified on a voxel-by-voxel basis to assess tumours. 
Although, there are many potential pitfalls with this technique there is still a benefit in at least 
investigating its potential. This was not investigating in the thesis but is certainly an area of future 
work which would be a beneficial area of research. Using the registration methodology and 
extracting semi-quantative parameters for assessing response on registered and subtraction 
images in the two datasets of mesothelioma and DLBCL patients could prove to produce more 
novel and accurate measures of predicting the survival of both sets of patients. While the 
registration was judged to be accurate, whether it is accurate enough to allow successful voxel-
by-voxel analysis to produce response parameters is unknown and something that would need 
consideration in attempting this sort of research. Equally, even if non-rigid registration was 
considered to be accurate enough, the studies have shown that changes in TV would significantly 
influence results so this would also have to be worked around. There are clearly pitfalls to this 
proposed area of research and this technique, if ever to be successful, is certainly in its infancy. 
However, that does not mean it cannot be a valuable area of research. The PETTRA software was 
designed with this in mind and is set-up to display images of pre-therapy images with registered 
post-therapy images with the ability to segment TVs and applying them to both scans a possibility 
amongst other tools. Unfortunately, there was not time to do such analysis for this thesis. 
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Two datasets of patients with mesothelioma and DLBCL were analysed using PETTRA software 
to assess response measures in terms of predicting survival. Analysis of 14 patients with 
mesothelioma assessed a range of response parameters including SUVmax, SUVpeak, TV, TLG and 
IVH parameters. Different variations of these measures were also tested to try and assess the 
impact of different methodologies and segmentation methods on quantitative values and response 
prediction. SUVmax was computed using different normalisation methods, SUVpeak using different 
methodologies, TV and TLG using 13 different fixed threshold methods and nine adaptive 
threshold methods. With just 14 patients, assessment lacked statistical power, but pre- and post- 
therapy values of SUVmax, SUVpeak, TV and TLG showed some promise in predicting OS and PFS 
than the change between pre- and post- therapy values. This suggests that the volume and 
intensity of disease before or after therapy is more important than the change between them. IVH 
parameters had mixed results and while they can not be said to have showed a good indication of 
response, they may be worthy of further investigation. A comparison of different methodologies 
for obtaining SUVmax and SUVpeak parameters and different segmentation methods for obtained 
TV and TLG showed no real difference between them and their ability to predict OS or PFS.  
 
Unfortunately, a lack of patients make it hard to draw any definite conclusions from the dataset of 
mesothelioma patients, with just 14 patients it is much more likely a parameter will work out of 
chance rather than because it is an accurate measure of response. An additional issue with the 
dataset is that the type of disease and effect of treatment is very different when compared to a 
disease like lymphoma where there are more responders. With the mesothelioma patients, no 
patients responded to treatment to reach a complete response, so parameters were merely trying to 
identify patients with longer survival times rather than those which had a complete response. 
While this is still valuable, it means that the results cannot be considered to be at all likely to 
correspond with results from other diseases compared to a number of studies on different types of 
lymphoma, for example. 
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The most interesting findings from the analysis on the group of mesothelioma patients was the 
comparison between different measures of response in terms of using different segmentation 
methods for TV and TLG measures and using different units and methodology for SUVmax and 
SUVpeak values. While once again, conclusions must be considered tentative due to a lack of 
patients, the results suggest that the methodology and segmentation methods used have very little 
influence on the success of these measures to predict survival with all showing very similar 
results when being statistically compared with PFS or OS. However, doing a similar study on the 
DLBCL dataset with more patients available would be beneficial to see if this remains the case 
over a larger dataset or a significantly different type. The evaluation of segmentation methods on 
the mesothelioma dataset was a useful comparison but perhaps the number of methods used, 
particularly the number of fixed threshold methods used, could have been reduced and the time 
used to investigate more segmentation methods on the DLBCL dataset. 
 
Analysis of 85 patients with DLBCL measured SUVmax, TV and TLG on pre- and post- therapy 
PET scans with segmentation achieved using a fixed 2.5 SUV threshold region growing 
algorithm, to obtain TV and TLG. Statistical analysis showed some correlation between most 
measures and OS and PFS, however, ROC analysis revealed that none of the methods were useful 
at predicting five-year PFS or OS. Further work on this dataset is still ongoing with more 
response measures being applied as, unlike the mesothelioma dataset, it has a large number of 
patients and, therefore, more statistical power. Interestingly, along with the mesothelioma dataset, 
pre- and post- therapy parameters alone appear to be good indicators of patient survival, 
suggesting that the actual response seen from the pre-therapy to post-therapy scan is not as 
relevant as the volume or intensity of disease either before or after one cycle of chemotherapy.  
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The analysis on the 85 DLBCL patients has shown that the parameters used are not capable of 
simple dividing patients into groups of responders and non-responders to treatment. However, 
further statistical analysis is needed to investigate what the data does show. It may be possible 
that they can still divide patients into potentially worthwhile categories or produce statistical 
analysis which shows that some parameters may be more valuable than others. Unfortunately, 
there was not time to do this to incorporate the work into this thesis. In addition to this, further 
work on registration should be worked into the analysis of the two patients groups studied and 
used to investigate other response parameters, along with those used in the mesothelioma dataset. 
There is clearly more work to be done on the DLBCL data, especially as this dataset has grown 
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